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Existing hormonal contraception is highly effective and widely used; however, there is
a move towards developing novel compounds that do not have some of the adverse
health risks associated with the oestrogen content. Mifepristone, a progesterone
receptor antagonist, has potential to be developed as a safe and effective oestrogen-free
contraceptive pill. The current studies investigate various effects ofmifepristone on the
hypothalamic-pituitary-ovarian axis and reproductive tissues.
The first study investigates the effect of daily low-dose mifepristone on proliferation
markers [phospho-histone H3 (pH3) mitosis marker] and steroid receptors [oestrogen
receptor (ER), progesterone receptor (PR), androgen receptor (AR)] in the
endometrium. There was a significant down-regulation in pH3 and PR expression
following mifepristone treatment whereas AR expression was up-regulated. Since
androgens antagonize oestrogen-effects on the endometrium, mifepristone-induced AR
up-regulation could play a role in its anti-proliferative effects.
The second study investigates the effects of daily low-dose mifepristone on
endometrial parameters [microvasculature, vascular endothelial growth factor (VEGF)
and glucocorticoid receptor (GR)] which may be associated with changes in
endometrial vascular function. The majority (15/16) of subjects were amenorrhoeic,
mean oestradiol (E2) concentrations remained in the mid-proliferative range and most
(9/16 subjects) endometrial samples showed proliferative histology. GR expression
was induced in the nuclei of glands and surface (luminal) epithelium and there was a
significant increase in micro-vessel density and decrease in stromal VEGF following
treatment. Glucocorticoids can modulate angiogenesis and the high incidence of
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mifepristone-induced amenorrhoea may be related change in the regulation of vascular
function.
The third study investigates the effects of daily low-dose mifepristone on vaginal
morphology, histology, steroid receptor and natural anti-microbial [Serine Leukocycte
Protease Inhibitor (SLPI)] content. There was no change in vaginal thickness, steroid
receptor and SLPI content and distribution following mifepristone treatment. The
absence of changes, in contrast to other oestrogen-free hormonal contraception, is
reassuring.
The fourth study investigates the effect of three single doses (10, 25 and 200 mg) of
mifepristone on menstrual cycle and the feasibility of timing administration as a once-
month-contraceptive pill based on the length of previous menstrual cycles (calendar).
Only 45% of women were in the peri-ovulatory (correct timing) phase of the cycle on
the day of drug administration and an increasing dose of mifepristone was associated
with an increasing chance of having a delayed period (P<0.001). It is not possible to
use the calendar approach to identify the correct time of administration ofmifepristone
and mifepristone disrupts menstruation in a dose-dependent manner. The endometrial
mechanisms and contraceptive efficacy of low (<10 mg) once-a-month dose need to
be investigated in future studies.
In conclusion, endometrial and vaginal effects reported demonstrate safety of daily
low-dose mifepristone treatment whereas a once-a-month administration based on the
calendar disrupts menstruation and is unlikely to provide effective and reliable
contraception.
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Progesterone, one of the key sex steroid hormones, modulates a variety of reproductive
functions including differentiation of the endometrium, control of implantation,
maturation of the mammary epithelium, modulation of GnRH pulsatility, oocyte
release from the ovary and maintenance of the uterus in a quiescent state by inhibiting
myometrial contractility (Csapo and Pulkkinen 1978; Conneely, Mulac-Jericevic et al.
2001). Although these actions have led to major pharmacological applications of
progestins (synthetic progestogen; progestagen is a compound which produces effects
similar to progesterone) in contraception and hormone replacement therapy (HRT), the
most outstanding development in reproductive pharmacology has been the introduction
ofmifepristone, the first potent synthetic anti-progestagen. Its first clinical application
was to induce termination of pregnancy and although the therapeutic promise is
extensive (Table 1.1), the ethical and political issues surrounding its abortifacient use
have largely overshadowed its development.
This focus of this review is the development of mifepristone as a novel method of
female contraception.
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Table1.1:ClinicalApplicationsofProgester eRecept rnt gon sts ClinicalApplicationDose(mg) Short-termadministration 1.Medicalterminationofpregnancy100-600 2.Medicalmanagementoffo talde s50-600 3.Labourinduction50-200 4.Contraception10-200 Long-termadministrationfmifepristone 1.Leiomyoma5-50 2.Endometriosis5-100 3.Contraception0.5-5 4.Cushing'syndrome>200 5.Majordepressionwithpsychoticfeatures>200 6.Alzheimer'sdis ase>200 7.Steroidreceptorcontainingtumours(br ast,ov yend me rium,pr st temeningioma)>200 Source:referothreviewsandfe enceth r in(B r ,Br wtl.2003;SpitzChabb rt-BuffetMedu il5;Fi land Gemzel-Danielsson2006) 11
1. The medical and social history ofmifepristone
The discovery of progesterone in 1929 (Allen. 1929) was soon followed by efforts to
develop an anti-progesterone. It was the discovery of progesterone receptor (PR)
(O'Malley, McGuire et al. 1969) that led to widespread investigation into potential PR
ligands. During their quest to synthesise a new glucocorticoids, chemists at Roussel
Uclaf (Paris) discovered a novel method of producing 11-(3 substitutes of the steroid
skeleton (Belanger, Philibert et al. 1981). They identified a 11 [3-(4~
dimethylaminophenyl)-17(3 -hydroxy-17a-propinyl-4,9-estradiene-3-one (RU38486;
abbreviated RU486) which demonstrated a greater affinity for progesterone and
glucocorticoid receptors than their naturally occurring ligands. RU486 (non¬
proprietary name mifepristone) was quickly put to test and the anti-progesterone
activity was confirmed by demonstration of early pregnancy termination (Herrmann,
Wyss et al. 1982). Medical abortion was first approved in France in 1988, followed by
approvals in the United Kingdom (1991) and Sweden (1992). However, it was not
until the turn of the century that medical abortion was approved in several other
European countries and the United States. Mifepristone is now licensed in combination
with a prostaglandin as an abortifacient in many countries across the world (Ulmann
2000; Fiala and Gemzel-Danielsson 2006). However, international anti-abortion
politics (Ulmann 2000; Joffe and Weitz 2003) have kept the pharmaceutical industry
away from developing this promising compound for treatment of other medical
conditions.
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2. Chemical structure ofmifepristone.
Mifepristone (RU38486) is a beta-aryl-substituted, 19-nortestosterone-derived
compound which lacks the C-19 methyl group of natural progesterone and
glucocorticoids (Figure 1.1).
The two main structural modifications of steroid skeleton are the phenyl-
aminodimethyl group perpendicularly grafted onto the 11-p position and the 1-
propynyl side-chain substitution at the 17-a position. The high binding affinity for PR
is attributed to both these variations whereas the size and positioning of the 11-P
substitution determines the anti-progesterone activity and the 17-a side-chain
modulates anti-glucocorticoid activity (Evans 1988; Garcia, Benhamou et al. 1992).
Although compounds with varied anti-progesterone and anti-glucocorticoid activity
have been developed, to date no pure progesterone antagonist totally devoid of anti-
glucocorticoid activity has been described.
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Figure1.1:Structu alfo m lofRU38486(abbreviated4 ) h,c h3c^
c=c—ch3
Chemicalname: Non-proprietaryname: Molecularweight: Molecularformul :
11(3-(4-dimethylaminophenyl)-17(3 hydrox -17a-propinyl-4,9-estradien -3- ne Mifepristone 429.58 C29H35NO2 14
3. Pharmacokinetics ofmifepristone
Only an oral preparation ofmifepristone is available commercially for clinical use and
dose of 0.5-800 mg has been administered in various therapeutic studies. Mifepristone
is rapidly absorbed (70%) from the gut and peak levels appear in plasma within 1-3
hours. It undergoes extensive first-pass hepatic metabolism and its bioavailability is
reduced to 40%.
Mifepristone binds to serum uj- acid glycoprotein (AAG), orosomucoid (Steingold,
Matt et al. 1990) and the high-affinity, limited-capacity binding explains long half-life
(20-40 hours) and divergent dose-dependent pharmacokinetics. Mifepristone follows
linear-order kinetics initially, but, when the binding capacity of AAG is saturated at
oral dose 100 mg, it follows zero-order kinetics (Swahn, Wang et al. 1986;
Heikinheimo, Lahteenmaki et al. 1987). Doses ofmifepristone exceeding 100 mg do
not lead to higher plasma levels, but more susceptibility to metabolism. There is no
difference in serum profiles between men, non-pregnant and pregnant women, or
between morning and evening administration of the drug (Shi, Ye et al. 1993).
Three metabolites of mifepristone have been identified (Heikinheimo, Kontula et al.
1987; Heikinheimo, Lahteenmaki et al. 1987): mono-demethylated (RU42633), di-
demethylated (RU42848) and hydroxylated (RU42698) metabolites. The metabolism
of RU486 to RU42633 and RU42698 is rapid but di-demythlation to RU42848 occurs
much more slowly and to a much lesser extent. The metabolites are less active but their
abundance allows them to participate in the global action of the compound. These
metabolites are excreted in the urine (10%) and in the faeces via the biliary system
(90%)
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4. Cellular mechanism of action
4.1 Nuclear Receptor Superfamily
The effect of steroid hormones is mediated through specific intracellular proteins, the
steroid receptors, which belong to the superfamily of nuclear receptors (NR) (Evans
1988). Like all otherNR's, steroid receptors have a modular structure with distinct
regions corresponding to independent functional and structural domains that can be
exchanged between related receptors without loss of function (Brosens, Tullet et al.
2004)(Figure 1.2).
Figure 1.2: Functional domains of nuclear steroid receptors
a/b c D e
The steroid receptors comprise five regions (Brosens, Tullet et al. 2004; Gronemeyer,
Gustafsson et al. 2004)
1. A/B region: The amino terminus (NIK) contains a transactivation function (AF-1
and AF-3), which is of variable length and sequence in the different family
members, and is recognized by co-activators and/or other transcription factors.
2. C region: The central DNA-binding domain (DBD) has two zinc-finger motifs that
are common to the entire family followed by a C-terminal extension (CTE). The
CTE contains amino acids required for the recognition of specific target DNA
sequences called hormone response elements (HRE) and receptor dimerization.
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3. D region: The hinge is quite variable within the NR superfamily. It acts as a bridge
between the DBD and ligand-binding domain (LBD), enabling the NR to adopt
different conformations by means of rotation. This region might also include
localization signals that determine the intracellular localization of the NR.
4. E region: The carboxy-terminal (COOH) ligand-binding domain (LBD), whose
overall architecture is well conserved between the various family members,
nonetheless diverges sufficiently to guarantee selective ligand recognition. This
domain also has the ligand-induced transactivation function (AP2) that is crucial
for interaction with co-regulators and heat shock proteins. It is crucial for receptor
dimerisation. A glycin at position 722 in this region of human PR is critical for
mifepristone binding (Benhamou, Garcia et al. 1992).
There are two isoforms/subtypes each of the steroid receptors, oestrogen receptor (ER),
progesterone receptor (PR) and androgen receptor (AR), which differ structurally and
this multiplicity contributes to signal diversity and specificity of the respective ligands.
The two isoforms of the human PR (Clarke & Sutherland, 1990); an amino-terminal
truncated PR-A (94 kDa) and the full-length PR-B (114 kDa), arise from a single gene
and function as transcriptional regulators of progestin-responsive genes. The additional
domain at the amino terminus of PR-B encodes a third transactivation function (AF3)
which allows binding of a subset of co-activators to PR-B that are not efficiently
recruited by progestin-bound PR-A. The structure and reproductive functions of the PR
and its two isoforms are well characterised (Conneely and Lydon 2000; Conneely,
Lydon et al. 2000; Leonhardt and Edwards 2002; Conneely, Mulac-Jericevic et al.
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2003; Leonhardt, Boonyaratanakornkit et al. 2003; Mulac-Jericevic and Conneely
2004).
Human genital skin fibroblasts contain both the full-length (110 kDa) androgen
receptor isoform (AR-B) and an amino-terminally truncated (87 kDa) isoform (AR-A).
The two isoforms are expressed in a wide variety of human foetal and adult tissues
(Wilson and McPhaul 1994; Wilson and McPhaul 1996). Although AR isoforms are
structurally analogous to those of the PR, their reproductive function is not well
characterised.
The two ER subtypes, ERa and ERp, are encoded by different genes (Kuiper, Enmark
et al. 1996; Mosselman, Polman et al. 1996). ERa and ERP have a highly homologous
DNA binding domain (DBD) but differ in the ligand-binding domain (LBD) and the
transactivation function (AF-1). Although both subtypes can bind 17P-oestradiol with
high affinity, they are differentially expressed in many tissues and have distinct
transactivation properties (Kuiper, Carlsson et al. 1997; Paech, Webb et al. 1997).
4.2 Receptor Binding Affinity (RBA) of mifepristone
Mifepristone binds with high affinity to both the PR (RBA 506 %, progesterone 100
%) and the GR (RBA 685 %, dexamethasone 100%) (Elger, Bartley et al. 2000). It has
a relatively low-affinity to the AR (RBA AR 13%, PR 103-105%, and GR 80%)
(Attardi, Burgenson et al. 2002). The mineralocorticoid receptor (MR) which is
structurally similar to GR demonstrates no affinity. In vivo and vitro studies clearly
demonstrate virtually no affinity to the ER (Philibert 1984; Zou, Marschke et al. 1999).
Mifepristone is a type 2 progesterone receptor antagonist (PRA); it is a pure antagonist,
but in the absence of progesterone, the steroid receptor-mifepristone complex may be
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transcriptionally active on some genes (Spitz and Bardin 1993) and partial agonistic
effect has been reported (Gravanis, Schaison et al. 1985; Terakawa, Shimizu et al.
1988). Mifepristone antagonises glucocorticoid and androgen actions.
Although mifepristone has virtually no binding to ERa and ERfi in-vitro, it acts as a
weak (IC50 >lpM) antagonist via ERa and as a fairly potent (IC50 ~ 200 nM)
antagonist via ER(3 from an ERE-driven reporter in cells that do not express PR (Zou,
Marschke et al. 1999). The underlying mechanism of ER(3 antagonism is unclear, the
hypothesis is that mifepristone is metabolized in these cells to a compound that is able
to bind to ERp with higher affinity than the parent compound (Zou, Marschke et al.
1999).
4.3 Transcription of steroid hormone action
Steroid receptors are held in a large multi-subunit complex containing heat-shock
proteins which maintain the receptor in active conformation ready for ligand binding.
Ligand-bound receptors, undergo conformational changes, dissociate themselves from
heat-shock proteins, undergo dimerisation and are assembled on target gene promoters
to activate or repress gene expression. Recruitment of ligand-bound nuclear receptors
to target gene promoter regions occurs directly through specific DNA sequences
(HRE) or indirectly through other DNA-binding transcription factors (Brosens, Tullet
et al. 2004). Ligand-bound nuclear receptors also recruit co-activators and co¬
mpressors which promote or repress transcription respectively. Genetic and
biochemical data have revealed a plethora of factors that mediate nuclear receptor
function and it is beyond scope of this manuscript to review all aspects of
transcriptional regulation.
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4.4 Transcription of progesterone and mifepristone
When expressed individually in cultured cells, PR-A and PR-B display different
transactivation properties (Conneely, Mulac-Jericevic et al. 2003; Mulac-Jericevic and
Conneely 2004). Agonist-bound PR-B functions as a strong activator of transcription
of several PR dependent promoters and in a variety of cell types in which PR-A is
inactive. Further, when both isoforms are co-expressed in cultured cells, in cell and
promoter contexts in which agonist bound PR-A is inactive, the PR-A can repress the
activity of PR-B (Vegeto, Shahbaz et al. 1993) and other steroid receptors including
ER (McDonnell and Goldman 1994), AR, GR and MR (McDonnell, Shahbaz et al.
1994; Saatcioglu, Claret et al. 1994). PR-A and PR-B proteins also respond differently
to progesterone antagonists. While antagonist bound PR-A is inactive, antagonist
bound PR-B can be converted to a strongly active transcription factor by modulating
intracellular phosphorylation pathways (Beck, Weigel et al. 1993; Sartorius, Groshong
et al. 1994).
The binding of both progesterone and mifepristone produces conformational changes
in the form of PR that permits it to bind to DNA. The two isoforms of human PR, PR-
A and PR-B form homo and/or hetero-dimers (A:A, B:B or A:B) which bind to
progesterone response elements (PRE) in the promoter region of progesterone genes.
The mifepristone-PR dimer complex has a higher affinity for PRE than the
progesterone-PR dimer complex. In the case ofprogesterone, this binding increases the
transcription of these genes, producing progesterone effects whereas in the case of
mifepristone, an inhibitory function in the carbox-terminal region of LBD renders this
DNA-bound receptor transcription inactive. This is the basis of the progesterone
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antagonistic action of mifepristone underlying its abortifacient and contraceptive
actions.
Progesterone and mifepristone also interact with the transcription machinery by
association with co-activators and co-repressors (Liu, Auboeuf et al. 2002; Smith and
O'Malley 2004). Co-activators amplify transcriptional regulation and include steroid
receptor co-activator (SRC) family members and receptor-interacting protein 140 (RIP
140). Co-repressors include nuclear receptor co-repressor (NCoR) and silencing
mediator of retinoic acid and thyroid hormone receptor (SMRT). There is an
intracellular equilibrium of co-activators and co-repressor in a tissue-specific manner
which is modulated by agonist or antagonist ligands.
5. Toxicology in animals and safety in human trials
Roussel Uclaf conducted a comprehensive toxicology program in the mid-1980s and
demonstrated the safety of the compound for short-term human use (Deraedt, Vannier
et al. 1985). No long-term toxicity and carcinogenicity studies were performed and
information on the safety of mifepristone after repeated and long-term administration
is provided by various research studies investigating its therapeutic role in breast
cancer, meningioma, endometriosis, uterine leiomyomata in doses ranging from 0.5 to
800 mg daily. Common side effects observed during long-term treatment with doses of
up to 200 mg daily include fatigue, nausea, anorexia and vomiting. Weight loss, skin
rashes, cessation of menses in premenopausal women, transient thinning of the hair
and hot flushes have also been reported (Grunberg, Weiss et al. 1991; Lamberts, Koper
et al. 1991; Grunberg 1994). Uncommon side effects include decrease in libido and
gynaecomastia (Grunberg 1994), biochemical hypothyroidism (Heikinheimo, Ranta et
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al. 1997), transient elevation in hepatic enzymes (Murphy, Kettel et al. 1993; Cameron,
Thong et al. 1995; Murphy, Morales et al. 1995; Kettel, Murphy et al. 1998; Eisinger,
Meldrum et al. 2003) [Onapristone, which is closely related structurally to
mifepristone, was withdrawn from clinical trials because of its effect on hepatic
enzymes (Klijn, Setyono-Han et al. 2000)] and low serum potassium levels (Romieu,
Maudelonde et al. 1987; Chu, Matthias et al. 2001). Although, hypoadrenalism
secondary to glucocorticoid antagonism has been reported with doses exceeding 200
mg per day (Laue, Lotze et al. 1990; Lamberts, Koper et al. 1991), it is an uncommon
occurrence in humans with an intact pituitary-adrenal axis.
Mifepristone crosses the placental barrier (Hill, Selinger et al. 1991) and although
abnormalities have been reported in surviving foetuses following administration of
mifepristone-prostaglandin regimen for medical abortion, the data on mifepristone-
only administration is reassuring (Sitruk-Ware, Davey et al. 1998; Sitruk-Ware 2006).
6. Anti-fertility effects
The key anti-fertility effects are the suppression of ovulation and endometrial
disruption (Batista, Cartledge et al. 1992; Ledger, Sweeting et al. 1992; Croxatto,
Salvatierra et al. 1993; Cameron, Thong et al. 1995; Danielsson, Swahn et al. 1997;
Croxatto, Kovacs et al. 1998; Brown, Cheng et al. 2002; Baird, Brown et al. 2003).
Other reproductive targets include induction of luteolyis (Schaison, George et al. 1985;
Ottander, Hosokawa et al. 2000), and possible interference with tubal (Christow, Sun
et al. 2002) and sperm function (Serres, Yang et al. 1994; Yang, Serres et al. 1994;
Yang, Serres et al. 1996).
6.1. Effect on hypothalamo-pituitary axis, follicular development and ovulation
22
The effects ofmifepristone on hypothalamo-pituitary axis, follicular development and
ovulation vary depending on dose, timing and duration of administration.
Administration of mifepristone during the follicular phase of the menstrual cycle
delays the oestrogen rise and the luteinizing hormone (LH) surge, but has no effect on
endometrial development during the implantation period, whereas, administration of an
adequate dose immediately after ovulation mifepristone will significantly inhibit
endometrial development.
Follicular administration
Short-term (3mg/kg in the first 3 days) administration in the early follicular phase does
not alter the ovarian or menstrual cycle (Stuenkel, Garzo et al. 1990), whereas, a
similar administration after ultrasound documentation of a dominant follicle arrested
follicular development, suppressed oestradiol levels and delayed/inhibited onset of LH
surge and ovulation (Liu, Garzo et al. 1987). The mechanism by which mifepristone
interferes with the mid-cycle LH surge is complex and possible involves a direct
reduction in sensitivity of the pituitary gonadotropin to the positive feedback effects of
oestrogen (Baird, Thong et al. 1995).
A daily low-dose administration of 5 mg or 10 mg of mifepristone throughout one
menstrual cycle prevents the leading follicle from achieving maturity and from
producing the circulating oestradiol levels necessary to trigger the LH surge (Ledger,
Sweeting et al. 1992; Croxatto, Salvatierra et al. 1993). A daily low-dose
administration of 1-5 mg for duration of 3-15 days after selection of dominant follicle
impairs follicular growth (Batista, Cartledge et al. 1992; Batista, Cartledge et al. 1994;
Croxatto, Salvatierra et al. 1995). Further reduction in daily dose (1 or 2 mg) may
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allow full follicular growth, but, is still sufficient to inhibit ovulation (Ledger,
Sweeting et al. 1992; Croxatto, Salvatierra et al. 1993; Baird, Thong et al. 1995;
Cameron, Thong et al. 1995).
The mechanism by which mifepristone interferes with follicular development is not
clear. Mifepristone interrupts follicular growth after selection of the dominant follicle
(Messinis, Krishnan et al. 1997) and hypotheses include an increase in progesterone
receptors in the theca and granulosa cells of the dominant follicle (Iwai, Nanbu et al.
1990), decrease in follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
(Permezel, Lenton et al. 1989) and reduction in the sensitivity of the selected follicle
to FSH (Messinis, Krishnan et al. 1997). The hypotheses are based on studies of
varying methodology and dose and it is possible that all three mechanisms play a role
depending on dose and time of administration.
Only two studies have reported endocrine effects of administration of single dose
mifepristone in the follicular phase. A single dose of 5 mg administered when the lead
follicle reached a diameter of 12-14 mm retarded its growth for 12-48 h after
treatment (Croxatto, Salvatierra et al. 1995). A single dose of 10 mg administered
when lead follicle was >15 mm, or approximately 2 days prior to the LH surge,
delayed or inhibited the LH surge in all subjects (Marions, Hultenby et al. 2002). A
dose-related delay in menstruation has been reported when 3 single doses of
mifepristone were given for emergency contraception (1-week delay in menses; 600-
mg = 36%, 10 mg = 18%) (WHO 1999). It is however impossible to ascertain the




Administration during the early-luteal phase (peri-ovulatory, after initiation of LH
surge, LH + 0 to LH + 2) does not prolong the follicular phase and ovulation is not
arrested (Liu, Garzo et al. 1987; Brown, Williams et al. 2003).
Mid-luteal phase administration ofmifepristone increases the amplitude and frequency
of LH pulses due to block in the suppressive effect of progesterone (Garzo, Liu et al.
1988; Shoupe, Mishell et al. 1990). This is followed by a decrease in the secretion of
total LH and pulse amplitude suggesting direct pituitary action.
Late luteal administration of single-dose mifepristone reduces both frequency and
amplitude of LH pulses suggesting a hypo-thalamo-pituitaiy action (Garzo, Liu et al.
1988).
Intermittent administration
Intermittent administration of dose below 10 mg does not inhibit ovulation (Gemzell-
Danielsson, Westlund et al. 1996; Marions, Danielsson et al. 1998; Cheng, Weng et al.
2001). Higher doses may prolong the follicular phase and inhibition of ovulation is
inconsistent (Spitz, Croxatto et al. 1993; Chen and Xiao 1997; Cheng, Weng et al.
2001; Godfrey, Mawson et al. 2004; Pei, Xiao et al. 2007). Once-a-week treatment did
not did not influence the length of the luteal phase (Gemzell-Danielsson, Westlund et
al. 1996).
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Table 1.2 and 1.3: The effect of mifepristone administration on ovarian and
endometrial function.
Single dose
1. Peri-ovulatory (LH+0-2) 10, 200, 400 mg, (Gemzell-Danielsson, Swahn et al.
1993; Gemzell-Danielsson, Svalander et al. 1994; Cameron, Critchley et al.
1997; Hapangama, Brown et al. 2001; Marions, Hultenby et al. 2002; Brown,
Williams et al. 2003)
2. Mid-luteal 200 mg, (Shoupe, Mishell et al. 1987)
3. Late-luteal 400, 600 mg, (Dubois, Ulmann et al. 1988; Lahteenmaki, Rapeli et
al. 1988; Couzinet, Le Strat et al. 1990)],
Intermittent administration: 2.5 mg (Gemzell-Danielsson, Westlund et al. 1996), 5 mg
(Gemzell-Danielsson, Westlund et al. 1996; Marions, Danielsson et al. 1998; Cheng,
Weng et al. 2001), 10 mg (Spitz, Croxatto et al. 1993; Cheng, Weng et al. 2001;
Godfrey, Mawson et al. 2004), 25 mg (Chen and Xiao 1997; Pei, Xiao et al. 2007), 50
mg (Spitz, Croxatto et al. 1993; Pei, Xiao et al. 2007)
Short-term administration:
1. Early follicular: 3mg/kg daily for 3 days (Stuenkel, Garzo et al. 1990)
2. Late follicular: 3mg/kg daily for 3 days (Stuenkel, Garzo et al. 1990)
3. Mid-luteal: 3 mg/kg daily for 3 days (Garzo, Liu et al. 1988); 25-100 mg daily
for 4 days (Schaison, George et al. 1985; Swahn, Johannisson et al. 1988)
Continuous daily low-dose mifepristone: 0.1 mg (Danielsson, Swahn et al. 1997), 0.5
mg (Danielsson, Swahn et al. 1997), 1 mg (Batista, Cartledge et al. 1992; Croxatto,
Salvatierra et al. 1993; Croxatto, Kovacs et al. 1998), 2 mg (Ledger, Sweeting et al.
1992; Cameron, Thong et al. 1995; Brown, Cheng et al. 2002; Baird, Brown et al.
2003) , 5 mg (Ledger, Sweeting et al. 1992; Croxatto, Salvatierra et al. 1993; Cameron,
Thong et al. 1995; Brown, Cheng et al. 2002; Baird, Brown et al. 2003; Lakha, Ho et
al. 2007), 10 mg (Croxatto, Salvatierra et al. 1993)
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6.2. Effect on endometrial development and implantation
Pre-ovulatory administration
There was no effect on endometrial morphology following administration 50 mg daily
on cycle days 7-10 (Swahn, Johannisson et al. 1988). There was minimal effect on
endometrial development (on cycle day LH+6-8) following administration of single
dose of 10 mg 2 days prior to ovulation (Marions, Hultenby et al. 2002). Expression of
the [33 integrin subunit in the glandular epithelial cells was decreased in 2/6 subjects,
whereas, other markers of receptivity were the same as observed in control cycles.
Peri-ovulatory administration
Single dose (200-800 mg) administration in the early luteal phase (LH+0 to LH + 2)
causes changes in endometrial secretory activity, expression of steroid receptors,
especially progesterone receptors, integrins and leukaemia inhibitory factor (LIF) at
the expected time of implantation (Li, Dockery et al. 1988; Swahn, Bygdeman et al.
1990; Maentausta, Svalander et al. 1993; Gemzell-Danielsson, Svalander et al. 1994;
Cameron, Critchley et al. 1997; Danielsson, Swahn et al. 1997; Dockery, Ismail et al.
1997; Critchley, Tong et al. 1999; Hapangama, Critchley et al. 2002; Brown, Williams
et al. 2003) without affecting vaginal bleeding patterns (Swahn, Bygdeman et al. 1990;
Gemzell-Danielsson, Swahn et al. 1993; Gemzell-Danielsson, Svalander et al. 1994;
Hapangama, Critchley et al. 2002; Brown, Williams et al. 2003). Similar changes in
endometrial secretory profiles of vascular endothelial growth factor, transforming
growth factor /? - 1, leukemia inhibitory factor and glycodelin have been observed in
the rhesus monkey following mifepristone administered on day LH+2 (Ghosh, Kumar
et al. 1998; Lalitkumar, Sengupta et al. 1998). Mifepristone inhibits progesterone-
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induced down-regulation of ER and PR (Swahn, Bygdeman et al. 1990; Maentausta,
Svalander et al. 1993; Cameron, Critchley et al. 1997; Critchley, Tong et al. 1999;
Hapangama, Critchley et al. 2002). It also affects expression of calcitonin (Kumar, Zhu
et al. 1998) and prostaglandin dehydrogenase (Cameron, Critchley et al. 1997) and
release of PGF2 through the uterine fluid (Gemzell-Danielsson and Hamberg 1994).
The changes are likely to prevent implantation and contraceptive efficacy of such an
approach has been demonstrated in two studies (Gemzell-Danielsson, Swahn et al.
1993; Hapangama, Brown et al. 2001). Peri-ovulatory administration also changes
uterine contractility to a pattern more usually seen in the late luteal phase (Gemzell,
Swahn et al. 1990), perhaps adding to the contraceptive effect.
The effect of 10 mg had a similar but much less marked effect (Marions, Hultenby et
al. 2002). The endometrium was slightly out of phase, and the down-regulation of
progesterone receptor concentration was inhibited in five of the six women. The effect
on markers for endometrial receptivity was less marked. It is difficult to know if the
effects with lower dose are sufficient to inhibit implantation. The efficacy of 10 mg
dose mifepristone when used for emergency contraception (WHO 1999) and the
possibility to extend the interval between the unprotected sexual intercourse and
treatment to 120 hours (Ashok, Wagaarachchi et al. 2001; Hamoda, Ashok et al. 2004)
suggest that this may be the case.
Post-ovulatory fluteal-phase) administration
Mid-luteal administration of a single dose (50-200 mg) of mifepristone induces
endometrial bleeding within 72 hours (Schaison, George et al. 1985; Shoupe, Mishell
et al. 1990; Greene, Kettel et al. 1992) and endometrium shows shrinkage of glandular
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lumen and leukocyte infiltration and vascular infiltration (Swahn, Johannisson et al.
1988).
The mechanism of endometrial bleeding following mid-luteal administration is poorly
understood. Luteolysis is dose-dependent (Schaison, George et al. 1985), however,
endometrial bleeding occurs whether or not luteal regression is induced by the
compound, indicating that mifepristone acts directly upon the endometrial tissue. A
direct vascular effect has been suggested (Johannisson, Oberholzer et al. 1989) and our
group has proposed a role for modulation of local prostaglandin production (Cheng,
Kelly et al. 1993; Hapangama, Critchley et al. 2002). The progesterone levels in the
peri-ovulatory phase are relatively low and consequently, expression of endometrial
ER and PR is maximal, whereas, the opposite is true in the mid-luteal phase of the
menstrual cycle. Therefore peri-ovulatory administration will prevent progesterone-
induced changes, whereas, mid-luteal administration will antagonise progesterone-
induced changes in the endometrium. When luteolysis is incomplete, a second bleed
has been reported at expected time of menstruation (Schaison, George et al. 1985;
Garzo, Liu et al. 1988; Swahn, Johannisson et al. 1988).
Late-luteal (Dubois, Ulmann et al. 1988; Lahteenmaki, Rapeli et al. 1988; Couzinet, Le
Strat et al. 1990) phase administration disrupts the endometrium to a degree likely to
prevent implantation.
Intermittent administration
Intermittent (weekly) administration of mifepristone disrupts endometrial maturation
(Gemzell-Danielsson, Westlund et al. 1996; Cheng, Weng et al. 2001). The number of
endometrial glands and glandular diameter decreased during weekly administration of
31
2.5 or 5mg ofmifepristone for 8 weeks, but this decrease was not significant for the
2.5 mg group. Despite only minor effects on endometrial morphology, both regimens
reduced secretory activity (Gemzell-Danielsson, Westlund et al. 1996).
6.3. Effect on corpus luteum
Administration of high doses of mifepristone during the mid- to late-luteal phase
results in shedding of the endometrium and vaginal bleeding within a few days of the
treatment. If premature menstruation is not accompanied by luteolysis (approximately
20 - 60% of cases), the endometrial and ovarian cycles are desynchronized and a
second bleeding episode occurs at the time of the expected menstruation (Schaison,
George et al. 1985; Garzo, Liu et al. 1988; Swahn, Johannisson et al. 1988). The
manner in which mifepristone induces luteolysis in certain situations is not precisely
known, but could be indirect through withdrawal of LH support (Mais, Kazer et al.
1986), as evidenced by a reduction in amplitude and frequency of LH pulses and
blunting of the pituitary LH response to GnRH (Schaison, George et al. 1985; Garzo,
Liu et al. 1988). It may also depend on the age of the corpus luteum (Swahn,
Johannisson et al. 1988).
6.4. Effect on oocyte maturation and fertilization
Mifepristone treatment does not alter oocyte maturation and fertilization potential. 100
mg mifepristone was administered 1 h before induction of ovulation with injection of
5000 IU of human chorionic gonadotropin (hCG) in 20 subjects in whom follicular
growth was stimulated with clomiphene for 5 days (Messinis and Templeton 1988).
Laparascopy (for tubal sterilization) was performed 34 h after hCG and all follicles
with a diameter of >15 mm were aspirated and collected oocytes submitted to in vitro
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fertilization. 20 women similarly stimulated with clomiphene but not receiving
mifepristone served as a control group. The number of retrieved oocytes, the rate of
fertilization and the cleavage rate did not differ between the mifepristone group and
controls (Messinis and Templeton 1988).
6.5. Effect on tubal milieu and function
The tubal microenvironment is of great importance to ensure normal embryo
development (Smotrich, Stillman et al. 1996). Too rapid or too slow tubal transport
could also be expected to cause desynchronization between the embryo and the tube,
and/or blastocyst and endometrium. The role of progesterone in regulating tubal
transport has been confirmed (Mahmood, Saridogan et al. 1998) and mifepristone
reversed the inhibitory effect of high doses of progesterone on ciliary movement. ER
and PR expression in the fallopian tube is regulated by the changing ovarian steroid
hormones (Amso, Crow et al. 1994; Shah, Nandedkar et al. 1999). Following 200 mg
of mifepristone on LH+2, PR expression increased in epithelial and stromal cells
(Christow, Sun et al. 2002). There was also an effect on ER expression, although less
pronounced and restricted to the epithelial cells. Modulation of progesterone regulated
tubal microenvironment (Smotrich, Stillman et al. 1996) and tubal transport
(Mahmood, Saridogan et al. 1998) may add to contraceptive mechanism of
mifepristone.
6.6. Effect on the human spermatozoa
Progesterone triggers the acrosome reaction of capacitated human spermatozoa in vitro
and a rise in intracellular calcium is one of the first events observed following the
binding ofprogesterone to the sperm cell. Mifepristone inhibits this calcium influx and
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subsequent acrosome reaction (Serres, Yang et al. 1994; Yang, Serres et al. 1994). It
can also interfere with the ability of sperm to fertilise eggs (Yang, Serres et al. 1996).
7. Contraceptive Approaches
7.1. Daily pill
Our group reported the first large contraceptive efficacy study of low-dose
mifepristone in 2002 (Brown, Cheng et al. 2002). 90 subjects, 40 in Edinburgh and 50
in China were randomised to 2 or 5 mg mifepristone daily for 120 days. The study
design is illustrated in Figure 1.3.
Figure 1.3: Low-dose mifepristone for 120 days - study design
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Briefly, subjects maintained a daily menstrual diary and a weekly urinary steroid
(metabolites of oestrogen and progesterone) profile. Transvaginal ultrasound (TVUSS)
and safety checks (symptom reporting, medical examination, haematology and
biochemical investigations) were carried out pre-treatment and at 30, 60, 90, 120 and
150 days of treatment. Pipelle endometrial biopsies were collected at 3 time-points;
pre-treatment mid-proliferative phase of menstrual cycle and 60 and 120 days
following administration of mifepristone. Only 10 women in Edinburgh and all
subjects in Shanghai used mifepristone as their only method of contraception.
The principal outcomes are summarised in Table 1.4 (Brown, Cheng et al. 2002).
Table 1.4: Low-dose mifepristone for 120 days - principal outcomes
Edinburgh (n=50) Shanghai (n=40)
2 mg 5 mg 2 mg 2 mg
An-ovulation 90% 95% 98% 98%
Amenorrhea 65% 88% 90% 90%
Pregnancy 0/10 0/40
The different thresholds for endometrial disruption (0.5 mg) and suppression of
ovulation (2 mg), raise the prospect of endometrial contraception; prevention of
implantation without disruption of ovulation. The contraceptive efficacy of 0.5 mg
daily was investigated in 32 subjects (Marions, Viski et al. 1999). 5 pregnancies
occurred in 141 at-risk treatment cycles, which is significantly less than if no
contraception was used. Although the results are disappointing, they indicate the




Intermittent administration of dose below 10 mg does not inhibit ovulation (Gemzell-
Danielsson, Westlund et al. 1996; Marions, Danielsson et al. 1998; Cheng, Weng et al.
2001) and although the endometrium is disrupted, the pregnancy rate is
disappointingly high (Marions, Danielsson et al. 1998; Cheng, Weng et al. 2001). A
recent Chinese study has reported high efficacy using 25-50 mg weekly dose (Pei,
Xiao et al. 2007).
7.3. Once-a-month pill
There are two once-a-month contraceptive approaches using administration of a single
dose ofmifepristone (200-800 mg); administration in the early and late luteal phase of
the menstrual cycle respectively. Late-luteal administration is a post-implantation
contraceptive (Dubois, Ulmann et al. 1988; Lahteenmaki, Rapeli et al. 1988; Couzinet,
Le Strat et al. 1990; Swahn, Bygdeman et al. 1999) which reduces its wider
acceptability and all three studies investigating its use reported pregnancy rates
between 5-19%. On the other hand, early-luteal (peri-ovulatory, within 48 hours of the
LH surge) administration, markedly retards endometrial development to a degree
which is likely to prevent implantation (Swahn, Bygdeman et al. 1990; Maentausta,
Svalander et al. 1993; Gemzell-Danielsson, Svalander et al. 1994; Cameron, Critchley
et al. 1997). The biggest advantage of the peri-ovulatory once-a-month approach is that
it does not alter the length of the menstrual cycle (Swahn, Bygdeman et al. 1990;
Gemzell-Danielsson, Swahn et al. 1993; Gemzell-Danielsson, Svalander et al. 1994;
Hapangama, Brown et al. 2001; Brown, Williams et al. 2003) thereby facilitating its
continued use. Between 12-35% women experience light vaginal bleeding commence
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within a few days ofmifepristone and lasting 2-3 days (Swahn, Bygdeman et al. 1990;
Gemzell-Danielsson, Swahn et al. 1993; Hapangama, Brown et al. 2001).
The contraceptive efficacy of a once-a-month administration ofmifepristone has been
demonstrated in two studies (Gemzell-Danielsson, Swahn et al. 1993; Hapangama,
Brown et al. 2001). 21 Swedish women used 200 mg mifepristone on day LH + 2
every month as their only contraceptive method for 1-12 months (Gemzell-Danielsson,
Swahn et al. 1993). There was only 1 pregnancy out of 124 "at risk" cycles, giving a
probability of pregnancy of 0.008. The subsequent menstrual cycle was not disrupted,
although 35% ofwomen did report slight vaginal bleeding 2-3 days after treatment. In
another study, the contraceptive efficacy of 200 mg ofmifepristone administered once-
a-month for 6-7 consecutive menstrual cycles on day LH + 2 in 32 women from
Edinburgh was compared to the natural fecundity of a control group, comprising 20
women who were trying to conceive (Hapangama, Brown et al. 2001). There were two
pregnancies out of a total of 178 cycles in the treatment group (probability of
pregnancy 0.01) and 12 pregnancies out of a total of 50 cycles in the control group
(probability ofpregnancy 0.25-0.32).
The timing of administration of mifepristone is critical to the success of the peri-
ovulatory once-a-month approach. Administration during the follicular phase of the
menstrual cycle (too early), inhibits follicular development, delays the mid-cycle LH
surge and prolongs the length of the cycle (Croxatto, Salvatierra et al. 1995; Marions,
Hultenby et al. 2002) whereas administration in the mid to late luteal phase (too late)
induces bleeding within a few days and this is often followed by a second bleed at the
time of the expected menses (Shoupe, Mishell et al. 1987; Dubois, Ulmann et al. 1988;
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Lahteenmaki, Rapeli et al. 1988; Couzinet, Le Strat et al. 1990; Swahn, Bygdeman et
al. 1999). Thus a single dose of mifepristone administered outside the critical peri-
ovulatory time results in irregular bleeding which many women find unacceptable.
In the two studies which demonstrated the efficacy of the method, the peri-ovulatory
window of administration was identified by the mid-cycle peak of LH in urine using
urine test sticks (Ovu-quick, Organon) in Sweden (Gemzell-Danielsson, Swahn et al.
1993) and a home-use fertility monitor (Persona, Unipath Ltd) in Edinburgh
(Hapangama, Brown et al. 2001). Both approaches are expensive and probably too
demanding on user compliance to be used routinely. In the Edinburgh study for
example, subjects failed to perform tests on 24% of the days required, with 42% of
cycles having at least one missed test at time of highest fertility (Hapangama, Glasier
et al. 2001). 11.2% of LH surges were missed as a consequence of imperfect use of the
monitor.
Our group has demonstrated that mifepristone given on the day of the LH surge
(LH+0), retards endometrium sufficiently to prevent implantation without interfering
with ovulation (Brown, Williams et al. 2003). This observation widens the peri-
ovulatory 'window of opportunity' for administering mifepristone to at least 3 days
(LH+0 to LH+2) and allows more flexibility to investigate a cheaper and simpler
method of timing administration.
7.4. Emergency contraception
Administration of a single dose (600 mg) of mifepristone within 72 hours of
unprotected intercourse is an effective emergency contraceptive (Glasier, Thong et al.
1992; Webb, Russell et al. 1992). A large multicentre study has reported efficacy of
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much lower doses (10, 50 and 100 mg) (WHO 1999). Whereas the 600 mg dose
prevented all the expected pregnancies, the lower doses prevented only 85% and the
most likely explanation is the reduced 'endometrial contraceptive' effect with lower
doses. Other studies have since confirmed contraceptive efficacy of 200 (Ashok,
Wagaarachchi et al. 2001) and 10 (Hamoda, Ashok et al. 2004) mg administered
within 120 hours ofunprotected intercourse.
8. Endometrial effects ofmifepristone
A variety of endometrial effects have been reported depending on study methodology
and background endocrine milieu at time of administration. These include proliferative
(oestrogen-like), anti-proliferative (anti-oestrogen) and secretory (progesterone-like)
effects.
8.1 Effects on proliferation and histology
Following long-term administration of mifepristone, primate endometrium undergoes
severe atrophy (Chillik, Hsiu et al. 1986; Koering, Healy et al. 1986; Wolf, Hsiu et al.
1989; Neulen, Williams et al. 1996; Slayden, Zelinski-Wooten et al. 1998) whereas the
characteristic finding in pre-menopausal human endometrial samples following low-
dose mifepristone treatment is a proliferative histology and marked reduction in
cellular proliferation (Baird, Brown et al. 2003).
Endometrial histology following 60 and 120 days of treatment is summarised in Table
1.5 (Baird, Brown et al. 2003).
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2mg 24 proliferative 20 proliferative 15 proliferative
2 not assessable 5 cystic dilatation/inactive 9 cystic dilatation/inactive
1 not assessable 2 not assessable
5mg 23 proliferative 10 proliferative 12 proliferative
1 not assessable 10 cystic dilatation/inactive 9 cystic dilatation/inactive
1 complex hyperplasia 1 secretory
1 menstrual type 2 not assessable
2 not assessable
Shanghai
2mg 14 proliferative 15 proliferative 10 proliferative
6 not assessable 1 cystic dilatation/inactive 2 cystic dilatation/inactive
1 menstrual type 1 secretory
1 secretory 1 menstrual
2 not assessable 6 not assessable
5mg 16 proliferative 13 proliferative 11 proliferative
6 not assessable 1 menstrual type 1 cystic dilatation/inactive
5 not assessable 1 secretory
7 not assessable
Work carried out in the 1930s (Allen. 1929; Markee 1940)) established that ovarian
steroids, oestradiol (E2) and progesterone (P4), were responsible for the changes in
endometrial structure and function throughout the menstrual cycle. The majority of
circulating oestrogen is derived from developing ovarian follicles and the remainder
from extra-ovarian aromatisation of adrenal precursors. Unopposed oestrogen in the
follicular phase of the cycle induces proliferative changes in the endometrium.
Following ovulation, progesterone secreted by the corpus luteum induces secretory
changes that make the uterus receptive to implantation. Endometrial shedding
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(menstruation) is initiated by the fall in concentration of progesterone that follows
luteal regression.
The degree of ovarian suppression following long-term mifepristone treatment is dose-
dependent. Ovarian suppression is also clearly related to the level of background
ovarian activity at the start of administration (Brown, Cheng et al. 2002). Chinese
subjects had lower baseline ovarian activity (lower E2) compared to the Edinburgh
subjects (Brown, Cheng et al. 2002). Following mifepristone administration, the
Chinese subjects showed a significant fall in E2 levels whereas the Edinburgh subjects
continued to secrete oestrogen in the mid-follicular range (Brown, Cheng et al. 2002)
Hyperplastic changes
A functional blockade of progesterone following administration ofmifepristone raises
concerns of risk of endometrial hyperplasia and pre-malignant changes secondary to
effect of prolonged unopposed oestrogen. The risk appears to be largely dose-
dependent.
In women, following high doses of mifepristone (50 mg/day for 6 months) variable
effects such as atypical cystic changes have been described in endometrium (Murphy,
Kettel et al. 1995). The endometrium demonstrated numerous mitotic figures;
however, was no conclusive evidence of atypical hyperplasia. Endometrial polyps
(Martineau and Levental 2000; Grunberg, Weiss et al. 2006) and hyperplasia
(Grunberg, Weiss et al. 1991; Grunberg 1994; Newfield, Spitz et al. 2001; Grunberg,
Weiss et al. 2006) have been reported following long-term administration of high-dose
mifepristone for inoperable meninigiomas (200 mg/d) and intractable Cushing's
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syndrome (400 mg/d). There were no cases of atypia and the hyperplasia regressed on
cessation ofmifepristone treatment (Newfield, Spitz et al. 2001).
Hyperplastic endometrial effects have also been observed with lower doses of
mifepristone. Administration of lmg mifepristone daily for 150 days was associated
with increased endometrial thickness and dilated glands in 25 and 34% of the
monophasic cycles respectively (Croxatto, Kovacs et al. 1998). Our group reported a
significant increase in endometrial thickness (TVUSS) of the Edinburgh subjects by 60
days of mifepristone treatment whereas the Shanghai subjects showed a significant
decrease. The endometrii in both groups were histologically proliferative and a small
number of samples showed cystic dilatation (Baird, Brown et al. 2003). Endometrial
thickness determined by ultrasound examination correlates poorly to histology-defined
proliferation as it may also represent tissue oedema, fluid collection or benign stromal
thickening (Fleischer, Wheeler et al. 1999; Mourits, Van der Zee et al. 1999; Liedman,
Lindahl et al. 2000). One Edinburgh subject in the 5-mg group showed features of
complex hyperplasia after 60 d of treatment, but after 120 days this subject's
endometrium had become inactive. No cases showed any evidence of cytological
atypia (Baird, Brown et al. 2003).
A high incidence of simple endometrial hyperplasia (28%) was observed in women
receiving 5 or 10 mg mifepristone daily for 6 months, for the treatment of symptomatic
leiomyoma (Eisinger et al., 2003). Data from this study have since been re-evaluated
(Steinauer, Pritts et al. 2004) and the authors (Eisinger, Bonfiglio et al. 2005) have now
reported a longer follow-up. Simple hyperplasia was seen in 13.9 % at 6 months and
4.8 % at 12 months. All cases of hyperplasia occurred in the 10 mg group. No
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endometrial sample showed cytologic atypia. The same group have now reported a
further study of 52 subjects with symptomatic leiomyoma treated with mifepristone 5
mg daily for 26 weeks (Fiscella, Eisinger et al. 2006). There were no cases of
endometrial hyperplasia.
The precise mechanism for these hyperplastic effects on the endometrium remains
unknown. Mifepristone does not bind to ER (Philibert 1984; Zou, Marschke et al.
1999). High-dose mifepristone stimulates the HPA axis and there is an increase in
ACTH and Cortisol. On occasion this is accompanied by elevation of androstenedione,
oestrone, testosterone and oestradiol (Lamberts, Koper et al. 1991; Heikinheimo, Ranta
et al. 1997; Heikinheimo, Ranta et al. 2000). It is thus possible that endometrial
aromatization of these adrenal androgens may enhance the estrogen milieu locally.
However, recent studies have shown that mifepristone inhibits aromatase induction in
human breast adipose tissue (Schmidt and Loffler 1997) and blocks
medroxyprogesterone acetate-induced aromatase activity in endometrial stromal cells
(Tseng, Mazella et al. 1986). Continuous administration of mifepristone in daily doses
of 10 mg and below are not associated with increases in Cortisol (Croxatto, Salvatierra
et al. 1993). Hence the endometrial effects noted with these doses are not related to
aromatization but could be a consequence of an unopposed oestradiol effect on the
endometrium. Other explanations relate to the effects of the ER and PR isoforms. FJRji
is anti-proliferative in several models (Weihua, Saji et al. 2000) and often functions as
a transdominant repressor of ERa transcriptional activity (Hall and McDonnell 1999).
Mifepristone can act as a potent ER(3 antagonist (Zou, Marschke et al. 1999) and post-
transcriptional effects of unopposed ERa could explain the observed oestrogenic
effects. Mulac-Jericevic et al.(Mulac-Jericevic, Mullinax et al. 2000) have shown that
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selective ablation of PR-A results in a gain of progesterone-dependent proliferative
activity mediated through PR-B. PR-B increases whereas PR-A diminishes oestradiol
responsiveness in the uterus. The precise effect on the endometrium may thus be
dependent on the ratio of the different isoforms ofER and PR.
Anti-proliferative effects
Despite the mixed histopathological reports, at a cellular level, anti-proliferative effects
have been reported in both animal (van Uem, Hsiu et al. 1989; Wolf, Hsiu et al. 1989;
Hodgen, van Uem et al. 1994; Katkam, Gopalkrishnan et al. 1995; Zelinski-Wooten,
Slayden et al. 1998) and human (Croxatto, Salvatierra et al. 1993; Cameron, Critchley
et al. 1996; Croxatto, Kovacs et al. 1998) studies. Mifepristone does not bind to ER
and the mechanism of this anti-proliferative effect, first described in 1989 as "non¬
competitive anti-estrogenic effect" (Wolf, Hsiu et al. 1989), remains largely
unexplained. Several hypotheses which have been formulated to account for these
observations include inhibition of the oestrogen receptor gene transcription by the PR-
A isoform (McDonnell and Goldman 1994), reduced endometrial blood supply due to
atrophy of spiral arteries (Chwalisz, Brenner et al. 2000), blockade of progesterone-
dependent growth factors (Koji et al., 1994), inhibition of angiogenesis (Greb,
Heikinheimo et al. 1997; Grow, Reece et al. 1998), apoptosis modulation via growth
factors such as NKkB (Slayden, Hirst et al. 1993; Han and Sidell 2003), cell cycle
blockade (Cameron, Critchley et al. 1996; Heikinheimo, Hsiu et al. 1996) and anti¬
oxidant effect ofmifepristone (Parthasarathy, Morales et al. 1994).
More recently, a role for endometrial AR has been proposed based on robust data in
primate and human studies (Brenner, Slayden et al. 2002; Brenner, Slayden et al.
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2003). Exogenous and endogenous androgens can suppress oestrogen-induced
endometrial proliferation (Futterweit and Deligdisch 1986; Miller, Bedard et al. 1986;
Rose, Dowsett et al. 1988; Tanaka, Umesaki et al. 1999) and androstenedione can
inhibit human endometrial cell growth and secretory activity in vitro (Tuckerman,
Okon et al. 2000). A recent study in postmenopausal women confirmed the anti-
oestrogen, anti-proliferative effects of testosterone (Zang, Sahlin et al. 2007).
Administration of mifepristone is associated with an increase in AR (Slayden, Nayak
et al. 2001) and increase androgen-AR transcription can mediate these anti¬
proliferative. Further evidence of the role played by androgens in this anti-proliferative
effect is the observation that the pure anti-androgen, flutamide, blocks the anti¬
proliferative effects of the progesterone receptor antagonists (PRA) ZK137316 and
ZK230211 in the endometrium (Slayden and Brenner 2003). Flutamide also blocked
the hyalinizing degeneration of the spiral arteries induced by PRA (Slayden and
Brenner 2003). Endometrial parameters (mean + sem) from this study are reported in
Table 1.6.
Table 1.6: Primate flutamide study - endometrial parameters.
E2 E2 + PRA E2 + PRA + Flutamide
Weight (mg) 360 ± 32 64+ 10a 265 ± 92
Thickness (mm) 3.3 + 0.4 1.1 ±0.3a 2.2 + 0.6
Stromal Compaction 45.5 + 3.4 142.3 + 63.7a 54.9 + 4.6
Mitotic Index 6.3 + 0.6 0.3 + 0.3a 5.2 + 3.8
a=P<0.05 compared to other values in the same row
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The role of AR in E2-induced epithelial cellular proliferation was investigated in the
immature rat uterus (Weihua, Ekman et al. 2002). The authors propose a pathway in
which, in response to E2, there is sequential activation ofERa followed by elevation of
the levels of AR, increased IGF-1 (insulin growth factor 1) secretion, and epithelial
cellular proliferation. When administered together with E2, flutamide significantly
inhibited E2-induced proliferation of the luminal epithelium (Weihua, Ekman et al.
2002).
There is no data on the anti-proliferative effects of long-term (>30 days) mifepristone
administration. Cellular proliferation in paraffin embedded mifepristone-treated
endometrial samples has been previously assessed by direct counting ofmitotic cells in
H&E section (Baird, Brown et al. 2003) and immunohistochemistry for proliferating
cell nuclear antigen (PCNA) (Cameron, Critchley et al. 1996) and Ki67 (Cameron,
Critchley et al. 1996; Baird, Brown et al. 2003) proteins. There was a significant
reduction in mitotic count and Ki67 expression (Baird, Brown et al. 2003). Because
Ki67 protein is expressed during several phases of the cell cycle, e.g., Gl, S, G2 and
M, counts of Ki67 positive nuclei in paraffin sections are numerically greater than
mitotic counts, though the Ki67 is usually well correlated with the mitotic index
(Gerdes, Lemke et al. 1984; Endl and Gerdes 2000). Mifepristone may block
completion of the cell cycle at G2-M interphase (Heikinheimo, Hsiu et al. 1996) so
that Ki67 protein persists for some time after cell division has been arrested. Therefore
Ki67 counts may fail to reveal the impact of mifepristone treatment on suppression of
oestrogen-dependent proliferation (Cameron, Critchley et al. 1996). Direct counting of
mitotic cells in H&E section is time-consuming process that requires highly skilled
observers (Hall and Levison 1990). A new marker of phosphorylated proteins
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associated with mitosis, phospho-histone H3 (pH3) has been validated in paraffin
embedded endometrial tissues and shows an excellent correlation with the mitotic
count (Brenner, Slayden et al. 2003). This marker which directly assesses current
status of cellular mitosis has not been used to investigate proliferation in mifepristone-
treated endometrial samples.
8.2 Expression of endometrial sex steroid receptors
Steroid receptor expression across the menstrual cycle
Steroids interact with their target organs via specific nuclear receptors. The expression
of endometrial sex steroid receptors (PR, ER, AR), all of which are nuclear proteins,
varies both temporally and spatially across the menstrual cycle (Garcia, Bouchard et al.
1988; Lessey, Killam et al. 1988; Snijders, de Goeij et al. 1992; Critchley, Brenner et
al. 2001; Slayden, Nayak et al. 2001). The expression of ER and PR are under dual
control of oestrogen and progesterone. Both endometrial ER and PR are up-regulated
during the follicular phase by oestrogen and subsequently down-regulated in the luteal
phase by progesterone acting at both the transcriptional and the post-transcriptional
levels (Chauchereau, Savouret et al. 1992). The cyclical changes are mostly limited to
the superficial layers of the endometrium, whereas stroma and glands of the basal layer
express ER and PR throughout the cycle.
AR is expressed predominantly in the endometrial stroma, and there is considerably
higher intensity ofAR expression during the follicular as compared to the luteal phase
(Slayden, Nayak et al. 2001). It is absent from the glandular and luminal
compartments.
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GR is expressed in the fibroblasts, lymphocytes and endothelial cells of the human
endometrial stroma. It is absent from the glandular and luminal compartments
(Bamberger, Milde-Langosch et al. 2001). These findings have been validated by co-
localisation ofGR using western blot analysis and immunohistochemistry.
Steroid receptor expression after mifepristone treatment
Short term treatment with PR antagonist, either during the menstrual cycle, or with
combined oestrogen therapy, leads to elevations of the two main uterine steroid
receptors, ER and PR (Neulen, Williams et al. 1990; Slayden and Brenner 1994;
Cameron, Critchley et al. 1996; Slayden, Zelinski-Wooten et al. 1998). Similar
observation has been reported following administration in the early luteal phase
(Maentausta, Svalander et al. 1993; Cameron, Critchley et al. 1996). This follows a
blockage ofprogesterone-induced down-regulation of these proteins.
ER and PR expression following chronic treatment has been shown to be increased,
decreased or unchanged depending on the dose and duration of treatment (Murphy,
Kettel et al. 1993; Murphy, Kettel et al. 1995; Danielsson, Swahn et al. 1997; Slayden,
Zelinski-Wooten et al. 1998). However, there is no data on steroid receptor expression
following administration of low-dose mifepristone for more than 30 days. GR
expression has not been investigated in mifepristone treated samples.
9. Effect on vagina
The data on effects of mifepristone on the vagina is limited to primate studies.
Mifepristone exhibits tissue specificity with significant endometrial effects in both
animal and human studies and a lack of any discernable effect on oviduct (Slayden,
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Hirst et al. 1993; Brenner and Slayden 1994; Slayden and Brenner 1994) and vagina
(Grow, Williams et al. 1996).
The state of the vaginal micro-environment affects a woman's risk of human immuno¬
deficiency virus (HIV) transmission. Several human and non-human primate studies
have shown long-acting progestagen treatment increases the transmission of HIV
(Rehle, Brinkmann et al. 1992; Ungchusak, Rehle et al. 1996; Nagachinta, Duerr et al.
1997), simian immuno-deficiency virus (SIV) (Marx, Spira et al. 1996), and other
sexually transmitted infections (STI's) (Morrison, Bright et al. 2004; MacLean 2005).
The underlying mechanisms are poorly understood. Experiments on hysterectomised
rhesus monkeys suggest that the vagina, rather than the cervix or uterus, is the main
portal ofviral entry (Miller, Alexander et al. 1992; Miller 1998).
The mechanisms by which existing contraceptive could affect HIV/STD transmission
through vagina remain obscure. Epithelial thickness and integrity modulate the ease of
access of virus to immune cells and sub-epithelial vasculature (Mingjia and Short
2002). Oestrogen-induced surface keratinisation and hyperplasia protects Rhesus
monkeys against SIV inoculation (Smith, Baskin et al. 2000; Smith, Mefford et al.
2004), whereas oestrogen-deficient women such as those who are post-menopausal
(HTVStudyGroup 1992; Aaby, Ariyoshi et al. 1996) or on long-acting gestagens, are at
increased risk ofHIV, presumably as a result of vaginal thinning.
Although SIV has been shown to cross intact vaginal epithelium of rhesus macaques
(Marx, Spira et al. 1996), progesterone treatment enhances SIV vaginal transmission
by causing profound vaginal atrophy (Marx, Spira et al. 1996; Hild-Petito, Veazey et
al. 1998). Hormonal contraception does not have similar effects on human vaginal
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thickness (Mauck 1998; Bahamondes, Trevisan et al. 2000; Eschenbach, Patton et al.
2000; Miller, Patton et al. 2000) despite significant fall in oestradiol levels (Miller,
Patton et al. 2000).
Vaginal epithelial thickness is regulated by the levels of circulating oestrogen.
Epithelial thickness is maximal at time of ovulation (Sjoberg, Cajander et al. 1988;
Ma, Lu et al. 2001; Farage and Maibach 2006) and decreases in the luteal phase and
post-menopause (Farage and Maibach 2006). The response of human vaginal
epithelium to progestagen-induced hypo-oestrogenism is variable. A small but
significant decrease (10 %) in thickness has been demonstrated in one study
(Ildgruben, Sjoberg et al. 2005) whereas most other studies have demonstrated no
change (Mauck, Callahan et al. 1999; Bahamondes, Trevisan et al. 2000).
Paradoxically, vaginal epithelial hyperplasia has been reported in users of depot
medroxyprogesterone acetate (DMPA), oral contraceptive pill and progesterone
implants (Ildgruben, Sjoberg et al. 2003).
Besides epithelial thickness and integrity, other biological variables such as vaginal
microflora (Klebanoff and Coombs 1991; Klebanoff, Hillier et al. 1991; Martin,
Richardson et al. 1999), immune cell populations (Spira, Marx et al. 1996; Hu,
Gardner et al. 2000) and natural anti-microbials (Draper, Landers et al. 2000; Pillay,
Coutsoudis et al. 2001; King, Critchley et al. 2003) also play an important role in
innate defences of the reproductive tract.
The two major families of natural anti-microbials are defensins and whey acidic
protein (WAP) motif containing proteins (King, Critchley et al. 2003). Secretory
leukocyte protease inhibitor (SLPI) is aWAP motif containing protein which is present
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at mucosal surfaces, where it regulates proteolytic enzymes during inflammatory
events. In addition to inhibiting several serine proteases, SLPI has antimicrobial
actions and acts as component of the innate immune system to protect epithelial
surfaces from infection. The role of natural anti-microbial molecules in the acquisition
of STI's has not been fully established. Levels of SLPI in vaginal fluid collected from
posterior fornix are decreased in women with lower genital tract infection (Draper,
Landers et al. 2000) and it has been suggested that high concentrations of SLPI in
vaginal fluid and saliva may limit the spread of HTV during vaginal delivery (Pillay,
Coutsoudis et al. 2001) and breast-feeding (McNeely, Dealy et al. 1995; Farquhar,
VanCott et al. 2002). Endogenous and exogenous sex-steroid hormones, in the form of
a combined oral contraceptive or levonorgestrel intrauterine system have been shown
to influence gene transcription of SLPI and other natural anti-microbials in the
endometrium (Fleming, King et al. 2003). Although SLPI has been identified in
vaginal fluid, its localisation and role within the vaginal epithelium has not been
studied.
The effect of low-dose mifepristone on the human vaginal morphology, steroid
receptor and SLPI content and distribution has never been characterised.
10. Effects on menstrual physiology
Regular menstrual bleeding is the outwardly manifestation of cyclical ovarian function.
Following puberty the average woman in developed countries may expect to
menstruate over 400 times until the ovaries fail at the time ofmenopause. In contrast,
in less well developed countries and in previous centuries, the majority ofwomen were
amenorrhoeic throughout most of their lives due to late puberty, pregnancy and
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prolonged lactation (Short 1984). In both women and primates, long-term
administration is associated with a reduction of menstrual bleeding and amenorrhea.
Although the amenorrhea is clearly related to degree of ovarian suppression, the
majority of women who have incomplete ovarian suppression or sporadic ovulatory
episodes report amenorrhea. It is possible that direct endometrial effects contribute
significantly to the causation of mifepristone-induced amenorrhea. The association
between dose, ovarian activity and vaginal bleeding pattern is reported in Table 1.7
(Brown, Cheng et al. 2002).
Table 1.7: Low-dose mifepristone for 120 days - degree of ovarian suppression
and amenorrhea









n(%) n (%) n (%) n n (%)
Edinburgh
2 mg 5(19) 9(35) 12 (46) 10 17(65)
5 nig 9(37) 10 (42) 5(21) 5 21 (88)
Shanghai
2 mg 12 (60) 7(35) 1(5) 2 18(90)
5 mg 14 (70) 3(15) 3(15) 1 18(90)
Many women discontinue oestrogen-free progestogen-only contraception due to
unpredictable vaginal bleeding. The mechanisms underlying these disturbances are still
poorly understood and this has prompted gradually escalating effort to study all aspects
of the clinical problem (Fraser and Hickey 2000). The activity and expression of a
number ofmolecular systems has been shown to be altered in endometrium exposed to
52
prolonged progestagen treatment, however, it is not clear how these changes link
together.
The endometrial histological response to progestogen treatment depends on the type
and dose ofprogestogen and on the degree of suppression of ovarian activity, and will
vary between individuals exposed to the same progestogen regimen and over time. The
correlation between histology and menstrual bleeding pattern is poor except for severe
atrophy which typically predicts amenorrhea. Endometrial angiogenesis has been the
focus of ongoing research in endometrium exposed to long-term progestagen
treatment. An increase in vascular density has been reported in following long-term
progestagen treatment (Hickey, Simbar et al. 1999) and density was shown to be
increased in atrophic endometrium compared to other histological patterns (Hickey,
Simbar et al. 1999). We have reported a proliferative histology (Baird, Brown et al.
2003) and high degree of amenorrhea (Brown, Cheng et al. 2002) on long-term anti-
progestogen treatment. This provides a unique opportunity to correlate histology,
angiogenesis and bleeding patterns.
Endothelial cells are difficult to distinguish morphologically and
immunohistochemistry staining is more sensitive than histology (Blackwell and Fraser
1988). Although there are numerous markers, no single marker can guarantee
identification of all endothelial cells under all circumstances. CD34 is a glycosylated
transmembrane glycoprotein expressed on the surface of hematopoietic stem cells and
stromal cells, which binds to vascular endothelium, particularly on the membrane
processes that interdigitate between endothelial cells (Stella, Cazzola et al. 1995). In
most tissues, CD34 is expressed in endothelial cells of both large and small vessels,
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including capillaries (Traweek, Kandalafit et al. 1991). However, CD34 has the
disadvantage that it may also stain vascular basement membrane and connective tissue
(Rees, Heryet et al. 1993). Also, CD34 may fail to identify larger endometrial vessels
(Fina, Molgaard et al. 1990; Song, Markham et al. 1995). An alternative marker is
platelet-endothelial cell adhesion molecule (PECAM, or CD31), expressed on
endometrial endothelial cells, mainly at intercellular junctions. CD31 is more precise
than CD34, vWF, and CD36 in identifying endometrial endothelial cells using
immunostaining (Rees, Heryet et al. 1993).
Vascular density is reported as number of vessels per unit area of endometrium.
Density has been shown to increase following long-term progestogen-induced
endometrial atrophy (Hickey, Simbar et al. 1999), whereas, a previous study by the
same group had reported a very small increase or no change following conditions of
spontaneous or induced endometrial atrophy (Hickey, Lau et al. 1996). In paraffin
embedded samples, it is not possible to distinguish between an increase in the total
number of endometrial vessels and an increase in their tortuosity because of stromal
and glandular regression. If vessels lengthen in atrophic endometrium, they may
become more tortuous and thus appear to be denser in a small biopsy sample. Most
studies have failed to correct the vascular density for changes in the stromal density
and glands.
Locally produced vasoactive substances probably play a key role in regulating
endometrial angiogenesis, although, these are influenced substantially by different
dosage regimens and routes of administration of contraceptive steroids (Smith 2001).
Vascular endothelial growth factor (VEGF), a key angiogenic factor, promotes
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microvascular endothelial cell proliferation, migration and assembly into new vessels
(Ferrara and Davis-Smyth 1997). Oestrogen promotes angiogenesis by regulating the
expression ofVEGF (Albrecht, Babischkin et al. 2003). The role of glucocorticoids in
modulating vascular function has been investigated. Prostaglandins influence
contractility of endometrial vessels and their permeability (Albrecht, Babischkin et al.
2003). An increase in the local concentration of prostaglandins in the endometrium is
involved in the mechanism of mifepristone-induced vaginal bleeding in the luteal
phase (Hapangama, Critchley et al. 2002). Glucocorticoids modulate prostaglandin
production in endometrial stromal cells and fibroblasts (Pakrasi, Cheng et al. 1983;
Schatz, Markiewicz et al. 1986; Neulen, Zahradnik et al. 1989; Delvin, Gagnon et al.
1990; Illouz, Boubli et al. 2000) and they may have an angiostatic role (Small, Hadoke
et al. 2005).
With clear health benefits of mifepristone-induced amenorrhea, especially to women
who suffer menstrual dysfunction, a better understanding of underlying endometrial
mechanisms can help in the development of techniques to treat or prevent the
unpredictable bleeding with existing and novel contraception.
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Chapter 2
ANTI-PROLIFERATIVE EFFECT OF MIFEPRISTONE
Mifepristone and other progesterone receptor antagonists exert anti-proliferative on
primate (van Uem, Hsiu et al. 1989; Wolf, Hsiu et al. 1989; Hodgen, van Uem et al.
1994; Katkam, Gopalkrishnan et al. 1995; Zelinski-Wooten, Slayden et al. 1998) and
human (Croxatto, Salvatierra et al. 1993; Cameron, Critchley et al. 1996; Croxatto,
Kovacs et al. 1998) endometrium. Since these compounds have virtually no affinity for
the oestrogen receptor, the mechanism of this 'no-competitive anti-oestrogenic
activity' (Wolf, Hsiu et al. 1989) remains largely unknown. Although various
hypotheses have been proposed, it is becoming increasingly clear that the androgen
receptor (AR) may mediate these effects.
AR is up-regulated in human endometrium following 21-30 days of low-dose
mifepristone treatment (Slayden, Nayak et al. 2001), but , there is no data on the
expression following long-term (> 30 days) treatment. The exact underlying
mechanism of AR up-regulation following mifepristone treatment is unknown,
however, endometrial samples from an-ovulatory PCOS women suggest an increase
secondary to unopposed oestrogen (Apparao, Lovely et al. 2002).
Endometrial samples were obtained from other studies (Cameron, Critchley et al.
1996; Brown, Cheng et al. 2002; Cameron, Glasier et al. 2003) and I carried out all the
laboratory work and data analysis.
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Aims & Objectives
The aim of the present study was
1. To investigate endometrial proliferation following treatment with low-dose
mifepristone using phospho-histone H3 mitosis marker.
2. To investigate steroid receptor content and distribution in women following
treatment with low-dose mifepristone.
3. To compare endometrial proliferation and steroid receptor expression in
mifepristone-treated samples with control groups whose endometrium was
exposed to unopposed oestrogen.
Material andMethods
Human endometrial samples were obtained from three different patient groups. The
local ethics committees (Institutional Review Board) approved each of the studies and
all the women provided written informed consent.
Mifepristone group:
A subset of 16 subjects who had paraffin-embedded endometrial tissue sufficient for
further analysis, were recruited at random from 58 volunteer subjects whose baseline
characteristics, endocrine and endometrial findings have been reported previously
(Brown, Cheng et al. 2002; Baird, Brown et al. 2003). Subjects were randomly
allocated to receive 2 and 5 mg of mifepristone daily for the 120 treatment days.
Subjects had a mean age of 30.5 years and a mean body mass index (BMI) of 24.5
kg/m2. Endometrial biopsies were collected using a Pipelle endometrial sampling
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device (Prodimed, Neuilly-en-Thelle, France) in the late follicular phase of the pre
treatment cycle (day 12), after 60 days ofmifepristone treatment and after 120 days of
treatment. Specimens were fixed in normal buffered formalin, processed and
embedded in paraffin wax.
Control groups:
Two groups of subjects whose endometria were exposed to unopposed oestrogen were
chosen as controls. Since unopposed oestrogen gives rise to 'persistent proliferative'
endometrium, the endometrium from these subjects could be compared with that of
subjects who remained an-ovulatory with mifepristone.
A group of subjects (n=6) with an-ovulatory polycystic ovarian syndrome (PCOS)
participating in a study (Cameron, Critchley et al. 1996) evaluating the effects of low
dose mifepristone on endometrial maturation and proliferation were recruited. Subjects
had a mean age of 25 years (range 23-38 years) and a mean BMI of 24.5 kg/m (range
18.7-27.6 kg/m2) and all had biochemical and ultrasound evidence of polycystic
ovaries. All women had an endometrial biopsy taken 21-23 days following a
progestogen-induced withdrawal bleed. The study design, endocrine and endometrial
findings have been reported (Cameron, Critchley et al. 1996)
A second group of postmenopausal subjects (1 year of amenorrhea or using hormone
replacement therapy for 2 years, n=5) participating in a study (Cameron, Glasier et al.
2003) evaluating effects of onapristone on postmenopausal endometrium were
recruited. Subjects had a mean age of 54.4 years (range 49-54 yrs) and a mean BMI of
26.6 Kg/m2 (range 20.9-33.8 Kg/m2). None of the women had used a hormone
preparation within the preceding six weeks. Women were instructed to take daily 2 mg
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17P oestradiol valerate (Schering UK, West Sussex) orally for 8 weeks (56 days).
Endometrial biopsy was performed in the 8th week of treatment (n=4). One subject
refused endometrial sampling. Endometrial histology was reported as proliferative in
all samples. The study design, endocrine and endometrial findings have been reported
(Cameron, Glasier et al. 2003).
Immunohistochemistry (EHC):
IHC was performed for the following proteins of interest: phospho-histone H3 (rabbit
anti-pH3: Upstate Biotechnology, Lake Placid NY), Oestrogen Receptor (mouse anti-
ER: Dako ER clone 1D5, Glostrup Denmark), Progesterone Receptor (mouse anti-PR:
Abbott-PR ICA, North Chicago, USA) and Androgen Receptor (mouse anti-AR: F39,
Biogenex). ER, PR, and AR IHC protocols followed those previously established in
our laboratory (Wang, Critchley et al. 1998; Critchley, Brenner et al. 2001; Slayden,
Nayak et al. 2001) whereas pH3 protocol followed that established by Brenner et al
(Brenner, Slayden et al. 2003).
All antibodies were mouse monoclonal except pH3 which was rabbit polyclonal. All
antibodies were tested individually at a range of dilutions and different antigen
retrieval conditions to determine the protocol which gave the least background and
highest specific staining (Table 2.1). Positive and negative controls were included and
in most cases the negative controls were performed by adding a matched IgG antibody
(mouse IgG, Sigma, Poole, Dorset, UK; rabbit IgG, Vector Laboratories,
Peterborough, UK) of the same species and same antibody concentration as the
primary antibody.
The generic IHC protocol was as follows:
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1. Preparation and rehydration of slides: 5pm paraffin embedded tissue sections
were dewaxed in Histoclear (National Diagnostics, UK), and rehydrated in
descending grades ofalcohol to distilled water (dH20).
2. Epitope retrieval: The tissue sections were subjected to epitope retrieval in a
pressure cooker (05 minutes) or microwave (10 minutes) using 0.01M Sodium
Citrate at ph 6 (Table 2.1) and were then allowed to cool for 20 minutes.
3. Endogenous peroxidise block: Endogenous peroxidase activity was quenched
by immersion in 3% hydrogen peroxide (BDH, Poole, UK) in methanol for 30
minutes at room temperature.
4. Avidin-Biotin block: For AR only, slides were incubated with avidin (Vector
Laboratories, Peterborough, UK) and biotin (Vector Laboratories,
Peterborough, UK) for 15 minutes each at room temperature.
5. Serum block: Non-specific binding of the primary antibody was blocked by
incubating the sections for 20 minutes at room temperature in a 1:5 dilution of
non-immune serum (Autogen Bioclear, Holly Ditch Farm, Wilts, UK) in buffer
containing 5% bovine serum albumin (BSA).
6. Primary antibody: Sections were incubated with primary and control
antibodies. The temperature and duration of incubation varied according to
protein of interest (pH3 = overnight at room temperature; ER and PR = 1 hour
at 37°C; AR = overnight at 4 °C).
7. Secondary antibody: The sections were incubated in biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK) in non-immune serum.
8. Detection system: Sections were incubated with avidin biotin peroxidase
complex (Vectastain HRP and Vectastain Elite PK 6101, Vector Laboratories,
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Peterborough, UK) for 30-60 minutes each at room temperature. The
peroxidase substrate 3,3 diamino-benzadine (DAB) (DAKO) was used as
chromogen.
9. Counterstain, dehydration and slide preparation: Sections were then
counterstained with haematoxylin, dehydrated in ascending grades of alcohol
to xylene and mounted using Pertex (Cellpath pic. Hemel Hampstead, UK).
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Semi-quantitative score: Location and intensity of immunostaining was measured
using a semi-quantitative scoring system. Sections were scored blind by two observers
(blind to study groups and to other's results). Immunostaining intensity and
distribution of epitopes in all tissue sections were assessed on an arbitrary four point
scale; 0 = no staining, 1 = mild staining, 2 = moderate staining, and 3 = intense
staining. This method of semi-quantitative scoring has been previously validated in our
laboratory (Wang, Critchley et al. 1998). A high correlation has been demonstrated
between objectively measured immunoreactivity (image analysis) and subjective semi¬
quantitative scoring of immunostaining patterns (Wang, Critchley et al. 1998).
Quantitative score: pH3 immunoexpression was assessed separately for glands and
stroma using image analysis. The system used a Carl Zeiss Axistop 2 microscope (x 40
objective) connected to a Macintosh G3 computer, using Openab 2.08 image analysis
software (Improvision, Coventry, UK). At least 12 fields of view were selected at
random from each tissue section. The glands and stroma from each digitised image
were interactively dissected. Using Openlab colour discrimination software, the total
number of pH3 expressing cells (brown product) and those not expressing pH3 (blue
hematoxylin) were measured separately for each digitised image. The number of pH3
expressing cells is reported as a percentage of total cells (brown and blue) per sample.
This method of image analysis has previously been described and validated in our
laboratories (Critchley, Kelly et al. 1996; Wang, Critchley et al. 1998).
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Statistical method:
Statistical analysis was performed using SPSS (SPSS, Inc., Chicago, IL, USA) and
Excel 2002 (Microsoft Corporation). Continuous data are expressed as mean with
standard errors and categorical data as median with range. Wilcoxon Signed Rank test
was used to analyse repeated measures of IHC scores on same subjects (treatment
versus pre-treatment) and the Mann-Whitney test was used to analyse independent
measures of IHC scores between mifepristone and PCO/PM groups. The risk of
spurious statistical results arising from multiple testing [4 statistical tests (2 repeated
measures, 2 independent measures) for each IHC protein per endometrial
compartment] was corrected for by using Bonferroni correction. The reported P value
is the unadjusted value; the bonferroni adjusted value is reported as Pb.
Results
Phospho-histone H3 mitosis marker (pFI3)
Mitotic activity as indicated by antibody to pH3 showed a highly significant decrease
(P<0.001) in the endometrium by day 60 of treatment (mean + sem - 0.89 + 0.14,
glands; 0.48 + 0.09, stroma) (Figure 2.1) as compared to pre-treatment proliferative
endometrium (mean + sem - 3.48 + 0.42, glands; 1.57 + 0.16, stroma) (Figure 2.2 a,
b). This decrease was demonstrable in both glands and stroma and was maintained at
120 days (mean + sem - 0.96 + 0.13, glands; 0.55 + 0.11, stroma) (Figure 2.2 c).
Endometrium from PCOS women showed higher mitotic activity in the glands (mean
+ sem - 4.72 + 0.74, P=0.168, NS) whereas post-menopausal (PM) women had a
significantly lower mitotic activity in the stroma (mean ± sem - 0.65 ±0.13, P=0.011,
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S) compared to proliferative day12 pre-treatment endometrium (Figure 2.1, 2.2 d). The
mitotic activity in the stromal compartment (PCO group mean + sem - 1.21 + 0.22)
and glands (PM group mean + sem - 2.00 + 0.55) were not significantly different to
proliferative samples.
Oestrogen receptor
There was no significant change in ER expression in surface epithelium, stroma and
glands (Pb=0.136) following treatment with mifepristone (Table 2.2; Figure 2.2 m, n,
o). There was no difference between women treated with 2 or 5 mg mifepristone. The
endometrium in both the control groups demonstrated strong ER staining in all three
endometrial compartments (Figure 2.2 p). This pattern was similar to that seen in day
12 pre-treatment proliferative phase samples.
Progesterone receptor
There was a reduction in PR expression in surface epithelium, glands and stroma by
day 60, which was maintained at 120 days (Table 2.3; Figure 2.2 i, j, k). There was no
difference between women treated with 2 or 5 mg mifepristone. There was strong PR
staining in all three endometrial compartments, surface epithelium, glands and stroma
in PCOS and postmenopausal groups (Figure 2.2 1). This pattern was similar to that
seen in day 12 pre-treatment proliferative phase samples.
Androgen receptor
Pre-treatment proliferative phase endometrium showed a strong expression of AR in
the stroma and minimal or absent expression in glands and surface epithelium (Table
2.4, Figure 2.2 e). There was a significant increase in AR expression in surface
epithelium, glands and stroma following treatment with mifepristone compared to that
65
seen in the proliferative phase pre-treatment sample. This increase occurred as early as
60 days (P<0.05) (Figure 2.2 f) and was maintained at day 120 (Figure 2.2 g). The
increase was most marked in the glandular compartment where a virtual absence of
expression in the proliferative pre-treatment sample (Figure 2.2 e) was replaced by
intense immunostaining in post-treatment samples (P<0.01) (Figure 2.2 f, g). There
was no difference between women treated with 2 or 5 mg mifepristone. Endometrium
from PCOS and oestrogen treated post-menopausal women showed a strong AR
expression in the stroma with minimal expression in glands and surface epithelium
(Figure 2.2 h). This pattern was similar to that seen in day 12 pre-treatment
proliferative phase samples. Expression in glands was significantly greater in the post-
mifepristone treatment samples than samples from both PCOS and post-menopausal
groups (P<0.05).
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Figure 2.1: Percentage of endometrial cells immunostaining for phospho H3 in
glands (a) and stroma (b) before and after treatment with daily mifepristone;
comparison with control groups, Polycystic Ovary (PCO) and Postmenopausal
(PM). The values are expressed as median (horizontal bar), mean (square dot) and
box plots showing 50 % of values (box) with range (whiskers).
X - P<0.001, significant decrease, mifepristone day 60 & 120 treatment endometrium
versus day 12 pre-treatment (Wilcoxon Signed Rank Test)
Y - P=0.01, significant decrease, day 56 E2 treated postmenopausal endometrium
versus day 12 pre-treatment (Mann Whitney Test)
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We confirm the anti-proliferative effects of low-dose mifepristone with a new mitosis
marker, phospho-histone H3 along with a significant increase in glandular AR
expression. Our study shows for the first time that following prolonged treatment with
mifepristone (120 days), there is a significant down-regulation ofPR.
Endometrial effects
Complex histological effects have been reported in mifepristone-treated endometrium;
and these vary according to study methodology, the progesterone receptor antagonist
(PRA) ligand and background endocrine milieu. The characteristic finding in
endometrial samples following daily low-dose treatment is proliferative histology and
marked reduction in cellular proliferation (Baird, Brown et al. 2003). Even where
significant suppression of ovarian function and oestradiol production results in
endometrial atrophy, a small number of samples continue to show cystic changes
(Baird, Brown et al. 2003), thus suggesting that some of the observed endometrial
changes are native to dose and type of PRA ligand. Although sporadic incidence of
hyperplastic changes have been noted following low-dose treatment (Croxatto, Kovacs
et al. 1998; Baird, Brown et al. 2003), persistent changes have only been reported
following daily-doses >10 mg (Murphy, Kettel et al. 1995; Eisinger, Meldrum et al.
2003; Eisinger, Bonfiglio et al. 2005). Even when massive hyperplasia has been
reported following very high daily dose of 400 mg, there was no cytological atypia
(Newfield, Spitz et al. 2001). Our findings using pH3, a specific marker of mitosis,
confirm that at the doses tested there is no cellular evidence of endometrial
hyperplasia. Although a proportion of the endometrial samples show cystic dilatation,
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the glands were lined by atrophic inactive epithelium in contrast to the pseudo-
stratified appearance in typical cystic glandular hyperplasia (Baird, Brown et al. 2003).
One subject showed complex hyperplasia following 60 days of treatment (Baird,
Brown et al. 2003). Reassuringly, her endometrium regressed to an inactive state at
120 days.
Studies in animal models generally support data in human endometrial samples.
Although, oestrogenic effects have been observed in the rats receiving long-term PR
antagonist treatment (Rumpel, Michna et al. 1993; Bigsby and Young 1994), the non-
human primate endometrium demonstrates endometrial atrophy and evidence of anti¬
estrogenic activity (Chillik, Hsiu et al. 1986; Koering, Healy et al. 1986; Wolf, Hsiu et
al. 1989; Ishwad, Katkam et al. 1993; Neulen, Williams et al. 1996; Slayden, Zelinski-
Wootenetal. 1998).
Primate endometrium
The principal target for PRA in the primate endometrium is the spiral arteriole
(Slayden, Zelinski-Wooten et al. 1998) which traverses almost the full thickness of the
endometrium whereas in human tissue, terminates at the myometrial-endometrial
interface (Chwalisz, Brenner et al. 2000). The peri-arteriolar degeneration of primate
endometrial spiral arteries leading in turn to their atrophy during prolonged treatment
may specifically reduce blood flow in the superficial endometrial layer, producing a
nutritionally deprived endometrium that cannot respond to oestrogen. Another
mechanistic pathway in the primate model is profound suppression of VEGF
expression (Greb, Heikinheimo et al. 1997; Greb, Kiesel et al. 1999). We report a
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small decrease in stromal VEGF expression in endometrial samples following low-
dose mifepristone treatment (refer chapter 3).
Role of the androgen receptor
Exogenous and endogenous androgens can inhibit oestrogen-induced endometrial
proliferation (Futterweit and Deligdisch 1986; Miller, Bedard et al. 1986; Rose,
Dowsett et al. 1988; Tanaka, Umesaki et al. 1999; Tuckerman, Okon et al. 2000; Zang,
Sahlin et al. 2007).
The role of endometrial AR is not clear, but, stromal AR would mediate any possible
effects of normal levels of endogenous androgens. Although low-dose mifepristone
treatment does not modulate circulating androgen levels, it up-regulates AR in glands
and hence androgens could have direct effects on glands in addition to stroma. An
increase in AR levels in mifepristone treated tissues could lead to an increased binding
of androgens, which might antagonize the effects of estrogens on endometrial growth.
Treatment with flutamide, a pure anti-androgen, blocked the anti-proliferative effect of
the PR antagonist ZK 137 316 in the non-human primate thus adding strong support to
the hypothesis that this effect of PR antagonist is mediated through changes in AR
(Slayden and Brenner 2003). It is possible that mifepristone itself directly mediates
these effects by interacting with AR for which the relative binding affinity is 13%
(Elger, Bartley et al. 2000).
We report a lack/minimal glandular AR expression in proliferative phase control
endometrial samples and this agrees with other reports (Mertens, Heineman et al.
1996; Adesanya-Famuyiwa, Zhou et al. 1999; Slayden, Nayak et al. 2001). Salyen et al
confirmed this using ligand binding, immunohistochemistry and in-situ hybridisation
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on the same set of endometrii (Slayden, Nayak et al. 2001). They reported an increase
in endometrial AR, notably in the glandular compartment, after 21-24 days of low-
dose (2 mg/day) mifepristone (Slayden, Nayak et al. 2001). We report a sustained
increase in glandular AR expression at 30-40 days (chapter 4) and at 60 and 120 days
of low-dose mifepristone treatment (present study).
Mechanism ofAR up-regulation
The factors regulating the expression ofAR in the endometrium are not clear. Our
observations in post-menopausal women treated with oestrogen, and in women with
PCOS, are in keeping with reports in women and non-human primates that oestrogen
induces AR expression in the endometrium (Fujimoto, Nishigaki et al. 1995;
Slayden, Zelinski-Wooten et al. 1998; Slayden, Nayak et al. 2001). Increased AR
expression has been reported in both stroma and glands of endometrium from women
with PCO (Apparao, Lovely et al. 2002). The expression was higher in those with
persistent proliferative endometrium and may merely reflect the effect of prolonged
exposure to unopposed oestrogen. Although this probably contributes to the changes
in women treated with long term mifepristone, it is likely that the massive up-
regulation ofAR which occurs especially in the glands as early as 21 days after
starting treatment is a specific effect of the PR antagonist (Slayden, Nayak et al.
2001). In our study the endometrial biopsy, from women with PCO, collected 21
days after a progestagen induced menses, showed a small increase in AR expression
in glands and a similar observation was made in oestrogen-treated women.
ER and PR expression
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Short term treatment with PR antagonist, either during the menstrual cycle, or with
combined oestrogen therapy, leads to elevations of the two main uterine steroid
receptors, ER and PR (Neulen, Williams et al. 1990; Slayden and Brenner 1994;
Cameron, Critchley et al. 1996; Slayden, Zelinski-Wooten et al. 1998) whereas
expression following chronic treatment has been shown to be increased, decreased or
unchanged depending on the dose and duration of treatment (Murphy, Kettel et al.
1993; Murphy, Kettel et al. 1995; Danielsson, Swahn et al. 1997; Slayden, Zelinski-
Wooten et al. 1998). We have demonstrated a down-regulation of PR after 60 days
treatment. ER expression however remained unchanged in all endometrial
compartments. The mechanisms involved are poorly understood, but could result from
either chronic anti-mitotic activity (Heikinheimo, Hsiu et al. 1996) affecting cellular
protein synthesis or androgen-AR interactions.
PR-A is transcriptional repressor of PR-B and ER. Similarly ER(3 is a transcriptional
repressor of ERa (proliferative activity). Hence the ratio of ER and PR isoforms may
determine the balance of oestrogenic and anti-oestrogenic endometrial effects in
mifepristone treated samples. The ER antibody used in this study (Clone 1D5, Dako)
immunostains ERa and expression decreased in glands (P=NS), however was
unchanged in the stroma. We have investigated ER-isoform expression after 30-40
days of 5mg mifepristone daily (chapter 4). Both ERa and ERp were strongly
expressed in endometrium following 30-40 days of treatment; however there was no
pre-treatment control biopsy for comparison. More data is obviously needed, however,
it is unlikely that the observed endometrial changes which are reported within 21 days
of treatment, are secondary to a modulation of ER isoforms. The role of ER and PR




Women often discontinue oestrogen-free contraceptive methods such as progestogen-
only pill (POP) due to a high incidence of break through bleeding (Belsey and Farley
1988). In contrast the majority of women who take mifepristone have no periods and
many women now regard the absence of periods as a desirable side-benefit (Glasier,
Smith et al. 2003). The mechanism underlying these disturbances in endometrial
function is poorly understood and not clearly related to levels of endogenous or
exogenous steroid hormones (Fraser, Hickey et al. 1996).
Mifepristone-induced amenorrhea is clearly related to degree of ovarian suppression
(Brown, Cheng et al. 2002), but, a more direct modulation of vascular function cannot
be ruled out. Endometrial vascular function is regulated by locally produced vasoactive
substances such as VEGF and these are influenced substantially by different dosage
regimens and routes of administration of contraceptive steroids (Smith 2001).
Glucocorticoids are other potential modulators of angiogenesis and vascular function
either through direct angiostatic (Small, Hadoke et al. 2005) or indirect prostaglandin-
modulated (Pakrasi, Cheng et al. 1983; Schatz, Markiewicz et al. 1986; Neulen,
Zahradnik et al. 1989; Delvin, Gagnon et al. 1990; Illouz, Boubli et al. 2000; Albrecht,
Babischkin et al. 2003) mechanisms.
Endometrial samples were obtained from a previous study (Brown, Cheng et al. 2002)
and I carried out all the laboratory work and data analysis.
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Aims and Objectives
The aim of this study was
1. To investigate the effects of low-dose mifepristone on endometrial microvessel
density, VEGF and GR expression
2. To correlate endometrial microvessel density, VEGF, GR expression with
endometrial histology and bleeding patterns.
Material andMethods
A subset of 16 subjects who had paraffin-embedded endometrial tissue sufficient for
further analysis, were recruited at random from 58 volunteer subjects whose baseline
characteristics, endocrine and endometrial findings have been published previously
(Brown, Cheng et al. 2002; Baird, Brown et al. 2003). These 16 subjects were the same
subset as for study 1. The local ethics committees (Institutional Review Board)
approved the study and all subjects provided written informed consent. Subjects were
randomly allocated to receive 2 (n = 8) and 5 mg (n = 8) of mifepristone daily for the
120 treatment days. Subjects had a mean age of 30.5 years (range 24 to 40) and a mean
BMI of 24.5 kg/m2 (range 21 to 34). Endometrial biopsies were collected using a
Pipelle endometrial sampling device (Prodimed, Neuilly-en-Thelle, France) in the late
follicular phase of the pre treatment cycle (day 12), after 60 days of mifepristone
treatment and after 120 days of treatment. Specimens were fixed in normal buffered
formalin, processed and embedded in paraffin wax.
Immunohistochemistry (IHC):
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Immunohistochemistry was performed for the following proteins: Vascular Endothelial
Growth Factor (rabbit anti-VEGF: SantaCruz Biotechnology, California, USA), CD31
(mouse anti-CD31: Novacastra Laboratories, Newcastle upon Tyne, UK) and
Glucocorticoid Receptor (mouse anti-GR: Novocastra Laboratories, Newcastle upon
Tyne, UK). IHC protocols followed those previously published (Nayak, Critchley et al.
2000; Bamberger, Milde-Langosch et al. 2001).
All antibodies were mouse monoclonal except VEGF which was rabbit polyclonal and
antibodies were tested individually at a range of dilutions and different antigen
retrieval conditions to determine the protocol which gave the least background and
highest specific staining (Table 3.1). Positive and negative controls were included and
in most cases the negative controls were performed by adding a matched IgG antibody
(mouse IgG, Sigma, Poole, Dorset, UK; rabbit IgG, Vector Laboratories,
Peterborough, UK) of the same species and same antibody concentration as the
primary antibody.
The generic IFIC protocol was as follows:
1. Preparation and rehydration of slides: 5pm paraffin embedded tissue sections
were dewaxed in Histoclear (National Diagnostics, UK), and rehydrated in
descending grades of alcohol to distilled water (dH20).
2. Epitope retrieval: The tissue sections were subjected to epitope retrieval in a
pressure cooker (05 minutes) or microwave (10 minutes) using 0.01M Sodium
Citrate at ph 6 (Table 3.1) and were then allowed to cool for 20 minutes.
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3. Endogenous peroxidise block: Endogenous peroxidase activity was quenched
by immersion in 3% hydrogen peroxide (BDH, Poole, UK) in methanol for 30
minutes at room temperature.
4. Avidin-Biotin block: slides were incubated with avidin (Vector Laboratories,
Peterborough, UK) and biotin (Vector Laboratories, Peterborough, UK) for 15
minutes each at room temperature.
5. Serum block: Non-specific binding of the primary antibody was blocked by
incubating the sections for 20 minutes at room temperature in a 1:5 dilution of
non-immune serum (Autogen Bioclear, Holly Ditch Farm, Wilts, UK) in buffer
containing 5% bovine serum albumin (BSA).
6. Primary antibody: Sections were incubated at 4°C with primary and control
antibodies overnight.
7. Secondary antibody: The sections were incubated in biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK) in non-immune serum.
8. Detection system: Sections were incubated with avidin biotin peroxidase
complex (Vectastain HRP and Vectastain Elite PK 6101, Vector Laboratories,
Peterborough, UK) for 30-60 minutes each at room temperature. The
peroxidase substrate DAB (DAKO) was used as chromogen.
9. Counterstain, dehydration and slide preparation: Sections were then
counterstained with haematoxylin, dehydrated in ascending grades of alcohol
to xylene and mounted using Pertex (Cellpath pic. Hemel Hampstead, UK).
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Location and intensity of immunostaining was measured using a semi-quantitative
scoring system. Sections were scored blind by two observers (blind to study groups
and to other's results). Immunostaining intensity and distribution of epitopes in all
tissue sections were assessed on an arbitrary four point scale; 0 = no staining, 1 = mild
staining, 2 = moderate staining, and 3 = intense staining. This method of semi¬
quantitative scoring has been previously validated in our laboratory (Wang, Critchley
et al. 1998) and high correlation has been demonstrated between objectively measured
immunoreactivity (image analysis) and subjective semi-quantitative scoring of
immunostaining patterns (Wang, Critchley et al. 1998).
Vessel counts and Stromal density:
Vessel counts and stromal density were measured using image analysis. The system
used a Carl Zeiss Axistop 2 microscope (x 40 objective) connected to a Macintosh G3
computer, using Openab 2.08 image analysis software (Improvision, Coventry, UK).
At least 12 fields of view were selected at random from each tissue section at a
magnification of x 40. The glands and stroma from each digitised image were
interactively dissected.
All immunostained (brown) structures were considered positive and counted for each
digitised image, even if lumen was not identified. A similar methodology has been
described to study changes in vessel density following norplant use (Hickey, Simbar et
al. 1999). The results were averaged and expressed as vessels per square mm. Vessel
density was corrected for an increase in stromal density which subjectively appears to
be increased following mifepristone treatment (Baird, Brown et al. 2003; Baird, Brown
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et al. 2003). The total number of cells not expressing CD31 (blue hematoxylin) were
measured separately for each digitised image using Openlab colour discrimination
software and results are expressed as vessels per 1000 stromal nuclei. This method of
image analysis has previously been described and validated in our laboratories
(Critchley, Kelly et al. 1996; Wang, Critchley et al. 1998).
Stromal density was expressed as the total number of stromal nuclei (brown CD31 and
blue hematoxylin) per square millimetre ofendometrial tissue.
Statistical methods:
Statistical analysis was performed using SPSS (SPSS, Inc., Chicago, IL, USA) and
Excel 2002 (Microsoft Corporation). Continuous data are expressed as mean with
standard errors and categorical data as median with range. Wilcoxon Signed Rank test
was used to analyse repeated measures of IHC scores and stromal and vessel density
(treatment versus pre-treatment). The risk of spurious statistical results arising from
multiple testing [2 statistical tests for each IHC protein per endometrial compartment]
was corrected for by using Bonferroni correction. The reported P value is the
unadjusted value; the bonferroni adjusted value is reported as Pb.
Results
Endometrial histology, serum oestradiol and bleeding patterns
All 16 pre-treatment endometria were sampled in the proliferative phase. Following
treatment 9/16 endometria were still proliferative at 60 and 120 days respectively. 4
endometria showed cystic dilatation of the glands (Figure 3.2 e) and 5 inactive
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epithelium at 60 days and 120 days of treatment respectively. Serum oestradiol levels
remained in the mid-proliferative range following treatment (mean+sem- 511+70.21
pmol/1, pre-treatment; 459+90.94 pmol/1, mifepristone 60 days; 290+63.39 pmol/1,
mifepristone 120 days). There was no significant change in the level of oestradiol
following treatment (P>0.05, Bonferroni correction). 7/8 women on 2 mg mifepristone
and all 8 women on 5 mg of mifepristone were completely amenorrheic during
treatment. There was no significant difference (P>0.05, Mann-Whitney test) between
women treated with 2 or 5 mg mifepristone for any parameters studied except GR
expression in the vascular endothelium at 60 days of treatment [median (range) at 60
days = 3 (3), 2mg group; 2 (2-3), 5 mg group; P = 0.012, Bonferroni correction, Mann-
Whitney Test]. The 2 and 5 mg datasets are therefore combined and results reported
are for all 16 subjects.
Stromal density
An average of 0.5 (sem = 0.05) square millimetre of endometrial stroma was examined
in the pre-treatment samples and 0.37 (sem=0.04) square millimetres in the treatment
samples. Stromal density as expressed as nuclei per square millimetre of endometrial
tissue increased significantly (24 %) by day 60 of treatment (P<0.001) and the increase
(18%) was maintained at 120 days (P<0.05, Figure 3.1; mean + sem - 8057 + 355, pre-
treatment; 10003 + 355, day 60; 9510 + 351, day 120).
Microvessel density
Vessel density per square millimetre of endometrial tissue increased (47 %) by day 60
of treatment (P<0.01, Figure 3.1, Figure 3.2 b). This increase was highly significant
and was maintained (49%) at 120 days (P<0.01, Figure 3.2 c; mean + sem - 267 + 18,
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pre-treatment; 392 + 32, day 60; 398 ± 37, day 120). To compensate for an increase in
stromal density, microvessel density was calculated per total nuclei in each
endometrial sample. There was a modest (P=0.08, NS) increase (15 %) by day 60 and
a significant (P<0.01) increase (34 %) by day 120 of treatment (Figure 3.1, Figure 3.2
b, c; mean + sem - 33 + 1.9, pre-treatment; 38 + 2.1, day 60; 42 + 2.75, day 120.
VEGF
VEGF protein was strongly expressed in the cytoplasm of endometrial glands and
surface epithelium. Expression in the stroma was patchy and faint (Table 3.2, Figure
3.2 e). VEGF expression remained unchanged in the glandular [median (range) = 2(1-
3) pre-treatment, 1(1-3) day 60 and 1(0-2) day 120], surface epithelium [median
(range) = 1(0-3) pre-treatment, 1(0-3) day 60 and 1(0-2) day 120] and endothelial cells
[median (range) = 1(0-2) pre-treatment, 0.5(0-2) day 60 and 1(0-1) day 120] following
treatment with mifepristone. There was a small decrease (P<0.01) in stromal
expression [median (range) = 1(0-2) pre-treatment, 0(0-2) day 60 and 0(0-1) day 120]
ofVEGF following 120 days of treatment (Table 3.2, Figure 3.2 f, g).
GR
The proliferative phase pre-treatment endometrial samples showed strong
immunoexpression in the nuclei of stromal [median (range) = 2(0-3)] and endothelial
[median (range) = 3(1-3); Table 3.3, Figure 3.2 p] cells and a complete absence of
expression in the surface epithelium [median (range) = 0(0-0); Figure 3.2 i] and glands
[median (range) = 0(0-0); Table 3.3, Figure 3.2 i, j]. Following treatment with
mifepristone, nuclear immunoexpression was induced in glands [median (range) = 0(0-
2) day 60 and 1(0-2) day 120, P<0.05] and surface epithelium [median (range) = 1(0-3)
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day 60 and 1(1-3) day 120, PO.Ol]. This was evident by 60 days and maintained at
120 days (Table 3.3, Figure 3.2 k, 1, m, n). Immunoexpression in the stroma [median
(range) = 2(1-3) day 60 and 2(1-3) day 120] and endothelial cells [median (range) =
3(2-3) day 60 and 3(2-3) day 120; Figure 3.2 q, r] was unchanged.
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15000-1 a : stromal density (nuclei per sq mm)
750-| b: microvessel density (vessels per sq mm)
1"
c: microvessel density (vessels per 1000 nuclei)
Figure 3.1: Density of
endometrial stroma (a) and
microvessel (b, c) in women
before and after treatment
with mifepristone.
The values are expressed as
median (horizontal bar),
mean (square dot) and box
plots showing 50 % ofvalues
(box) with range (whiskers),
a - p<0.01, significant
increase, mifepristone day 60
& 120 treatment
endometrium versus day 12
pre-treatment (Wilcoxon
Signed Rank Test)
b - p <0.05, significant
increase, mifepristone day 60
& 120 treatment
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Mifepristone-induced amenorrhea has obvious health benefits. Investigation of
potential underlying mechanism shows an increase in glandular GR and microvessel
density and a decrease in stromal VEGF.
Endometrial histology and vascular density
Histological appearance of the endometrium does not correlate well with menstrual
patterns except the development of extreme histological atrophy, which typically
predicts amenorrhea. In the primate model, continuous mifepristone induces marked
endometrial atrophy and the spiral arteries are the primary targets that are damaged or
inhibited by progesterone antagonists like mifepristone (Chwalisz, Brenner et al.
2000). Microvessel density shows a variable increase in conditions of spontaneous
(post-menopausal) and induced (norplant, danazol and goserelin) endometrial atrophy
and the mechanisms involved may vary according to the nature of the atrophic
stimulus (Hickey, Lau et al. 1996; Hickey, Simbar et al. 1999). In women exposed to
high and medium dose progestogens and long-term users of levonorgestrel-releasing
intrauterine system (Mirena), a decrease in endometrial vascular density has been
observed (Song, Markham et al. 1995; Oliveira-Ribeiro, Petta et al. 2004). In the
present study over 90% women were amenorrhoeic. The endometrium was
proliferative and there was a significant increase in microvessel density. We used
CD31 to identify the vessels as preliminary studies with the alternate
immunohistochemical marker CD34 were unsatisfactory. The use of CD31 may
explain the discrepancy in the numerical count of vessels per area of endometrium
between our study and that by other investigators (Hickey, Lau et al. 1996; Lau,
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Affandi et al. 1999; Schindl, Birner et al. 2001). Moller et al used CD31 to identify
vessels in endometrial samples of 16 normally menstruating pre-menopausal women
and reported wide individual variation in vessel density (Moller, Rasmussen et al.
2001). There was no consistent variation over the menstrual cycle.
Vasoactive compounds
VEGF is a major regulator of endothelial cell proliferation, angiogenesis,
vasculogenesis and capillary hyperpermeability (Ferrara and Davis-Smyth 1997;
Ferrara 1999; Smith 2001). The presence of VEGF mRNA, protein and its receptors
has been demonstrated in the human and primate endometrium throughout the
menstrual cycle (Torry, Holt et al. 1996; Ferrara and Davis-Smyth 1997; Meduri,
Bausero et al. 2000; Nayak, Critchley et al. 2000; Moller, Lindblom et al. 2002; Nayak
and Brenner 2002; Sugino, Kashida et al. 2002). Proliferative endometrium
demonstrates prominent glandular immunoreactivity and faint, inconsistent staining in
stromal cells similar to observations in the present study (Sugino, Kashida et al. 2002).
Mifepristone abolished VEGF expression in the endometrial glandular epithelium of
cynomolgous monkeys (Greb, Heikinheimo et al. 1997) and this might represent a
mechanism for the suppression of angiogenesis and severe endometrial atrophy
observed following mifepristone treatment in the primate model. In the present study,
VEGF immunoexpression was significantly reduced in the stroma following
mifepristone treatment. There was a non-significant reduction in glandular
immunoexpression and microvessel density was significantly increased following
treatment. It has been suggested that VEGF may not be the primary regulator of
endothelial cell proliferation in the human endometrium (Gargett, Lederman et al.
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1999). Besides VEGF, other factors such as angiopoetin and fibroblast growth factor
also regulate endometrial angiogenesis (Smith 2001). VEGF regulates vascular
permeability and the decrease in stromal VEGF may explain the increase in stromal
density following treatment with mifepristone (Ferrara 1999; Ferrara 1999).
Role ofGR and glucocorticoids
The most striking observation in our study was the change in the expression ofGR and
its location. In the normal menstrual cycle GR is located only in the nuclei of
endometrial stromal and endovascular cells and is absent in the glands (Bamberger,
Milde-Langosch et al. 2001). In our study, the pre-treatment proliferative phase
samples showed a strong nuclear receptor expression in the stroma and a complete
absence in the glands and surface epithelium. Following treatment with low-dose
mifepristone, there was a significant induction of nuclear GR expression in both glands
and surface epithelium. Although the presence of GR has been reported in the luminal
(surface) epithelium of rat uterus (Korgun, Dohr et al. 2003) this is the first study to
report the presence of nuclear glucocorticoid receptors in endometrial gland cells.
Mifepristone binds strongly to GR and PR but more weakly to AR (Spitz and Bardin
1993) and we have shown (chapter 2) that chronic treatment with low-doses
mifepristone up regulates AR and down regulates PR in the endometrium (Narvekar,
Cameron et al. 2004). The underlying cellular mechanisms are poorly understood, but,
the striking temporo-spatial up-regulation of AR and GR in the glands and surface
epithelium suggest that they share common mechanistic pathways.
The exact physiological role of GR and glucocorticoids in the human endometrium is
not clear. The expression pattern points to a functional role in the complex process of
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decidualisation (Bamberger, Milde-Langosch et al. 2001). Several effects of
glucocorticoids on endometrial cells have been reported. Uterine events such as
menstruation, implantation, cervical softening and parturition share similarity with
non-reproductive inflammatory situations (Kelly 1996). At high concentrations,
glucocorticoids inhibit most immunological responses and are well-known anti¬
inflammatory agents. Prostaglandins have a pivotal role in menstruation and
endometrial bleeding (Baird, Cameron et al. 1996) and glucocorticoids have been
shown to suppress PGF2a production (Schatz, Markiewicz et al. 1986; Neulen,
Zahradnik et al. 1989; Delvin, Gagnon et al. 1990; Illouz, Boubli et al. 2000) and
phospholipase A2 (Pakrasi, Cheng et al. 1983), one of the enzymes considered to be
rate-limiting in generating free arachidonic acid for prostaglandin synthesis. An
increase in the local concentration of prostaglandins in the endometrium has been
postulated in the mechanism of bleeding observed following administration of single-
dose mifepristone in the mid-luteal phase (Hapangama, Critchley et al. 2002). The
expression ofGR in endothelial cells suggests a role for glucocorticoids in modulation
of angiogenesis in the endometrium as has been reported in the rat aorta (Small,
Hadoke et al. 2005). Endogenous and exogenous glucocorticoids, exert tonic inhibition
whereas treatment with a glucocorticoid receptor antagonist enhances angiogenesis in
the mice model (Small, Hadoke et al. 2005). An increase in GR expression could
potentate the effects of circulating glucocorticoids on the endometrium thereby
suppressing local prostaglandin concentrations and inhibiting angiogenesis. Contrary
to theoretical expectations, we have demonstrated a small increase in microvessel
density. This increase may represent a counting artefact in endometrial sections
following stromal compaction and gland dilatation. A better understanding of the role
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of glucocorticoids and androgens and their receptors in the endometrium is needed to
reconcile the different endometrial effects into a working hypothesis.
Glucocorticoids and fertility
Glucocorticoids may also modulate human fertility. Elevated levels of glucocorticoids
disrupt normal uterine development and implantation (Campbell 1978; Monheit and
Resnik 1981; Bigsby 1993; Hicks, Duran-Reyes et al. 1994). Mechanisms by which
glucocorticoids may influence implantation include their known effects on actin
polymerization, lysosomal activity, PG synthase, PGE nitric oxide synthase, and matrix
metalloproteinases (Salamonsen 1996), all of which have known roles in implantation.
Excess glucocorticoid exposure can disturb the normal pattern of growth and
differentiation of the primate fetus (Arcuri, Battistini et al. 1997). On the other hand,
Cortisol, may modulate local immunosuppressive activity within the decidua by
inhibiting the production of anti-inflammatory cytokines, such as IL-1 (Snyder and
Unanue 1982) thus protecting the developing blastocyst from maternal immune
rejection (Ricketts, Verhaeg et al. 1998). Although low-dose mifepristone is
contraceptive by inhibiting ovulation in up to 90% subjects (Brown, Cheng et al.
2002), an increase in surface (luminal) and glandular glucocorticoid receptor
expression may play a role in the endometrial anti-fertility effects ofmifepristone.
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Chapter 4
EFFECTS OF MIFEPRISTONE ON THE VAGINA
The state of the vaginal micro-environment affects a woman's risk of human immuno¬
deficiency virus (HIV) transmission. Oestrogen-induced surface keratinisation and
hyperplasia protects Rhesus monkeys against SIV inoculation, whereas oestrogen-
deficient women such as those who are post-menopausal or on long-acting progestagen
treatment, are at increased risk of HIV, presumably as a result of vaginal thinning.
Numerous other factors such as vaginal microflora, immune cell populations and
natural anti-microbials modulate innate defences of the reproductive tract.
The effects of hormonal contraception on vaginal defences to sexually-transmitted
infections have not been well investigated. The data on vaginal effects of mifepristone
is limited to a few primate studies.
I was fully involved in study design, recruitment and analysis of data. I recruited 5 out
of 8 subjects and carried out all the preliminary laboratory work on vaginal samples
which included methodology for vaginal thickness measurement, RNA extraction and
optimisation of immunohistochemistry protocols.
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Aims & Objectives
Since progestagen treatment increases and oestrogen treatment decreases HIV/SIV
transmission, the aim of the present study was to investigate whether the anti-
progestagen mifepristone modulates underlying mechanisms (vaginal morphology,
steroid receptor and natural anti-microbial [Secretory Leukocyte Protease Inhibitor
(SLPI)] which may modulate transmission.
Material andMethods
Study design: A single-centre, open, single-group study in female volunteers.
Subjects: Eight healthy subjects with mean age of 35 years (range 27-39 years), mean
body mass index (BMI) of 23 Kg/m2 (range 17.3 - 28.2 Kg/m2) and regular menstrual
cycles (25-42 days).
Inclusion criteria:
1. Women aged 18-40 inclusive.
2. Women with regular menstrual cycles.
3. Willing and able to take part in the study.
4. Prepared to use barrier contraception for the duration of the study, or those who
are sterilised or whose partner is sterilised.
5. Agree to refrain from vaginal medications during study period.
6. Agree to refrain from sexual intercourse 48 hours prior to vaginal biopsy.
7. Negative [3HCG test before commencing the study.
8. Written informed consent.
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Exclusion criteria:
1. Those who have used hormonal contraception in the past three months, or
depot hormones within six months of entering the trial.
2. Those who have breastfed in the past three months.
3. Abnormal vaginal discharge, clinically significant vaginitis, cervicitis.
4. Sexually transmitted diseases.
5. Those who have had an IUD in-situ in the past three months.
6. Long term use of any prescription drugs for a significant medical condition.
7. History of cervical intra-epithelial neoplasia (CIN).
8. History of cervical surgery which may make endometrial biopsy impossible.
9. Pregnancy.
10. Vaginal bleeding of unknown aetiology or inter-menstrual bleeding.
11. Other significant disease, e.g. Cardiovascular, renal or liver disease or
malignancy, sufficient to interfere with the evaluation of the study.
12. Clinically significant abnormal findings in the pre-entry laboratory screening
not related to the primary diagnosis or any other established or stable
conditions.
13. Chronic alcoholism, drug abuse or any other condition associated with poor
patient compliance.
14. Treatment with an investigational drug within one month of inclusion.
15. Current treatment with corticosteroids.
16. Known allergy to mifepristone.
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Ethical approval: The proposal was approved by the Local Ethical Committee
(Institutional Review Board). All subjects gave written informed consent.
Study visits: (Figure 4.1)
All subjects were screened before entering the study. Screening included a full
medical, gynaecological history and examination including measurement of height,
weight, blood pressure, and pulse. Blood samples were collected for measurement of
routine clinical chemistry and haematology (liver function tests, urea and electrolytes,
glucose, full blood count). (3HCG was measured to exclude pregnancy before entering
the trial. Subjects were studied for one pre-treatment cycle, one cycle of treatment
(approximately 33 days), and for one post-treatment cycle. Each subject was reviewed
on day 12 of the pre-treatment menstrual cycle (Visit 1), at the end of treatment (Visit
2), and on day 12 of the post-treatment menstrual cycle (Visit 3). Subjects were given a
menstrual record card and asked to record all vaginal bleeding. All women received
planned treatment for at least 5 days beyond expected date of menstruation (33 days)
so that any post-treatment vaginal bleeding was due to withdrawal of mifepristone
rather than a spontaneous menstruation.
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Assessment of ovarian function:
Ovarian function was monitored by measurement of ovarian steroids in urine and
plasma and by transvaginal sonography. All subjects collected twice-weekly samples
of early morning urine during the study period, starting in the early follicular phase
(day 1-5) of the pre-treatment cycle. Aliquots were frozen and stored at -20 C until
assayed for estrone glucuronide (EIG), pregnanediol glucuronide (PdG), and
creatinine (Cr). PdG was measured using a direct enzyme immunoassay, and EIG by
direct immunoassay. Ovarian follicular activity during treatment was compared with
that during follicular phase of the pre-treatment cycle and the activity was scored as
complete suppression, partial suppression and continued follicular activity. Ovulation
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was deemed to have occurred if the excretion of PdG exceeded 0.5 mmol/mol Cr and
was at least 3-fold higher than that in the preceding week. A detailed description of this
methodology is given in our previous report (Brown, Cheng et al. 2002). Blood
samples were collected at all study visits, and assayed for oestradiol (E2) and
progesterone (P4) using radioimmunoassay (RIA). Assay characteristics and
methodology have been described in our previous reports (Brown, Cheng et al. 2002).
A transvaginal ultrasound scan was carried out at all study visits and ovarian
dimensions, follicle number and diameter, and presence of ovarian cysts were
recorded.
Vaginal biopsy:
A full thickness vaginal biopsy was taken from the lateral vaginal wall 4 cm proximal
to the hymeneal ring on day 12 of the pre-treatment cycle (Visit 1) and again after
completion of treatment (Visit 2). 1 ampoule of Citanest with Octapressin (3%,
prilocaine hydrochloride 30 mg/mL, felypressin 0.03 unit/mL, Dentsply) was injected
into the lateral vaginal wall as a local anaesthetic and haemostatic agent. This also
elevated the target vaginal tissue sufficiently to permit easy access for a biopsy.
Vaginal biopsy was performed using a long Shumaker forceps. Vaginal tissues were
stored in RNAlater (Applied Ltd, Cambridgeshire, UK, RNAlater is an aqueous
storage reagent to stabilise and protect RNA) and neutral buffered formalin (NBF; for
future preparation of paraffin embedded tissue for immunohistochemistry). A second
biopsy was taken if adequate sample was not obtained with the first biopsy. Vaginal
bleeding from the biopsy site was controlled using either silver nitrate or ifnecessary a
vicryl 3-0 suture (Ethicon, UK), depending on the amount ofbleeding.
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An endometrial biopsy was collected using Pipelle endometrial sampler (Prodimed,
Neuilly-en-Thelle, France) at end of treatment (Visit 2), fixed in NBF, and embedded
in paraffin. Endo-cervical and posterior fornix swabs were collected at all study visits
to screen for infection which might influence the parameters studied in target vaginal
tissues.
Safety parmeters:
At each study visit, blood pressure and pulse were measured, and blood was taken for
measurement of routine clinical chemistry and haematology. In addition, each subject
was asked to report any health problems or adverse events that had occurred since the
last visit.
Vaginal thickness measurement:
Vaginal tissue samples were embedded in paraffin and serial 5pm sections were cut at
90 degree angle to the vaginal surface epithelial layers. The sections were stained with
haematoxylin and eosin and digital images were captured at 10 eyepiece magnification
using a Spot microscope connected to a Windows PC computer. Image Proplus 4.5
(Media Cybernetics, Silver Spring, USA) software was calibrated to match the
eyepiece used to capture the image. The surface and basement membrane of vaginal
epithelium was outlined using a trace tool within the software (Figure 4.2). The
software automatically calculated the average distance between the two traced outlines.
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Figure 4.2: Vaginal thickness measurement
Immunohistochemistry (IHC):
IHC was carried out on both the vaginal and endometrial biopsies for the following
proteins of interest: oestrogen receptor alpha (mouse anti-ERa: Novocastra, Newcastle-
upon-Tyne, UK), oestrogen receptor beta (mouse anti-ERfi: Serotec, Oxford, UK),
progesterone receptor (mouse anti-PR: Novocastra, Newcastle-upon-Tyne, UK),
androgen receptor (rabbit anti-AR: Santa Cruz Biotechnology Inc., Santa Cruz,
California, USA), phospho-histone H3 (rabbit anti-pH3: Upstate Biotechnology, Poole,
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UK) and secretory leukocyte protease inhibitor (mouse anti-SLPI: Hycult
Biotechnology, Cambridge, UK). All antibodies used were mouse / rabbit monoclonal
except pH3 which was a rabbit polyclonal. They were tested individually at a range of
dilutions and different antigen retrieval conditions to determine the protocol which
gave the least background and highest specific staining (Table 4.1). Positive and
negative controls were included in every run. In most cases negative controls were
performed by adding a matched IgG control antibody (mouse IgG, Sigma, Poole,
Dorset, UK; rabbit IgG, Vector Laboratories, Peterborough, UK) of the same species
and at the same antibody concentration as the primary antibody. Protocols were either
carried out on the bench or using a Bond-X automated immunohistochemistry staining
machine (Vision Biosystems, Newcastle, UK).
The generic IHC protocol was as follows:
1. Preparation and rehydration of slides: 5pm paraffin embedded tissue sections
were dewaxed in Histoclear (National Diagnostics, UK), and rehydrated in
descending grades ofalcohol to distilled water (dH20).
2. Epitope retrieval: The tissue sections were subjected to epitope retrieval either
by heating the sections in a microwave oven (setting high), or in a Tefal Clipso
pressure cooker (setting 2/high, Tefal, Nottingham,UK). The buffer
concentration and duration of antigen retrieval varied dependent on protocol
(Table 4.1). Sections were then allowed to cool for 20 minutes.
3. Endogenous peroxidise block: Endogenous peroxidase activity was quenched
by immersion in 3% hydrogen peroxide (BDH, Poole, UK) in methanol for 30
minutes at room temperature.
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4. Avidin-Biotin block: For AR only, slides were incubated with avidin (Vector
Laboratories, Peterborough, UK) and biotin (Vector Laboratories,
Peterborough, UK) for 15 minutes each at room temperature.
5. Serum block: Non-specific binding of the primary antibody was blocked by
incubating the sections for 20 minutes at room temperature in a 1:5 dilution of
non-immune serum (Autogen Bioclear, Holly Ditch Farm, Wilts, UK) in buffer
containing 5% bovine serum albumin (BSA).
6. Primary antibody: Sections were incubated at 4°C with primary and control
antibodies overnight.
7. Secondary antibody: The sections were incubated in biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK) in non-immune serum.
8. Detection system: Sections were incubated with avidin biotin peroxidase
complex (Vectastain HRP and Vectastain Elite PK 6101, Vector Laboratories,
Peterborough, UK) for 30-60 minutes each at room temperature. The
peroxidase substrate DAB (DAKO) was used as chromogen.
9. Counterstain, dehydration and slide preparation: Sections were then
counterstained with haematoxylin, dehydrated in ascending grades of alcohol
to xylene and mounted using Pertex (Cellpath pic. Hemel Hampstead, UK).
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Immunohistochemistry analysis:
We used a descriptive methodology as there is no quantitative or semi-quantitative
methodology established for analysis of vaginal tissue samples in our laboratory. The
intensity and distribution of immunostaining for ERa, ER(3, PR, AR, pH3 and SLPI is
described for vagina (epithelium and stroma) and endometrium (glands, stroma and
surface epithelium) and differences between pre and post-treatment samples are
analysed.
RNA extraction:
Tissue was minced using a standard sterile surgical scalpel blade and immersed in 2
millilitres of TRI-reagent (Sigma-Aldrich, St Louis, USA). The mixture was
homogenised for 60 seconds and incubated overnight at 4 degree Celsius. The
following day, tissue sample was warmed to room temperature and 200 micro litre of
bromochloropropane was added. The mixture was centrifuged at 14000 rpm at 4
degrees Celsius for 15 minutes and aqueous phase RNA (supernatant) was transferred
to a fresh tube. 500 micro litre of isopropanol was added and incubated at 4 degree
Celsius for 60 minutes. The mixture was centrifuged for 10 minutes, supernatant
discarded and pellet washed with 1 millilitre of 70% ethanol. The mixture was
centrifuged for 5 minutes and supernatant discarded allowing the pellet to dry for 5
minutes. The pellet was re-suspended in 20 micro litre of RNA solution. To
standardise measurements between the various biopsy specimens, the same amount of
RNA was assessed in each sample. The amount of specific amplicon is related to
ribosomal 18S, which is constant relative to the amount of cDNA present, and
subsequently, to an experimental internal control. The RNA was reverse transcribed
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(TaqMan Reverse Transcription Reagents Kit, Applied Biosystems) and PCR
(Polymerase Chain Reaction) amplified (TaqMan Universal Master Mix, No Amp
Erase UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's
instructions. PCR amplification of cDNA was performed on an ABI Prism 7700
Sequence Detection System (Applied Biosystems). Specific forward and reverse
primers (300 nmol/1) and probe (200 nmol/1, all synthesised by BioSource UK,
Nivelles, Belgium) for the natural antibiotic were also added. Ribosomal 18S cDNA
was measured using TaqMan Ribosomal RNA Control Reagents (VIC dye, Applied
Biosystems) in each sample as an internal control following the manufacturer's
protocol. Samples were measured in triplicate and no template controls were included
in all runs. Primers and probes for quantitative PCR were designed using the PRIMER
EXPRESS program (Applied Biosystems, Table 4.2) (King, Critchley et al. 2000;
King, Fleming et al. 2002; Fleming, King et al. 2003; King, Critchley et al. 2003;
King, Fleming et al. 2003; King, Morgan et al. 2003) and probes were fluorescently












Statistical analysis was performed using SPSS (SPSS, Inc., Chicago, IL, USA) and
Excel 2002 (Microsoft Corporation, Reading, UK). Sex steroid and vaginal thickness
are expressed as mean with either standard error of mean or standard deviation.
Menstrual cycle data are expressed as mean and range. Wilcoxon Signed Rank test was
used to compare repeated measures of sex steroid level, menstrual data, vaginal
thickness and natural anti-microbial RNA content before and after treatment.
Results
All eight subjects completed the study. The subjects took mifepristone 5mg/day orally
for an average of 33 days (range 28-40). The average length of the control menstrual
cycle was 27 (range 24-29) and that of the control menstrual period 5.7 days (range 4-
9). All eight women reported amenorrhoea during ingestion ofmifepristone. The time
from discontinuing the mifepristone treatment to the next menstrual period was 17
days (range 10-23), thus the length of the mifepristone cycle was 50 days (range 38 -
63). Average length of the menstrual period post discontinuation of mifepristone was
5.1 days (range 4-7).
During the treatment with mifepristone seven of the eight subjects experienced either
complete suppression of ovarian activity (3/8 women, Figure 4.3 a, subject 08) or
persistent follicular activity but no ovulation (4/8 subjects, Figure 4.3 b, subject 04). In
the remaining subject (subject 07, Figure 4.3 c) there was a 3 fold rise in the excretion
of pregnanediol in the first 10 days of treatment suggesting the formation of a corpus
luteum (07). However there was no menstrual bleeding when the level of pregnanediol
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dropped 14 days after starting the mifepristone. In this subject a persistent ovarian cyst
of 42 mm diameter was detected at completion of treatment (day40) when the level of
progesterone (14nmol/) was slightly raised consistent with a persistent unruptured
partially luteinised follicle.
Multiple follicles were detected by transvaginal ultrasound (diameter of the largest
ranged from 10 to 29mm) in all 8 subjects. The concentrations of E2 in blood samples
collected at visit 2 on the last day of mifepristone treatment were compatible with
persistent follicular activity (496 + 57 pmol/1). In 7/8 women the concentration of
progesterone was <10nmol/l (3 + 1 nmol/1) indicating lack of ovulation.
Endometrial histology
Endometrial biopsies obtained at the end ofmifepristone treatment displayed inactive
or weakly proliferative endometrium in 7 of the 8 subjects. In one subject (subject 09)
tortuous glands with evidence of intra-luminal secretion were seen. As expected there
was strong immunostaining of ERa andp, PR and AR in both glands and stroma.
Histological evidence ofmitosis was absent or infrequent in all samples.
Vaginal histology and vaginal thickness
Vaginal biopsy was obtained in all subjects without complications both before and
after mifepristone administration. The pre-treatment vaginal biopsy was performed in
the follicular phase prior to ovulation (mean 12 menstrual day, range 7-16 menstrual
day) in 7 of the 8 subjects (estradiol mean+sem- 659+141pmol/l, progesterone
mean+sem- 4.3+1.nmol/1). In the remaining subject (subject 05) ovulation had already
occurred on the day of biopsy (day 14 of menstrual cycle) as indicated by high
114
circulating concentration of progesterone (44nmol/l). Post-treatment vaginal biopsy
was performed on day 33 (range 28-40) of treatment.
The histology of the vagina showed the expected basal layer of epithelium mounted by
up to 20 layers ofmore superficial desquamating cells (Figure 4.2). Vaginal thickness
was not altered during administration of mifepristone (342 ± 40 micron vs. 303 ± 69
micron, P= 0.2, NS.)
Steroid receptor expression in the vagina (ERa. ERB, AR, PR)
There was nuclear staining of ERa, ER[3, and AR in both vaginal stroma and in the
epithelium. Immuno-reactivity extended through the basal and intermediate layers but
not the superficial layer of vaginal epithelium (Figure 4.4). Staining was far more
evident in the epithelium as compared to the stroma. There was no significant
difference in sex steroid receptor immunostaining after mifepristone administration.
Apart from a few scattered nuclei in the stroma the basal layer of vaginal epithelium
immunostaining for PR was confined to stroma (Figure 4.4). There was no significant
difference in PR immuno-reactivity after administration ofmifepristone.
pF13 immuno-reactivity
pH3 immunostaining was confined to scattered nuclei in the basal layers of the vaginal
epithelium (Figure 4.4). There was no significant change in immuno-expression
following treatment with mifepristone.
SLPI mRNA and protein expression
SLPI mRNA was present in vagina and this epitope was localised to the superficial
layer of the vaginal epithelium both before and after mifepristone administration
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(Figure 4.4). SLPI immunostaining was also demonstrated in the superficial layers of
luminal and glandular epithelium of the endometrium (Figure 4.4). SLPI mRNA
expression was unchanged following treatment with mifepristone (P>0.05, Wilcoxon
test).
Safety parameters
There was no derangement of heart rate, blood pressure or of haematology and
biochemistry parameters including liver function tests dining the study. Vaginal and
cervical bacteriology swab tests cultured negative for all subjects. Vaginal biopsy was
well tolerated by all women. One woman had possible low-grade endometritis
following endometrial biopsy and was successfully treated with a 7 day course of
antibiotics.
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Figure 4.3: Excretion of metabolites of ovarian steroids in women taking 5mg of
mifepristone for 31-36 days
Estrone (E1G) and Pregnanediol (PdG); x axis = timescale, day 0 = start of treatment;
pre-treatment (negative values), treatment (boxed) and follow-up cycle are shown;
black bars = menstrual episodes; arrow - vaginal biopsy; a: complete suppression of
ovarian activity; b: persistent follicular activity but no ovulation; c: single ovulatory
episode and no menstruation following fall in pregnanediol levels
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Figure 4.3: Urinary steroid profile
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Figure 4.4: Immunohistochemical (IHC) localisation of estrogen receptor alpha
(ERa), estrogen receptor beta (ERJ3), progesterone receptor (PR), androgen
receptor (AR), phospho-Histone H3 (pH3) and serine leukocyte protease inhibitor
(SLPI) in the vagina [epithelium (epth), stroma (str)] and endometrium [gland
(glnd) and stroma (str)] before and after treatmentwith 5 mg mifepristone.
Scale bar = 100 microns; inserts = negative controls; strong expression of ERa (a,b),
ERp (d,e), and AR (j,k) in the basal and para-basal layers of epithelium and a relative
lack of PR (g,h) in the epithelium, no observed change following treatment; PH3
expression in the basal layers (m,n; arrows) and endometrium (post mifepristone - o;
arrows); strong expression of all steroid receptors in the post-treatment endometrium
(c,f,i,l); SLPI confined to superficial layers ofvaginal epithelium (p,q) and endometrial
glands (r).
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The vagina is a key portal of entry for HIV and other STIs. We report the effect of
mifepristone on different parameters involved in the natural defences of the vagina to
infection. Vaginal epithelial thickness, steroid receptor and SLPI and distribution were
unchanged following treatmentwith mifepristone for 30-40 days.
Vaginal epithelial thickness
Vaginal epithelial thickness is regulated by the levels of circulating oestrogen.
(Sjoberg, Cajander et al. 1988; Ma, Lu et al. 2001; Farage and Maibach 2006). There is
a significant reduction in circulating oestrogen levels following long-term progestagen
treatment (Miller, Patton et al. 2000) and severe vaginal atrophy has been
demonstrated in primate studies and this clearly increases the risk of SIV transmission
(Marx, Spira et al. 1996). However the response of human vaginal epithelium to
progestagen-induced hypo-oestrogenism is variable with most studies reporting no
change (Mauck, Callahan et al. 1999; Bahamondes, Trevisan et al. 2000), one study
reporting a small but significant decrease (10 %) (Ildgruben, Sjoberg et al. 2005) and
another, paradoxically, an increase (Ildgruben, Sjoberg et al. 2003).
It is difficult to reconcile all available data into a working hypothesis due a difference
in study designs and methodology. The vagina has diverse embryological origins
(Ulfelder and Robboy 1976) and Ildgruben et al used a cross-sectional study design
and sampled lateral vaginal fomices, whereas we used a longitudinal study design and
sampled lateral mid-vaginal wall in keeping with other reports (Mauck, Callahan et al.
1999; Bahamondes, Trevisan et al. 2000).
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Although vaginal epithelium clearly responds to circulating oestrogen, the underlying
cellular and molecular mechanisms are poorly understood. We localised pH3, a marker
for mitosis and cellular proliferation to a few scattered nuclei in the basal layers of the
vaginal epithelium. The strong nuclear expression of ER and AR in the basal and para¬
basal layers suggests a role in the regulation of epithelial proliferation. Oestrogen
treatment induces surface keratinisation and hyperplasia of primate vaginal epithelium
and we expected similar change in mifepristone-treated vaginal samples due to
unopposed oestrogen effect. The observed epithelial thickness in control samples in the
present study (mean pre-treatment thickness 342 microns) is comparable to other
reports (Mauck, Callahan et al. 1999; Bahamondes, Trevisan et al. 2000; Ildgruben,
Sjoberg et al. 2003). Thickness was unchanged following mifepristone treatment and
this agrees with similar work in cynomolgus monkeys (Grow, Williams et al. 1996).
There are several possible explanations for our findings. Firstly, mifepristone treatment
did not have any effect on level of circulating steroid hormones. Secondly, PR was
localised to a few scattered nuclei in the basal layers of vaginal epithelium and hence
mifepristone, a high-affinity PR ligand, did not have any direct epithelial effects.
Steroid receptor content and distribution
Consistent with previous reports we have demonstrated a strong immuno-expression of
ER, AR and a relative lack ofPR in the vaginal epithelium compared to sub-epithelial
stroma (MacLean, Nicol et al. 1990; Hodgins, Spike et al. 1998; Blakeman, Hilton et
al. 2000; Pelletier and El-Alfy 2000; Gebhart, Rickard et al. 2001; Traish, Kim et al.
2002; Berman, Almeida et al. 2003; Fu, Rezapour et al. 2003). The role ofAR in the
genital tract is unclear, but AR may play a role in regulating endometrial proliferation
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(Brenner, Slayden et al. 2003; Slayden and Brenner 2003; Narvekar, Cameron et al.
2004), modulating vaginal blood flow (Berman, Almeida et al. 2003) and female
genital sexual arousal (Traish, Kim et al. 2002).
Endometrial findings
The endometrium sampled at end of mifepristone treatment showed persistent
proliferative histology and strong ER, PR and AR expression which is consistent with
our previous reports (Baird, Brown et al. 2003; Narvekar, Cameron et al. 2004).
SLPI
The expression, regulation and role of natural anti-microbial compounds in the female
reproductive tract is extensively reviewed elsewhere (King, Critchley et al. 2003).
SLPI has been shown to play an important role in limiting transmission of HTV
(McNeely, Dealy et al. 1995; Pillay, Coutsoudis et al. 2001; Farquhar, VanCott et al.
2002) and other lower genital tract infection (Draper, Landers et al. 2000). SLPI
mRNA has been demonstrated in vaginal fluid previously (Draper, Landers et al. 2000;
Pillay, Coutsoudis et al. 2001).We have demonstrated mRNA in vaginal tissue and
immuno-localised the protein to the superficial layers of the vaginal epithelium. The
expression in superficial layers of surface and glandular endometrium is in keeping
with previous reports (King, Critchley et al. 2000). Natural anti-microbial expression is
modulated by hormonal treatment and up-regulation of endometrial SLPI by
progesterone is attenuated in presence of mifepristone (King, Morgan et al. 2003).




DEVELOPING MIFEPRISTONE AS A ONCE-A-MONTH CONTRACEPTIVE
PILL
Women across different continents and cultures have expressed a desire for a once-a-
month contraceptive pill (Glasier, Smith et al. 1999). Mifepristone has shown great
promise to be developed as a once-a-month contraceptive pill, however, a practical and
reliable method of timing administration is not available.
The peri-ovulatory 'window of opportunity' to administer mifepristone is 3 days and
existing technology to identify this window is complex, expensive, cumbersome and
not infallible. Women with regular menstruation may be able to estimate this window
by a simple calendar approach by recording the dates ofmenstrual bleeding and take
the pill at the appropriate time thus allowing the method to be easily used at home.
This multi-centre study was designed and co-ordinated by the Contraceptive
Development Network. 399 women in 5 international centres participated in the study.
I recruited all 80 women in the Edinburgh centre and was involved in the design, co¬
ordination, collation and analysis of data from all centres.
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Aims andObjectives
The aim of the study was
1. To test the feasibility of using a calendar approach (12th day before next
menses as calculated from the length of previous menstrual cycles) to identify
the correct time for administration of mifepristone as a once-a-month
contraceptive pill.
2. To investigate the effect of three different doses of mifepristone (lOmg, 25mg
or 200mg) on the length of the menstrual cycle and pattern of menstrual
bleeding.
Material andMethods
Setting: 5 family planning centres across the world [Edinburgh (Scotland), Sagamu
(Nigeria), Cape Town (South Africa), Hong Kong and Shanghai (Peoples Republic of
China)].
Study Design: double-blind, parallel group, randomised controlled trial. The effect of
three different doses of mifepristone (lOmg, 25mg or 200mg) on the length of the
menstrual cycle and pattern ofmenstrual bleeding was compared with placebo.
The rationale for testing the three doses ofmifepristone was as follows. Contraceptive
potential of 10 and 200 mg mifepristone has been reported. A dose of 200mg has been
shown to be contraceptive, but given at the wrong time (too early or too late) will
frequently result in menstrual irregularity (Swahn, Johannisson et al. 1988). A dose of
lOmg mifepristone has been shown to be effective when used for emergency
contraception (WHO 1999) but has an effect on endometrial development which is less
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marked than the effect of 200 mg (Marions, Hultenby et al. 2002). This dose may be
less likely to cause cycle disruption but also less likely to be effective. An intermediary
dose of 25mg was chosen as an empirical compromise between anti-nidatory
endometrial effects, efficacy and potential for cycle disruption by mifepristone. All
classical dose finding studies are designed to span the lowest possible effective dose
(even if itmay be too low) and the highest dose deemed as safe.
Subjects: The intention was to recruit a total of 400 subjects (80 per centre) from
women aged 18-40 years attending family planning clinics.
Inclusion Criteria:
1. female volunteers aged 18-40 years inclusive
2. prepared to use barrier methods for the duration of the study, already have an
IUD in-situ, previously sterilized (subject or partner), or not requiring
contraception.
3. regular menstrual cycles of between 25-35 days with no greater than 3 day's
variation in the past 3 months.
4. willing to provide written informed consent.
Exclusion Criteria:
1. those who have used any type of hormonal contraception within 3 months of
starting the trial.
2. clinically relevant abnormal findings during the physical/gynaecological
examination.
3. those who have breastfed in the past three months.
4. current treatment with corticosteroids.
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5. treatment with an investigational drug within one month of inclusion.
6. long term use of any prescription drugs for a significant medical condition.
7. chronic alcoholism, drug abuse or any other condition associated with poor
patient compliance.
8. undiagnosed vaginal bleeding.
9. other significant disease eg. cardiovascular, renal or liver disease or
malignancy, sufficient to interfere with the evaluation of the study.
Ethical approval: The proposal was approved by the local Ethical Committee
(Institutional Review Board) in each centre. Written informed consent was obtained
from all subjects.
Study visits:
A full medical and gynaecological history and examination were obtained at
recruitment (Visit 1). The duration of menstrual bleeding was determined in the same
manner. For the duration of the study all episodes of vaginal bleeding were recorded
on a menstrual diary card and spotting and bleeding were differentiated. Women
contacted the investigators in the first week of the intervention cycle and attended the
clinic 12 days before the anticipated date of next menses as estimated from their
normal cycle length (Visit 2). Pregnancy was excluded by a urine pregnancy test and
subjects were randomised to receive 10 mg, 25mg, or 200mg mifepristone, or placebo.
A blood sample was collected for the measurement of LH and progesterone. Women
were reminded to record any menstrual bleeding or adverse events on the record card.
The subject contacted the investigators and returned the record card after onset of
menses in the cycle that followed treatment cycle (Visit 3).
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Study medication and randomisation:
The study medication was dispensed as 10, 25, 200mg of mifepristone or placebo
tablets provided by the Shanghai Hualian Pharmaceutical Co Ltd, (370 Jiang Wan
Road West, Shanghai). The mifepristone tablets came in three different sizes so three
sizes of placebo were produced to match the size and colour of mifepristone tablets.
Each subject received a bottle containing one mifepristone (10 or 25 or 200 mg) plus 2
different sized placebo tablets. Women in the placebo group received all three placebo
tablets. The study was double-blind. Randomisation at visit 2 was performed by
blocked computer-generated randomisation for each centre to ensure a good balance of
numbers in the different treatment groups. Sealed envelopes were used to conceal the
treatment allocation until the women were registered as definite participants.
Blood samples, assays and analysis:
Blood samples collected by venepuncture on day of drug administration (Visit 2) were
centrifuged and the serum was stored at -20°C until analysis. Standard
radioimmunoassay techniques were used in each centre for the measurement of LH
and progesterone. Based on the laboratory normal values the samples were classified
as originating from three stages of the ovarian cycle:
1. Follicular - LH<10IU/1 and progesterone <5nmol/l
2. Luteal - LH<10 IU/1 and progesterone >20nmol/l
3. Peri-ovulatory - LH>10IU/1 and/or progesterone 5-20nmol/l
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Definitions:
Patterns of vaginal bleeding are an important factor in the acceptability of
contraceptive methods. The analysis of data obtained from daily menstrual diary
records is a major methodological problem to which no satisfactory solution exists.
The WHO recommended reference period method, introduced to avoid the arbitrary
rules and definitions required for an analysis based on the concept of a menstrual
cycle, is widely used and its application and limitations are reviewed elsewhere
(Belsey and Farley 1988). The minimum reference period for analysis is 90 days and
this methodology is not appropriate for our study design (short study period and single
'one-off intervention). However, definitions of various menstrual endpoints have been
adapted from those recommended by WHO (Rodriguez, Faundes-Latham et al. 1976;
Belsey, Machin et al. 1986; Belsey and Farley 1988).
A menstrual period was defined as 2 or more days of blood loss (bleeding or spotting)
with at least 1 day of bleeding and bounded at each end by > 2 bleeding/spotting-free
days (Belsey and Farley 1988). Isolated days of bleeding, or runs of spotting without
bleeding, were excluded. If there was < 1 day separating two sets of blood loss, this
was counted as a single menstrual period.
Normal cycle lengths were defined as follows. Cycle length and range were calculated
from the dates of the last three menstrual periods for women who kept a written record
(retrospective normal cycle length). Women who did not provide a record of the dates
ofmenstruation but claimed to have very regular cycles were asked to give an estimate
of normal cycle length and a range of variation (reported normal cycle length). Women
who did not keep a record of their cycles and who were unsure of their normal cycle
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length kept a prospective record of the next three cycles before the intervention cycle
(prospective normal cycle length).
Statistical methods:
The length of the intervention cycle was compared to that of the normal cycle length
(as defined earlier) and to the cycle length ofwomen treated with placebo. The primary
outcome measure was a lengthening or shortening of the normal menstrual cycle
length by more than five days following administration of the drug. A cut off of five
days was considered clinically significant as this degree of disruption would be likely
to result in a woman seeking advice (particularly if her period was delayed) and would
be sufficient to jeopardize the contraceptive effectiveness of the regimen. The
proportion of cycles disrupted by more than 5 days was compared between adjacent
randomized groups (i.e. placebo versus lOmg, lOmg versus 25mg and 25mg versus
200mg) by chi-squared tests, with Yates' correction at 5% level of significance. Based
on an estimated incidence of delayed cycles of 5% in the placebo group, the study had
> 80% power to detect significant differences of the order of 20% between adjacent
pairs of actively treated groups.
A secondary analysis of the incidence of lengthened cycles was carried out across all
four study groups using Chi-squared tests for trends. Chi-squared tests were used to




Starting from December 2001, a total of 399 women were recruited; 79 from Hong
Kong and 80 from each of the other four centres. Recruitment finished in April 2003.
They were randomised into four equally sized groups who were given a single dose of
placebo, 10, 25, or 200mg mifepristone. 391 of the 399 women were followed up after
the administration of drug. Eight women were withdrawn; six became pregnant prior
to first post-drug menstrual episode and two did not supply any diary data. Two
women became pregnant in the cycle following the intervention cycle and were
included in primary analysis.
Baseline characteristics are summarised in Table 5.1, 5.2. The four groups were similar
in age, parity and body mass index. Mean values (ranges) were 31 (18-40) years for
age, 1.2 (0-6) for parity and 24 (15-48) for BMI.
Current methods of contraception and duration of use are summarised in Table 5.3.
The majority of subjects used barrier methods of contraception (46%) followed by
intrauterine device (IUD) (20%) and sterilisation (16%). 15 % of women were not
sexually active and there was no difference in contraceptive usage across the treatment
groups. Mean (SEM) duration of use was 38 (8.5), 45 (6.2) and 51 (8.9) months for
IUD, barrier and sterilisation.
Although the overall mean cycle length was similar between the centres (29.3 ±5.4
days), there was considerable variation both between and within women [mean range
1.94 (s.d. 2.18) days based on 281 prospective menstrual episodes] in whom repeated
measurements were available prior to intervention cycle. Similarly the length of the
intervention cycle varied among women in the placebo-treated group. Only 85/97
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(89%) women had intervention cycle lengthened or shortened by more than 5 days
(Table 5.4).
There was a statistically significant, dose-related tendency for disruption of cycle
length (of more than ± 5 days) in the women who received mifepristone (Table 5.4)
from 16% of women treated with 10 mg, to 52% of women treated with 200 mg of
mifepristone (y_2=23.88; df=3; PO.OOl). However the difference between adjacent
drug groups in respect of menstrual delay was not significantly different (Table 5.4)
(for placebo versus 10 mg (y2=2.97; df=l; P=0.08); for 10 mg versus 25 mg (y2=1.88;
df=l; P=0.17); and for 25 mg versus 200 mg (y2=l .54; df=l; P=0.21). A dose-related
increase in the proportion of women experiencing menstrual cycles of a shorter
duration was also demonstrated (Table 5.4) but the difference between placebo and
mifepristone only reached statistically significance in the group treated with 200mg
(25%) (x2=19.34; dfr=l, P0.001).
More than half of study subjects provided an estimate of normal cycle length and a
range of variation (reported normal cycle length, n=199, 51%), the remainder provided
either a retrospective record of three menstrual periods (retrospective normal cycle
length, n = 87, 22%) or kept a prospective record of the next three cycles before the
intervention cycle (prospective normal cycle length, n = 105, 27%). There was no
difference in the principal outcome measure (variation in cycle length of more than 5
days) for all the three groups.
Hormone data were used to classify the time of the ovarian cycle when the drug was
given in the 389 women for whom the data were available (Table 5.5). When all the
groups and centres were combined, treatment (mifepristone or placebo) was given in
132
the peri-ovulatory period (the correct time) in only 179/389 (46%) of cycles. In 64/389
(16%) it was given in the follicular phase (before ovulation, too early) and in the
remainder (38%) in the luteal phase (after ovulation, too late).
The degree of cycle disruption was much less in the women who were given
mifepristone in the peri-ovulatory period (Table 5.5). Hundred and one of the 137
women in this group (74%) had their next menses within five days of the expected
time. In contrast, in the 200mg group 75% women who took the mifepristone in the
follicular phase had delay ofmore than five days in the onset of the next menses, while
in 59% of those taking it in the luteal phase, the menstrual cycle was shortened (Table
5.5). Menstrual characteristics of women who took mifepristone in the peri-ovulatory
phase are further classified by the type of normal cycle length in Table 5.6.
A few women (0, 2, 1 and 14 percent women in the placebo, 10, 25 and 200 mg groups
respectively) menstruated within a few days of administration of tablets and
experienced a second bleeding episode at the anticipated time of next menstruation.
This bleeding pattern was strongly associated (P<0.001) with administration of drug in
the luteal phase of the cycle.
In total, 8 women became pregnant during the study, 6 in the intervention cycle and 2
in the subsequent cycle. Relevant study characteristics of pregnant women are














































































































































































































Table 5.4: Percentage of subjects with length of intervention cycle shortened or
lengthened by more than 5 days
Treatment groups n Within 5 days Shortened Lengthened
Placebo 97 89 8 3
10 mg 97 84 6 10
25 mg 99 72 10 18
200 mg 98 48 26 26
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The ideal time to administer mifepristone is just after the start of LH surge and before
endometrium is primed for a progesterone-withdrawal bleed and a three day 'window of
opportunity' around the time of ovulation has been identified by biochemical and
ultrasound monitoring of menstrual cycle (Brown, Williams et al. 2003). In the present
study, we attempted to identify this peri-ovulatory window by prediction of length of
menstrual cycle with knowledge of each woman's previous menstrual pattern. This study
clearly demonstrates that such a calendar approach to timing the administration of once-a-
month mifepristone is not practical.
Timing of administration
Even with the flexibility of a three day window, treatment was mistimed in over half the
cycles. Although normal cycle length and the length of pre-intervention cycle correlated
well, there was unexpected variation in the length of intervention cycle with 11 % of
women in the placebo group demonstrating a variation of more than 10 days. This was
significantly more than our pre-study assumption (5 %) and may explain why mifepristone
was mistimed. A possible explanation may be menstrual cycle disruption due to
participation in research study (Brown, Williams et al. 2003). Seven women with regular
menstrual cycles were studied during a control cycle and then in a second cycle when 200
mg mifepristone was given in the peri-ovulatory phase. The intervention cycle was
slightly longer (30.2 + 0.7 days) than the control cycle (28.2+0.9 days, P = 0.09) due to
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prolongation of the follicular phase (16.50 + 1.0 days vs. 14.3 + 0.6 days, P = 0.06)
(Brown, Williams et al. 2003).
A large number of studies describing bleeding patterns have observed discrepancies
between women's claims of a regular menstrual cycle of usually 28 days and the actual
regularity of such patterns revealed by prospective recording. Regardless of the way in
which we calculated normal cycle lengths (retrospective recording, prospective recording
and reported normal length), there was no difference in the principal outcome measure
(variation in cycle length of more than 5 days) for all the three groups. Moreover, the
proportions of women with reported, retrospective or prospective (51, 22 and 27 %
respectively) records ofmenstrual cycle lengths are likely to be representative ofwomen
attending for contraceptive advice in different family planning settings.
Pattern ofmenstrual bleeding
The effect of treatment on cycle length was related to both the dose ofmifepristone and to
the timing of administration in relation to ovulation. Administration in the follicular phase
prolonged the cycle presumably by delay in onset of LH surge (Liu, Garzo et al. 1987;
Shoupe, Mishell et al. 1987; Swahn, Johannisson et al. 1988; Batista, Cartledge et al.
1992; Batista, Cartledge et al. 1994). Only the highest dose (200 mg) of mifepristone
caused a significant shortening of cycle by inducing a withdrawal bleed when
administered in the luteal phase (Shoupe, Mishell et al. 1987). More than one in ten
women treated with 200 mg of mifepristone experienced two bleeding episodes, one
progesterone-withdrawal and the other at the expected time ofmenstruation. Even women
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who received treatment during the peri-ovulatory phase of the menstrual cycle showed a
significant dose-dependent trend in cycle disruption (lengthening). Although the exact
functional form of these dose-bleeding relationships cannot be defined, such dose-related
effects on menstrual cycle length based on timing of administration in relation to ovulation
have not been reported previously. Results from a large randomised multi-centre trial
investigating the efficacy of 10, 50 and 600 mg of mifepristone for emergency
contraception (WHO 1999) confirm considerable disruption in the cycle ifmifepristone is
given on random days of the cycle.
Limitations of the study
Our study was not sufficiently powered to detect small (<20%) differences between
adjacent groups. The reported (16%) disruption in the 10 mg group is within confidence
interval of the estimate for the placebo group (mean 11%, 95% CI 4.7-17.3%). However,
the group sizes are small, so the precision of estimates is low. Although a larger study,
finding the same disruption rates (11% vs 16%) may demonstrate non-inferiority of the 10
mg dose, the variation in cycle length is such that fewer than 50% woment would take the
compound at the correct time. Also, published literature suggests that the 10 mg dose is
unlikely to disrupt endometrium sufficiently to support effective contraception.
Due to its inherent unreliablity, any dose of mifepristone administered using the calendar




The progesterone receptor antagonist, mifepristone, has tremendous therapeutic potential
as a safe and effective oestrogen-free contraceptive pill. Although there are many social
and political hurdles in its development, the scientific community is awaiting long-term
data on safety and efficacy.
The current studies investigated various effects of mifepristone on the hypothalamic-
pituitary-ovarian axis and reproductive tissues.
Endometrial proliferation and amenorrhea
Daily low-dose mifepristone is an effective contraceptive pill. Although concerns have
been raised of possible hyperplastic endometrial effects, the compound markedly inhibits
cellular proliferation despite proliferative histology. The majority of women also report
amenorrhea in contrast to other oestrogen-free progestogen only contraception.
We investigated potential endometrial mechanisms underlying the reported endometrial
anti-proliferative effects and amenorrhea. The results are as follows:
1. Anti-proliferative effect: Mifepristone down-regulates pH3, a mitosis marker, thus
confirming the cellular anti-proliferative effect previously demonstrated by
traditional markers such as mitosis count, PCNA and Ki67 which have technical
and logistic limitations.
2. Steroid hormones: Mifepristone up-regulates glandular AR and GR; down-
regulates stromal PR and has no effect on expression ofER.
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a. Up-regulation of AR by mifepristone has been reported before in human
and primate models, however, we are the first to report the presence of
glandular GR in the human model. The role of endometrial AR and GR is
unclear; however, their temporal and spatial expression suggests common
mechanistic pathways of regulation.
b. Mifepristone is an in-vitro antagonist of PR, AR and GR, however, in
contrast to AR and GR there is down-regulation of stromal PR. The
underlying mechanistic pathways are unclear and the impact on
progesterone dependent endometrial molecular functions needs to be
characterised.
c. There is a strong expression ofER (ER a, |3 at 30-40 days; ER a at 60 and
120 days) and it is unlikely that a modulation of ER-isoforms mediates
observed endometrial effects and function following mifepristone
treatment.
3. VEGF and micro-vessel density: The decrease in expression of stromal VEGF
which agrees with primate data may explain the increase in stromal density, a
characteristic finding in mifepristone-treated endometrium. Unlike the severe
vascular atrophy observed in the primate model, we demonstrated an in
microvessel density and this may be related to a counting artefact following
stromal compaction and gland dilatation.
4. GR and vascular endothelium: We demonstrated strong expression of GR in
endometrial endothelium. An induction of glandular GR should theoretically
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potentiate the tonic effect of glucocorticoids on angiogenesis. Although, there was
no numerical effect on micro-vessel density, the effect of glucocorticoid-GR on
other aspects ofvascular function is unknown.
Effects on the vagina
Long-term progestagen treatment increases transmission risk of HIV and other STI's,
presumably as a consequence of vaginal thinning and modulation of defence mechanisms.
There was no change in vaginal thickness and proliferation, steroid receptor and SLPI
content in the human vagina following 30-40 days of low-dose mifepristone (anti-
progestagen) treatment. However, these findings are reassuring for future development of
this compound for contraception and other gynaecological uses.
Once-a-month pill
Preliminary studies indicate that once-a-month administration of mifepristone is an
effective and much anticipated approach to contraception. The timing of administration is
crucial to success and a 3-day 'window of opportunity' has been identified in the peri-
ovulatory phase of the menstrual cycle. Our study demonstrates that a calendar-based
estimation of this therapeutic window cannot be used to identify the correct time to
administer mifepristone as a once-a-month contraceptive pill. It is difficult to envisage
how an easy and reliable way of defining the correct timing could be devised.
There was a greater variation in menstrual cycles in our subjects than previously reported
in similar or other populations and there is a dose-related lengthening or shortening of
menstrual cycle if mifepristone is given in the follicular or luteal phase respectively. The
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10 mg dose did not disrupt menstruation when compared to placebo, however, underlying
endometrial mechanisms to support contraceptive efficacy need to be investigated.
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CONCLUSIONS
1. AR may have a key role in mediating the anti-proliferative effect of low-dose
mifepristone.
2. Mifepristone-induced amenorrhea may be related to GR-mediated regulation of
vascular function.
3. Low-dose mifepristone has no appreciable effect on the vaginal thickness and
defences.
4. Mifepristone causes a dose-related disruption ofmenstruation and a calendar-based
approach to time administration of once-a-month contraception is ineffective.
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DIRECTION FOR FUTURE RESEARCH
The role of AR and GR in endometrium needs to be elucidated and the content and
distribution of steroid receptor (ER, PR) isoforms needs to be investigated in mifepristone-
treated endometrium.
The endometrial effects of very low (< 10 mg) single doses of mifepristone need to be
investigated and further work is needed to correlate degree of endometrial effect and
contraceptive efficacy. Since mifepristone disrupts the endometrium in a dose-dependent
manner, the lowest single dose which has sufficient anti-nidatory endometrial effect needs
to be established. Finding a simple and reliable timing methodology is still enigmatic!
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Mifepristone in daily low doses has contraceptive potential by
inhibiting ovulation. Follicular development is maintained,
and although the endometrium is exposed to unopposed es¬
trogen, there are no signs of hyperplasia or atypia. The mech¬
anism of this antiestrogenic action is unknown. We have
investigated the effect of daily low-dose mifepristone on pro¬
liferation markers and steroid receptors in surface epithe¬
lium, glands, and stroma of the endometrium. Endometrial
biopsies were collected from 16 women before (late prolifer¬
ative) and 60 and 120 d after taking 2 or 5 mg mifepristone
daily for 120 d. Endometrial proliferation (H3 mitosismarker)
and steroid (estrogen, progesterone, and androgen) receptor
content were studied using standard immunocyotchemistry
techniques. There was a significant decrease in the expression
of H3 mitosis marker (P £ 0.001) and progesterone receptor
(P < 0.05) in endometrial glands and stroma by d 60 of treat¬
ment. In contrast, the expression of androgen receptor in¬
creased (P < 0.01) in glands, surface epithelium, and stroma
comparedwith the pretreatment sample. These changeswere
maintained at 120 d of treatment. The expression of estrogen
receptor was unchanged in stroma and surface epithelium;
however, there was a significant decrease in expression after
120 d of treatment (P = 0.034). As androgens can antagonize
estrogen action, enhanced glandular androgen receptor ex¬
pression induced by mifepristone could play a role in its an¬
tiproliferative effects. (JClin EndocrinolMetab 89:2491-2497,
2004)
PROGESTERONE RECEPTOR (PR) antagonists havemany potential uses, including the treatment of endo¬
metriosis, fibroids, breast cancer, andmeningiomas (1). Mife¬
pristone is now licensed in many countries for medical ter¬
mination of pregnancy (2, 3). In low daily doses it can serve
as a novel, estrogen-free, contraceptive pill (4-6). Because
follicular development is maintained, the endometrium is
exposed to estrogen for prolonged periods unopposed by
progesterone, raising concerns about potential risks of en¬
dometrial hyperplasia (7-9). It has been demonstrated in
studies in nonhuman primates (10-14) and women (5, 6,15,
16) that mifepristone and other PR antagonists exert anti¬
proliferative effects on the endometrium. Such antiprolifera¬
tive properties carry enormous importance for the sustained
development of these promising compounds for long-term
use. Asmifepristone has no direct effect on estrogen receptor
(ER), the mechanism of this noncompetitive, antiestrogenic
activity still remains largely unknown (10).
There is substantial evidence that exogenous androgen can
have inhibitory effects on the female reproductive tract (17-
20). It has been suggested that the androgen receptor (AR)
could play an important role in the noncompetitive anties¬
trogenic actions of PR antagonists (21). Slayden et al. (21)
demonstrated a significant up-regulation of AR in endome-
Abbreviations: AR, Androgen receptor; BMI, body mass index; DAB,
3,3'-diaminobenzidine; ER, estrogen receptor; NGS, nonimmune goat
serum; NHS, nonimmune horse serum; PCOS, polycystic ovarian syn¬
drome; PR, progesterone receptor.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en¬
docrine community.
trium after 21-30 d of treatment with PR antagonists. How¬
ever, there are no data on the expression of AR after long-
term treatment with mifepristone.
We previously reported that daily doses of 2 and 5 mg
mifepristone for 120 d has contraceptive potential by sup¬
pressing ovulation and endometrial cyclicity (4). A striking
feature of the endometrium after treatment with low dose
mifepristone was a significant reduction in mitotic count and
Ki67 immunostaining compared with endometrium on d 12
of control cycles (6). Because Ki67 protein is expressed during
several phases of the cell cycle, e.g. Gx, S, G2, and M, counts
of Ki67-positive nuclei in paraffin sections are numerically
greater thanmitotic counts, although the Ki67 is usually well
correlated with the mitotic index (22, 23). Mifepristone may
block completion of the cell cycle at G2-M interphase (24), so
that Ki67 protein persists for some time after cell division has
been arrested. Therefore, Ki67 counts may fail to reveal that
mifepristone treatment suppressed estrogen-dependent pro¬
liferation (5). Direct counting ofmitotic cells in hematoxylin/
eosin-stained sections is a time-consuming process that re¬
quires highly skilled observers (25). We evaluated a new
marker of phosphorylated proteins associated with mitosis,
phospho-H3. This marker has been validated in paraffin-
embedded endometrial tissues and shows an excellent cor¬
relation with the mitotic count (26). The aim of the present
study was to examine endometrial proliferation and steroid
receptor content and distribution in women after treatment
with low dose mifepristone, with particular emphasis on the
role of the AR in mediating endometrial antiproliferative
effects.
2491
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Subjects and Methods
Human endometrial samples were obtained from three different pa¬
tient groups. The local ethics committees (institutional review board)
approved each of the studies, and allwomen providedwritten informed
consent.
Mifepristone group
A subset of 16 women, aged 18-40 yr, with regular menstrual cycles
(25-35 d) were studied for one pretreatment, four treatment, and one
posttreatment cycles from 58 volunteer women from Edinburgh previ¬
ously reported (4,6). Subjects were randomly allocated to receive 2 and
5 mgmifepristone daily for the 120 treatment d. Subjects had a mean age
of 30.5 yr and a meanbodymass index (BMI) of 24.5 kg/m2. Endometrial
biopsies were collected using a Pipelle endometrial sampling device
(Prodimed, Neuilly-en-Thelle, France) in the late follicular phase of the
pretreatment cycle (d 12), after 60 d of mifepristone treatment, and after
120 d of treatment. Specimens were fixed in normal buffered formalin,
processed, and embedded in paraffin wax. Endocrine and endometrial
findings have been reported previously (4, 6).
Control groups
Two groups of women whose endometrium was exposed to unop¬
posed estrogen were chosen as controls. As unopposed estrogen gives
rise to persistent proliferative endometrium, the endometrium from
these women could be compared with that of subjects who remained
anovulatory with mifepristone.
A group of women (n = 6) with anovulatory infertility due to poly¬
cystic ovarian syndrome (PCOS) participating in a study evaluating the
effects of low-dose mifepristone on endometrial maturation and pro¬
liferation were recruited (5). Subjects had a mean age of 25 yr (range,
23-38 yr) and a mean BMI of 24.5 kg/m2 (range, 18.7-27.6 kg/m2), and
all had biochemical and ultrasound evidence of polycystic ovaries (27).
All women had an endometrial biopsy taken 21-23 d after a progesto-
gen-induced withdrawal bleed.
A second group of postmenopausal women (1 yr of amenorrhea or
using hormone replacement therapy for 2 yr; n = 5) participating in
a study evaluating effects of onapristone on postmenopausal endo¬
metrium were recruited. The details of the study along with endo¬
crine and endometrial findings have been reported separately (28).
Subjects had a mean age of 54.4 yr (range, 49-54 yr) and a mean BMI
of 26.6 kg/m2 (range, 20.9-33.8 kg/m2). None of the women had used
a hormone preparation within the preceding 6 wk. Women were
instructed to take daily 2 mg 17/3-estradiol valerate (Schering UK,
Burgess Hill, West Sussex, UK) orally for 8 wk (56 d). Endometrial
biopsy was performed in the eighth week of treatment (n = 4). One
subject refused endometrial sampling. Endometrial histology was
reported as proliferative in all samples.
Immunocytochemistry
Immunocytochemistry was performed for the immunolocalization of
phospho-H3 (Upstate Biotechnology, Inc., Lake Placid, NY), Estrogen
receptor (ER clone ID5,DAKO,Glostrup Denmark), PR (Abbott-PR ICA,
Abbott Laboratories, Inc., North Chicago, IL) and AR (F39, BioGenex
Laboratories, San Ramon, CA). ER, PR, and AR immunostaining pro¬
cedures followed the methods previously described (21, 29, 30). The
phospho-H3 immunostaining procedures followed those described by
Brenner et al. (26).
Phospho-H3 mitosis marker
Paraffin sections (5 ^m) were dewaxed in Histoclear (National
Diagnostics, Atlanta, GA), rehydrated through a series of alcohols,
and washed with PBS. The slides were then subjected to pressure
cooker antigen retrieval in 0.01 m sodium citrate buffer at pH 6 for
5 min. Endogenous peroxidase activity was quenched by immersion
in 3% hydrogen peroxide (Merck & Co., Poole, UK) in distilled water
for 10 min at room temperature. Nonspecific binding of the primary
antibody was blocked by incubating the sections for 20-30 min at
room temperature in nonimmune goat serum (NGS; Vector Labora¬
tories, Inc., Peterborough, UK). A variety of dilutions (0.66,1, and 2
/xg/ml) of the primary antibody in NGS were assessed in preliminary
studies. The best compromise between signal to noise (specific stain¬
ing vs. background) for phospo-H3 was 1 /xg/ml (1:1000 dilution).
Slides were then incubated overnight at room temperature with rab¬
bit polyclonal phopho-H3 antibody (1:1000 dilution in NGS) or sim¬
ilarly with a control rabbit IgG antibody (1:1000 dilution in NGS). An
avidin-biotin peroxidase system was used as the detection system.
The slides were incubated in biotinylated horse antirabbit secondary
antibody (Vector Laboratories, Inc.) in NGS, followed by the avidin-
biotin peroxidase complex (Vectastain HRP, Vector Laboratories,
Inc.), for 60 min each at room temperature. The peroxidase substrate
3,3'-diaminobenzidine (DAB; Vector Laboratories, Inc.) was used to
visualize the reaction.
AR
Paraffin sections (5 /xm) were dewaxed in Histoclear (National Di¬
agnostics), rehydrated through a series of alcohols, and washed with
PBS. The slides were then subjected to pressure cooker antigen retrieval
in 0.01 m sodium citrate buffer at pH 6 for 5min. Endogenous peroxidase
activity was quenched by immersion in 3% hydrogen peroxide (Merck
& Co.) in distilled water for 10 min at room temperature. Nonspecific
binding of the primary antibody was blocked by incubating the sections
for 20-30 min at room temperature in nonimmune horse serum (NHS;
Vector Laboratories, Inc.). Slides were then incubated at 4 C with mono¬
clonal antihuman AR antibody F39.4 overnight (1:480 dilution in PBS/
BSA gel) or similarly with a control mouse IgG antibody (1:600 dilution
in PBS/BSA gel). An avidin-biotin peroxidase system was used as the
detection system. The slides were incubated in biotinylated horse an-
timouse secondary antibody (Vector Laboratories, Inc.) in NHS, fol¬
lowed by avidin-biotin peroxidase complex (Vectastain Elite PK 6101,
Vector Laboratories, Inc.), for 60 min each at room temperature. The
peroxidase substrate DAB (Vector Laboratories, Inc.) was used to visu¬
alize the reaction.
PR
Paraffin sections (5 /xm) were dewaxed in Histoclear (National Di¬
agnostics), rehydrated through a series of alcohols, and washed with
PBS. The slides were then subjected to microwave antigen retrieval in
0.01 m sodium citrate buffer at pH 6 for 10 min. Endogenous peroxidase
activity was quenched by immersion in 3% hydrogen peroxide (Merck
& Co.) in distilled water for 10 min at room temperature. Nonspecific
binding of the primary antibody was blocked by incubating the sections
for 20-30 min at room temperature in NHS (Vector Laboratories, Inc.).
Slides were then incubated at 37 C for 1 h with mouse monoclonal PR
antibody (1:40 dilution in NHS) or similarly with a control mouse IgG
antibody (1:6000 dilution in NHS). An avidin-biotin peroxidase system
was used as the detection system. The slides were incubated in biotin¬
ylated horse antimouse secondary antibody (Vector Laboratories, Inc.)
in NHS, followed by avidin-biotin peroxidase complex (Vectastain Elite
PK 6101, Vector Laboratories, Inc.) for 30min each at room temperature.
The peroxidase substrate DAB (Vector Laboratories, Inc.) was used to
visualize the reaction.
ER
Paraffin sections (5 /xm) were dewaxed in Histoclear (National
Diagnostics), rehydrated through a series of alcohols, and washed
with PBS. The slides were then subjected to microwave antigen re¬
trieval in 0.01 m sodium citrate buffer at pH 6 for 10 min. Endogenous
peroxidase activity was quenched by immersion in 3% hydrogen
peroxide (Merck & Co.) in distilled water for 10 min at room tem¬
perature. Nonspecific binding of the primary antibody was blocked
by incubating the sections for 20-30 min at room temperature in NHS
(Vector Laboratories, Inc.). Slides were then incubated at 37 C for 1 h
with mouse monoclonal ER antibody (1:25 dilution in NHS) or sim¬
ilarly with a control mouse IgG subtype 1 antibody (1:150 dilution in
NHS). An avidin-biotin peroxidase system was used as the detection
system. The slides were incubated in biotinylated horse antimouse
secondary antibody (Vector Laboratories, Inc.) in NHS, followed by
avidin-biotin peroxidase complex (Vectastain Elite PK 6101, Vector
Laboratories, Inc.), for 60 min each at room temperature. The per-
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oxidase substrate DAB (Vector Laboratories, Inc.) was used to visu¬
alize the reaction.
Immunocytochemistry score
Semiquantitative score. The location and intensity of immunostaining
were measured using a semiquantitative scoring system. Sections were
scored blind by two observers (blind to study groups and to the other's
results). This scoring system is a standard method used in previous
studies (29, 30). A high correlation has been demonstrated between
objectively measured immunoreactivity (image analysis) and subjective
semiquantitative scoring of immunostaining patterns (29). Immuno¬
staining intensity and distribution of epitopes in all tissue sections were
assessed on an arbitrary four-point scale: 0 = no staining, 1 = mild
staining, 2 = moderate staining, and 3 = intense staining. This method
of semiquantitative scoring has been previously validated in our labo¬
ratory (29).
Quantitative score. Phospho-H3 mitosis marker immunoexpression was
assessed separately for glands and stroma using image analysis. The
system used a Axistop 2 microscope (x40 objective; Carl Zeiss, Inc., New
York, NY) connected to a Macintosh G3 computer (Apple Computer,
Cupertino, CA), using Openab 2.08 image analysis software (Improvi-
sion, Coventry, UK). At least 12 fields of view were selected at random
from each tissue section. The glands and stroma from each digitized
image were interactively dissected. Using Openlab color discrimination
software, the totalnumber ofphospho-H3-expressing cells (brown prod¬
uct) and the number of those not expressing phospho-H3 (blue hema¬
toxylin) weremeasured separately for each digitized image. The number
of phospho-H3 expressing cells is reported as a percentage of total cells
(brown and blue) per sample. This method of image analysis has pre¬
viously been described and validated in our laboratories (29, 31).
Statistical methods
Statistical analysiswas performed using SPSS (SPSS, Inc.,Chicago, IL)
and Excel 2002 (Microsoft Corp., Redmond, WA). Continuous data are
expressed as the mean ± se, and categorical data are expressed as the
median and range. Nonparametric tests (Friedman's test, Wilcoxon's
signed rank test, and Mann-Whitney test), with and without Bonferroni
correction,were used to compare immunostaining scores at various time




Mitotic activity as indicated by antibody to phosphory-
lated histone H3 showed a highly significant decrease (P s
0.001) in the endometrium by d 60 of treatment (mean ± sem;
glands, 0.89 ± 0.14; stroma, 0.48 ± 0.09; Fig. 1) comparedwith
pretreatment proliferative endometrium (glands, 3.48 ± 0.42;
stroma, 1.57 ± 0.16; Fig. 2, A and B). This decrease was
demonstrable inboth glands and stroma and wasmaintained
at 120 d (glands, 0.96 ± 0.13; stroma, 0.55 ± 0.11; Fig. 2C).
Endometrium from PCOS women showed higher mitotic
activity in the glands (4.72 ± 0.74; P = 0.168, not significant),
whereas postmenopausal women had a significantly lower
mitotic activity in the stroma (0.65 ± 0.13; P = 0.011) com¬
pared with proliferative d 12 pretreatment endometrium
(Figs. 1 and 2D). The mitotic activity in the stromal com¬
partment (PCO group, 1.21 ± 0.22) and glands (postmeno¬
pausal group, 2.00 ± 0.55) was not significantly different
from that in proliferative samples.
AR
Pretreatment proliferative phase endometrium showed a
strong expression of AR in the stroma andminimal or absent
7 a: glands





Day 12 Prtrfif. Day 60 Mife. Day 120 Mife. Day 21 PCO Day 56 PM
Groups
Fig. 1. Percentage of endometrial cells immunostaining for phos-
pho-H3 in glands (A) and stroma (B) before and after treatment with
daily mifepristone; comparison with control, polycystic ovary (PCO)
and postmenopausal (PM) groups. The values are expressed as me¬
dian (horizontal bar), mean (square dot), and box plots showing 50%
of values (box) with range (whiskers). X, P £ 0.001, significant de¬
crease, mifepristone d 60 and 120 treatment endometrium vs. d 12
pretreatment by (Wilcoxon's signed rank test). Y, P = 0.01, significant
decrease, d 56 estradiol-treated postmenopausal endometrium vs. d
12 proliferative (by Mann-Whitney U test).
expression in glands and surface epithelium (Table 1 and Fig.
2E). There was a significant increase in AR expression in
surface epithelium, glands, and stroma after treatment with
mifepristone compared with that seen in the proliferative
phase pretreatment sample. This increase occurred as early
as 60 d (P < 0.05; Fig. 2F) and wasmaintained on d 120 (Fig.
2G). The increase was most marked in the glandular com¬
partment, where a virtual absence of expression in the pro¬
liferative pretreatment sample (Fig. 2E) was replaced by in¬
tense immunostaining in posttreatment samples (P < 0.01;
Fig. 2, F and G). There was no difference between women
treated with 2 or 5 mg mifepristone. Endometrium from
PCOS and estrogen-treated postmenopausalwomen showed
strongAR expression in the stroma,withminimal expression
in glands and surface epithelium (Fig. 2H). This pattern was
similar to that in d 12 pretreatment proliferative phase sam¬
ples. Expression in glands was significantly greater in the
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Fig. 2. Immunoexpression ofphospho-H3 (A-c), AR (E-G), PR (I-K), and ER (M-O) in endometrial glands (Gl.) and stroma (Str.) of a woman
before and after daily treatment with 5 mg mifepristone; comparison with endometrium of a postmenopausal woman on 56 d of unopposed
estrogen (HRT; 2 mg 17/3-estradiol; D, H, L, and P). Scale bar (D), 50 pm; brown, positive immunoexpression; blue, negative immunoexpression.
Significant reduction in immunoexpression ofphospho-H3 mitosis marker (arrows) after 60 d (B) and 120 d (c) of treatmentwith mifepristone
compared with follicular pretreatment d 12 endometrium (A) or endometrium from postmenopausal woman receiving unopposed estrogen
showing ongoingmitosis (D). Significant increase in AR immunoexpression after 60 d (F) and 120 d(G) of treatmentwith mifepristone compared
with follicular pretreatment d 12 endometrium (E) and endometrium from postmenopausal woman receiving unopposed estrogen (HRT; H).
Significant decrease in PR immunoexpression after 60 d (J) and 120 d (K) of treatmentwith mifepristone compared with follicular pretreatment
d 12 endometrium (I) and endometrium from a postmenopausal woman receiving unopposed estrogen (HRT) showing a similar distribution as
the pretreatment sample (L). Immunoexpression of ER in follicular pretreatment d 12 endometrium (M) and after 60 d (N) and 120 d (O) of
treatment with mifepristone and in endometrium from a postmenopausal woman receiving unopposed estrogen (HRT; P).
TABLE 1. AR immunoexpression expressed as the mean (median) in endometrium before and after treatment with daily mifepristone;
comparison with control, polycystic ovary (PCO), and postmenopausal (PM) groups
d 12 pretreatment
Mifepristone group (n — 16)
d 60 mifepristone d 120 mifepristone
PCO group (n = 6), d 21 PM group (n = 4), d 56
Surface 0.93 (1) 2.27 (2)° 2.14 (2)° 1.33 (2)6 1.50 (2)
Glands 0.44(0) 2.25 (2)" 2.06 (2)° 1.00 (l)6 1.00 (l)6
Stroma 2.25 (3) 2.69 (3)° 2.44 (3) 2.83 (3) 2.00 (2)
a P < 0.01, significant increase, mifepristone d 60 and 120 treatment endometrium us. d 12 pretreatment (Wilcoxon signed rank test).
6 P < 0.05, significant increase, mifepristone d 60 treatment endometrium vs. PCO/PM controls (Mann-Whitney U test).
postmifepristone treatment samples than in samples from
both PCOS and postmenopausal women (P < 0.05).
PR
There was a reduction in PR expression in surface epithe¬
lium, glands, and stroma by d 60, which was maintained on
120 d (Table 2 and Fig. 2, I-K). There was no difference
between women treated with 2 or 5 mg mifepristone. There
was strong PR staining in all three endometrial compart¬
ments (surface epithelium, glands, and stroma) in PCOS and
postmenopausal groups (Fig. 2L). This pattern was similar to
that in d 12 pretreatment proliferative phase samples.
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TABLE 2. PR immunoexpression expressed as the mean (median) in endometrium before and after treatment with daily mifepristone;
comparison with control, polycystic ovary (PCO), and postmenopausal (PM) groups
Mifepristone group (n = 16)
PCO group (n = 6), d 21 PM group (n = 4), d 56







1.88 (2) 1.86 (2)°
2.13(2)° 1.80(2)°







a P < 0.05, significant decrease, mifepristone d 60 and 120 treatment endometriumi vs. d 12 pretreatment (Wilcoxon signed rank test).
TABLE 3. ER immunoexpression expressed as the mean (median) in endometrium before and after treatment with daily mifepristone;
comparison with control, polycystic ovary (PCO), and postmenopausal (PM) groups
Mifepristone group (n = 16)
PCO group (n = 6), d 21 PM group (n = 4), d 56







2.63 (3) 2.53 (3)
2.88 (3) 2.56 (3)°







' P = 0.034, significant decrease, mifepristone d 120 treatment endometrium vs. d 12 pretreatment (Wilcoxon signed rank test).
ER
There was no significant change in ER expression in sur¬
face epithelium and stroma after treatmentwithmifepristone
(Table 3 and Fig. 2, M-O). Expression in glands was de¬
creased after 120 d (P = 0.034). This failed to reach signifi¬
cance after using Bonferroni's correction (P < 0.102). There
was no difference between women treated with 2 or 5 mg
mifepristone. The endometrium in both control groups dem¬
onstrated strong ER staining in all three endometrial com¬
partments (Fig. 2P). This pattern was similar to that in d 12
pretreatment proliferative phase samples.
Discussion
This study extends our previous report of the effects of
daily low-dose mifepristone on endometrial development
(4-6). We have confirmed antiproliferative effects of low
dose mifepristone with a new mitosis marker, phospho-H3,
along with a significant increase in glandularAR expression.
Our study shows for the first time that after prolonged treat¬
ment with mifepristone (120 d), there is a significant down-
regulation of PR.
Concern has been expressed previously that long-term use
of PR antagonists may lead to endometrial hyperplasia and
possible malignancy due to exposure of the endometrium to
the effects of unopposed estrogen (7-9). Evidence of estro¬
genic stimulation of the endometrium has been observed in
the rats receiving long-term PR antagonist treatment (32,33).
The nonhuman primate endometrium, however, demon¬
strates endometrial atrophy and evidence of antiestrogenic
activity (10, 34-38). In women, after high doses of mifepris¬
tone (25 and 50mg/d) variable effects, such as atypical cystic
changes, have been described in eutopic endometrium (8,
39). In a study in which women with pelvic endometriosis
were treated with 50 mg mifepristone/d for 6 months, there
was evidence of endometrial hyperplasia and numerous mi¬
totic figures (8). The occurrence of endometrial gland dila¬
tation in 34% of women receiving chronic treatment with
mifepristone (1 mg/d given for 150 d) has also been reported
(15). We reported previously that 18-23% of women treated
with 2 or 5 mg mifepristone/d developed cystic changes in
the endometrium, although the cysts were lined with inac¬
tive glandular tissue (6). There is a case report of an adoles¬
cent girl, aged 13 yr, with Cushingoid features and morbid
osteoporosiswho was treated with high doses (400mg/d) of
mifepristone for its antiglucocorticoid effect (7). However,
with each of the two 6-month courses ofmifepristone, given
9 months apart, she developed massive simple endometrial
hyperplasia. Therewas no evidence of atypia, and ER and PR
concentrations were in the normal range. This abnormality
resolved on cessation of treatment. Eisenger et al. (9) inves¬
tigating effects of 5 and 10 mg mifepristone daily for 6
months on uterine leiomyomata noted simple endometrial
hyperplasia in 28% of subjects. No atypical hyperplasia was
noted. Our findings using phospho-H3, a specific marker of
mitosis, confirm that at the doses tested, there is no evidence
of endometrial hyperplasia. Although a proportion of the
endometrial samples show cystic dilatation, the glands are
lined by atrophic inactive epithelium in contrast to the
pseudo-stratified appearance in typical cystic glandular hy¬
perplasia (6).
In agreement with previous reports (21, 40, 41), prolifer¬
ative phase control endometria demonstrated absent or min¬
imal AR expression. Treatment with a PR antagonist en¬
hances stromal and induces glandular AR expression (21).
Slayden et al. (21) used ligand binding, immunocytochem-
istry, and in situ hybridization on the same set of endometria
to ascertain the regulation of and localization of AR during
normal and hormonally regulated cycles and to evaluate
changes in AR in women and nonhuman primates treated
with PR antagonist (mifepristone or ZK 137 316). Treatment
of macaques with estradiol implants for 28 d significantly
increased AR mRNA in stromal cells, but not in the glands.
The highest levels of AR mRNA in both stroma and glands
were detected after combined treatment with estradiol and
PR antagonist (mifepristone or ZK 137 316) treatment. At all
stages of the human menstrual cycle, AR staining was lo¬
calized predominantly in the endometrial stroma, with no or
barely detectable staining in the glands. After mifepristone
treatment (2 mg/d for 21-24 d), there were distinct and
notable increases in AR staining of the glands and surface
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epithelium plus some enhancement of stromal AR staining
(21).
Short-term treatmentwithPR antagonist, either during the
menstrual cycle or with combined estrogen therapy, leads to
elevations of the two main uterine steroid receptors, ER and
PR (5, 42, 43). Expression after chronic treatment has been
shown to be increased, decreased, or unchanged depending
on the dose and duration of treatment (8,38,39,44).We have
demonstrated a down-regulation of PR after 60 d of treat¬
ment. ER expression decreased in glands, but remained un¬
changed in surface epithelium and stroma. The mechanisms
involved are poorly understood, but could result from either
chronic antimitotic activity (24) affecting cellular protein syn¬
thesis or androgen-AR interactions.
The endometrium is a target tissue for androgen action.
There is ample evidence of antiestrogenic effects of exoge¬
nous androgens in vivo (17-20), and androstenedione can
inhibit human endometrial cell growth and secretory activity
in vitro (45). Currently, the role of endogenous androgens in
the endometrium is not clear, but stromal ARwould mediate
any possible effects of normal levels of endogenous andro¬
gens. Treatment with mifepristone up-regulates AR in
glands; hence, androgens could have direct effects on glands
in addition to stroma. An increase in AR levels in mifepris-
tone-treated tissues could lead to an increased binding of
androgens, which might antagonize the effects of estrogens
on endometrial growth. Treatment with flutamide, a pure
antiandrogen, blocked the antiproliferative effect of the PR
antagonist ZK 137 316 in the nonhuman primate, adding
strong support to the hypothesis that this effect of PR an¬
tagonist ismediated through changes in AR (46). It is possible
that mifepristone itself directly mediates these effects by
interacting with AR, for which the relative binding affinity
is 13% (47).
The factors regulating the expression of AR in the endo¬
metrium are not clear. In the normal cycle, AR is confined to
the stroma, with little or no expression in the glands (21,40,
41). Our observations in postmenopausal women treated
with estrogen and in womenwith PCOS are in keeping with
reports in women and nonhuman primates that estrogen
stimulates AR expression in the endometrium (38, 48). In¬
creased AR expression in both stroma and glands of endo¬
metrium from women with PCO have been reported by
others (49). The expression was higher in those with persis¬
tent proliferative endometrium and may merely reflect the
effect of prolonged exposure to unopposed estrogen. Al¬
though this probably contributes to the changes in women
treated with long-termmifepristone, it is likely that the mas¬
sive up-regulation ofAR that occurs, especially in the glands,
as early as 21 d after starting treatment is a specific effect of
the PR antagonist (21). In our study the endometrial biopsy
from women with PCO, collected 21 d after progestagen-
induced menses, showed little, if any, AR expression in
glands and was similar to that observed in estrogen-treated
women.
Summary
In summary, we have shown that low dose mifepristone
treatment has a significant antiproliferative effect on the en-
Narvekar et al. • Mifepristone and Endometrial AR
dometrium. There is down-regulation of PR and ER and
up-regulation of AR. The mechanisms involved are poorly
understood. An increase in glandular AR content could me¬
diate the antiestrogenic, antiproliferative effects of PR an¬
tagonists. Whether androgens mediate all of these effects or
whether PR antagonists interact in concertwith other factors
remains to be established.
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Abstract
The progesterone antagonist mifepristone (RU486, Exelgyn) has been shown to exert a paradoxical agonist effect on postmenopausal
endometrium. We conducted a study to investigate the effects of the 'pure' antiprogestin onapristone (ZK 98 299, Schering AG) on post¬
menopausal endometrium. Seventeen postmenopausal subjects (45-62 years), took 2 mg ofoestradiol and either placebo, 1 mg onapristone
or lOmg ofonapristone, daily for 56 days. An endometrial biopsy was performed during the final week of treatment and assessed for histol¬
ogy and immunohistochemistry for oestrogen receptors (ER), progesterone (PR), androgen receptors (AR) and the cell proliferation marker
Ki 67. FSH fell in all 14 subjects who completed the study, consistent with the effect of oestradiol treatment. There was a dose-dependent
additive effect of onapristone on suppression of gonadotrophins. All endometrial biopsies showed proliferative endometrium. A similar
pattern and intensity of immunostaining of ER, PR and Ki 67 was observed in all groups, with positive immunoreactivity in both glands
and stroma. AR immunostaining was observed in both glands and stroma from all subjects, but there was an increase in intensity of
immunostaining within the glandular epithelium of women receiving lOmg onapristone. The antiprogestin onapristone, in contrast to
mifepristone, is not agonistic on postmenopausal endometrium and does not exert obvious antiproliferative effects. It does however cause
a dose dependent suppression of FSE1 and LH release.
© 2003 Elsevier Inc. All rights reserved.
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1. Introduction
It has previously been demonstrated in both animal mod¬
els and in human studies, that the antiprogestin mifepristone
(RU486, mifegyne, Excelgyn, Paris) exerts antiproliferative
effects on endometrium [1-5]. In oestradiol-treated cas¬
trate monkeys, treatment with low doses of mifepristone
induced secretory changes in the endometrium, but with
higher doses endometrial proliferation was inhibited [1,2].
An increase in apoptosis was also observed in both glands
and stroma [6]. In women of reproductive age, short term
studies (1 month) of continuous administration of low doses
of mifepristone (2-1Omg) have shown that despite anovu¬
lation and continued oestrogen secretion, the endometrium
appears 'hyporeactive' and devoid of mitoses [5,7]. It has
been suggested that the mechanism of such antiproliferative
effects may be mediated through an inhibitory effect on
the progression of cells through the mitotic phase of the
cell cycle [5], Clearly, such antiproliferative properties have
* Corresponding author. Tel.: +44-131-242-2691.
E-mail address: sharon.cameron@ed.ac.uk (S.T. Cameron).
enormous importance with regards long-term treatment with
antiprogestins and the implications for their potential use
for prevention and treatment of endometrial hyperplasia. In
pre-menopausal women, it has been suggested that contin¬
uous administration of low doses (2-5 mg) of mifepristone
could be used as an oestrogen-free contraceptive pill which
would preserve endogenous oestrogen secretion, but would
also protect the endometrium against hyperplasia [5,8,9].
Mifepristone has also been shown to exert antiprolifera¬
tive effects on the endometrium of postmenopausal women
[10], In the latter study, mifepristone was observed to exert
a paradoxical progesterone 'agonist' effect, inducing secre¬
tory changes in oestrogen primed endometrium, in addition
to suppressing markers of endometrial proliferative activ¬
ity. This has led to suggestions that antiprogestins (in con¬
junction with oestradiol treatment) could be developed as a
novel bleed-free form of hormone replacement therapy, that
may be devoid of the side-effects and break-through bleed¬
ing typically associated with progestogen use.
The identification of mitoses on morphological exami¬
nation or the immunohistochemical demonstration of cell
cycle-related antigens such as Ki 67 are accepted methods
0039-128X/S - see front matter © 2003 Elsevier Inc. All rights reserved,
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of assessing endometrial proliferative activity. The im-
munolocalisation of steroid receptors can also provide use¬
ful information regarding endometrial proliferative status.
Oestrogen and progesterone receptors are upregulated by
oestrogen and down regulated by progesterone [11], Fur¬
thermore, androgen receptor expression is maximal in pro¬
liferative endometrium [12], Thus, the presence or absence
of steroid receptors within the endometrium may give a
useful measure of net oestrogenic activity within the tissue.
Onapristone (ZK 98 299, Schering AG, Berlin), is an an-
tiprogestin which differs in several respects from mifepris¬
tone. Not only does it have a much shorter half-life, but it
is generally considered to be a pure progesterone antagonist
[13]. When administered in the immediate postovulatory pe¬
riod to women with regular menstrual cycles, it has been
shown to produce similar effects to mifepristone, in that it
does not disrupt the length of the luteal phase but retards
the development of a secretory endometrium [14], In order
to investigate whether onapristone might exhibit similar an¬
tiproliferative activity on postmenopausal endometrium to
that of mifepristone, we conducted a study to examine the
effects ofdaily administration of onapristone in conjunction
with oestradiol treatment in postmenopausal volunteers.
The effects of treatment on histology and the immunolo-
calisation of oestrogen receptors (ER), progesterone recep¬
tors (PR), androgen receptors (AR) and the cell proliferation
marker Ki 67 were chosen as markers of endometrial status
and proliferative activity.
2. Experimental
2.1. Materials and methods
Seventeen healthy postmenopausal women (with either
>1 year of amenorrhoea or using hormone replacement
therapy for >2 years) with an intact uterus, volunteered
for the study. Women were recruited from a community
menopause clinic at Dean Terrace Centre, Edinburgh. Sub¬
jects had a mean age of54.4 years (range 45-62 years) and a
mean body mass index of 25.5 Kg/m2 (range 21-34Kg/m2).
None of the women had used a hormone preparation within
the preceding 6 weeks. All women underwent a thorough
clinical assessment prior to commencing the study, which
consisted of a gynaecological and general physical exam¬
ination, together with measurement of height, weight and
blood pressure. A transvaginal ultrasound was performed
and a cervical smear was taken if none had been performed
within the last year. Blood was also collected for estimation
of haemoglobin, blood cell count, prothrombin time, serum
urea and electrolytes, creatinine, urate and tests of liver
function (bilirubin, alkaline phosphatase, alanine transam¬
inase and aspartate transaminase). In addition, blood was
also collected for measurement of follicle stimulating hor¬
mone (FSH), luteinising hormone (LH), progesterone, an-
drostenedione and Cortisol. These blood tests were repeated
on completion of the study. Subjects were issued with a
menstrual calendar on which they recorded details of any
bleeding episodes throughout the study period. The proto¬
col was approved by the local ethical subcommittee and all
volunteers gave written informed consent.
2.2. Study design
All subjects received tablets of 2mg 17(3 oestradiol daily
and were randomised to receive in addition either (i) placebo
tablets, or identical tablets of (ii) 1 mg onapristone or (iii)
10 mg onapristone, for 56 days. Subjects attended the re¬
search centre at the beginning of treatment (baseline) and
after 2, 4 and 8 weeks of treatment. A further 'follow-up'
visit was made 4 weeks after cessation of study medication.
At each visit, vital signs were recorded and a sample of
blood was collected. The plasma was separated immediately
at 4 °C and then frozen at —20 °C until assayed for FSH, LH,
oestradiol, progesterone, Cortisol and androstenedione by ra¬
dioimmunoassay [15]. Intra -assay co-efficients of variation
were 8.4, 6.9, 8.0, 8.0, 4.0 and 10% respectively; inter-assay
coefficients of variation were 9.7, 8.8, 11.0, 10.0, 6.0 and
10% respectively. Transvaginal ultrasonography (Siemens
Sonoline S 1-250 machine with a 7.5/5MHz vaginal probe)
was performed at the initial visit and after 4 and 8 weeks of
treatment to measure endometrial thickness. This was mea¬
sured as the maximum antero-posterior diameter of the en¬
dometrium in a plane through the central longitudinal axis
of the uterine body [16].
During the last week of study medication (week 8), an en¬
dometrial biopsy was also performed using a pipelle sampler
(Prodimed, Eurosurgical, UK). A portion of endometrium
was fixed immediately in (a) Bouin's solution for histo¬
logical assessment and (b) neutral buffered formalin for
immunohistochemistry, for an overnight fixation period at
4°C. Specimens were then processed, parrafin-embedded
and 5 |xm thick sections were cut. Sections for histological
assessment were stained with haematoxylin-eosin and as¬
sessed by an experienced gynaecological pathologist who
was unaware of the treatment type.
Immunohistochemistry was performed for the immunolo-
calisation of oestrogen receptor (ID5; Dako, Glostrup, Den¬
mark), progesterone receptor (ICA; Abbott, North Chicago,
IL, USA), androgen receptor (F-39, BioGenex) and the cell
cycle proliferation marker Ki 67 (NCL-Ki 67-MM1; Novo-
castra, Newcastle, UK).
2.2.1. Oestrogen receptor (ER) immunostaining
Oestrogen receptor immunostaining was conducted as
previously described using a microwave method of anti¬
gen retrieval [5]. A mouse monoclonal antibody (ID5;
Dako was used as the primary antibody (dilution 1:25))
and an avidin-biotin horseradish peroxidase (ABC) system
was used as the detection system. The chromogen was di-
aminobenzidine tetrahydrochloride (DAB), and slides were
lightly counterstained with Harris's haematoxylin.
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2.2.2. Progesterone receptor (PR) immunostaining
PR immunostaining was detected using the method as pre¬
viously described in detail [5], The staining protocol used a
ratmonoclonal antibody (Abbott-PR ICA) as the primary an¬
tibody (dilution 1:10) together with an alkaline phosphatase
anti-alkaline phosphatase (APAAP) detection system. The
chromogen was vector red (Vector SK 5100) and no coun-
terstain was applied.
2.2.3. Androgen receptor (AR) immunostaining
AR immunostaining was detected using a previously
described procedure [12], A pressure cooker method of
antigen retrieval was used, placing slides in 0.01 M sodium
citrate buffer at pH6 for 5 min. The staining protocol used a
monoclonal antihuman AR antibody (F-39, BioGenex, Lab
Inc.) as the primary antibody (dilution 1:480) together with
an avidin-biotin horseradish peroxidase (ABC) detection
system. The chromogen was diaminobenzidine tetrahy-
drochloride (DAB), and slides were lightly counterstained
with Harris's haematoxylin.
2.2.4. Ki 67 immunostaining
The immunohistochemistry protocol used has previously
been described in detail [5]. Briefly, a microwave method of
antigen retrieval was used together with a mouse monoclonal
primary antibody (NCL-Ki 67-MM1, Novo Castra) (dilution
1:100) in conjunction with an ABC detection system. The
chromogen was DAB, and slides were lightly counterstained
with Harris's haematoxylin.
2.2.5. Quantification
The intensity and distribution of ER, PR and AR im¬
munostaining was evaluated subjectively by two observers
(blinded to the treatment types) using a light microscope.The
immunostaining was assessed as none, mild, moderate or
intense staining. Assessment of Ki 67 immunostaining was
performed using an image analysis system (Colour vision,
Improvision, UK), as previously described [5], Ten fields
of view (x20 objective) were selected at random from each
tissue section. The ratio of the total area of positively stain¬
ing nuclei to the total area of all nuclei within glandular
and stromal compartments was generated. The mean per¬
centage immunostaining within glands and stroma in each
tissue section was calculated to provide an index of cell
proliferation.
2.2.6. Statistical analysis
Comparisons were perfomed using Students f-test, anal¬
ysis of variance (ANOVA), Tukey HSD pairwise compar¬
isons, or Mann Whitney as appropriate.
3. Results
Only fourteen of the seventeen subjects completed the
study. The study was terminated prematurely due to grow¬
ing concern about the incidence of elevated liver function
tests, in a separate study of women with breast carcinoma
receiving high doses of onapristone. Of the 14 subjects who
completed the study, there were the following numbers in
each treatment group: 2mg oestradiol and placebo (n = 5),
2mg oestradiol and 1 mg onapristone (n = 5), and 2 mg
oestradiol and lOmg onapristone (n = 4).
3.1. Effect on haematology and biochemistry
The haematological and biochemical tests were repeated
at the endofthe study. In addition, tests of liver functionwere
also performed during treatment, in the fourth week of study
medication. In all subjects, haematological parameters were
within the normal range. Serum biochemistry was normal
in all but one subject (Subject no. 16) who had elevated
transaminases during the fourth week of treatment (AST
128; normal range 5—45). Liver function tests in this subject
returned to normal on repeat testing 11 days after stopping
study medication.
3.2. Effect on gonadotrophins and ovarian hormones
There was a significant fall in FSH concentration in all
subjects over time (P — 0.0002). A further suppression
in FSH levels was seen however in the group of women
receiving 10mg of onapristone (P = 0.029) (Fig. 1). In the
groups receiving placebo and 1 mg onapristone, there was
no significant change in LH levels over the course of the
study. LH was however suppressed over time in the group
receiving 10mg onapristone (P < 0.001 with respect to
time, P — 0.003 with respect to treatment) (Fig. 2).
In all subjects, concentrations of plasma progesterone re¬
mained in the postmenopausal range throughout the study
(Progesterone <3 nmol/1). During the course of study treat¬
ment, oestradiol levels rose significantly in all groups (P <
0 2 4 8
Weeks of treatment
Fig. 1. The mean±S.E.M. concentrations of FSH in all treatment groups
at baseline, 2, 4 and 8 weeks of treatment. FSH is significantly decreased
over time in all groups *P = 0.0002. Suppression of FSH is significantly
greater in lOmg onapristone group than other groups *P = 0.029.
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Table 1
Mean ± S.E.M. concentrations of Cortisol and androstenedione concentrations at baseline (0 week) and end of study (8 weeks) in each group
Cortisol (nmol/1) Androstenedione (nmol/1)
0 week 8 weeks 0 week 8 weeks
Placebo 441.6 ± 94.2 458.9 ± 47.5 3.1 ± 0.6 3.1 ± 0.6
1 mg Onapristone 372.2 ± 55.9 512.6 ± 79.9 3.7 ± 0.4 3.6 ± 0.6
10 mg Onapristone 319.7 ± 40.3 476.8 ± 25.7 3.6 ± 0.4 4.4 ± 0.6
□ placebo
H 1mg onapristone
0 2 4 8
Weeks of treatment
Fig. 2. The mean ± S.E.M. concentrations of LH in all treatment groups
at baseline, 2, 4 and 8 weeks of treatment. LH is significantly suppressed
over time in group receiving 10 mg onapristone (P < 0.01). LH is signif¬
icantly suppressed in lOmg onapristone group compared to other groups
*P = 0.003.
0.01). Mean (±S.E.M.) concentrations of oestradiol during
the eighth week of treatment were 443.4 ± 122.7 498.8 ±
207.1 and 546.7 ± 249.9 pmol/1 (for placebo, 1 and 10mg
of onapristone groups respectively).There was no significant
difference between treatment type and oestradiol concentra¬
tions.
3.3. Effect on pituitary adrenal axis- Cortisol
and androstenedione
There was no significant change in the concentrations of
Cortisol or androstenedione during the course of treatment
(Table 1).
3.4. Effect on endometrium
Two subjects (both receiving lOmg onapristone) experi¬
enced bleeding during the course of the study. One of these
women (subject no. 4) bled during the last 2 weeks of treat¬
ment, for a total of9 days. The bleeding was initially light but
subsequently heavy. Transvaginal ultrasound performed at
this time, demonstrated an endometrial thickness of 18 mm.
Endometrial histology in this subject displayed features of
late proliferative endometrium. In the other woman (subject
no. 6), light bleeding occurred during the first week of treat¬
ment and lasted 4 days. No further bleeding occurred during
treatment and endometrial histology at the end of the study
was that ofweakly proliferative endometrium.
There was considerable inter-subject variability in en¬
dometrial thickness (as measured using transvaginal ultra¬
sound) within each treatment group, at the end of the study
(8 weeks). The range of the endometrial thickness in each
group was 2-13, 2-8 and 8-18 mm for placebo, 1 mg on¬
apristone and lOmg onapristone respectively. There was no
statistically significant difference in endometrial thickness
between treatment groups, with 9 out of 14 subjects having
an endometrial thickness of >4mm.
3.5. Histology
Out of the fourteen women who completed the study,
endometrial biopsies were obtained from eleven. In two
women, no tissue was obtained at biopsy and in one case,
the subject refused endometrial sampling. Out of these 11
samples, the following numbers where obtained from each
treatment group: placebo (n — 4), 1 mg onapristone (n — 3)
and lOmg onapristone (n — 4).
Fig. 3. Histology of endometrium from oestradiol and placebo group (a), oestradiol and 1 mg onapristone (b) and oestradiol and lOmg onapristone (c).
All endometrium shows similar proliferative appearance. Scale bar = 50 p.m.
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Fig. 4. Immunohistochemistry of oestrogen (brown) and progesterone receptors (red) in endometrium from oestradiol and placebo group (a, d), oestradiol
and 1 mg onapristone (b, e) and oestradiol and 10mg onapristone (c, f). (a-c) Similar intensity of positive oestrogen receptor immunostaining (brown)
can be observed in both glands and stroma, (d-f) Similar intensity of positive progesterone receptor immunostaining (red) can be observed in both glands
and stroma. Scale bar = 50 pm.
There were no cases of endometrial hyperplasia. All en¬
dometrial sections showed proliferative endometrium. There
were no secretory features and both mitoses and apoptotic
bodies were present in endometrium from all treatment types
(Fig. 3). Many biopsies also displayed inactive cystically di¬
lated glands.
3.6. Steroid receptor immunostaining
Positive immunoreactivity for ER was visualised as dark
brown nuclear staining and that of PR as bright red nuclear
staining. Both the distribution and the intensity of immunos¬
taining, for ER and PR was similar in endometrium from
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Fig. 5. Immunohistochemistry of androgen receptor (brown) and Ki 67 (brown) in endometrium from oestradiol and placebo group (a, d), oestradiol and
1 mg onapristone (b, e) and oestradiol and lOmg onapristone (c, f). (a) Endometrium from oestradiol and placebo group, demonstrating mild androgen
receptor immunoreactivity in glands and intense staining in stroma, (b) Endometrium from oestradiol and 1 mg onapristone group, demonstrating mild
androgen receptor immunoreactivity in glands and intense staining in stroma, (c) Endometrium from oestradiol and lOmg onapristone, treatment group
demonstrating intense androgen receptor immunostaining (brown) in both glands and stroma, (d-f) Similar intensity of positive Ki 67 immunostaining
(brown) can be observed in both glands and stroma. Scale bar = 50 pm.
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all treatment types, with all endometrial biopsies displaying
moderate positive glandular and stromal immunoreactivity
(Fig. 4).
Positive immunoreactivity for AR was identified as dark
brown nuclear staining. All biopsies displayed either moder¬
ate or intense AR immunostaining within the stroma. Mild
AR immunostaining was observed in the glands of both
oestradiol-only and 1 mg onapristone exposed endometrium,
but intense AR immunostaining but observed within the
glands of endometrium from the group receiving lOmg on¬
apristone. (Fig. 5).
3.7. Ki 67 immunostaining
Positive immunoreactivity for Ki 67 was visualised as
dark brown nuclear staining. The distribution and intensity
of immunostaining was similar within endometrium from all
treatment types, with moderate intensity of immunostaining
in both glands and stroma. There was no significant differ¬
ence in the proliferation index (% of positively staining nu¬
clei) as assessed using image analysis, between treatment
groups in either glandular or stromal compartments (Fig. 5).
4. Discussion
It has previously been reported that mifepristone ex¬
erts progesterone 'agonist' effects on postmenopausal en¬
dometrium [10]. In addition to inducing histological features
of secretory changes, markers of oestrogenic proliferative
activity in the endometrium were suppressed, including
decreased activity of the enzyme DNA polymerase a and
increased activity of oestradiol dehydrogenase [10]. In con¬
trast, in our study, onapristone was not observed to exhibit
either progestogenic or antiproliferative effects on the en¬
dometrium of postmenopausal subjects. This may reflect
real differences in the properties of the two antiprogestins,
which include different half-lives and mechanisms of bind¬
ing to the progesterone receptor [17,18], Furthermore,
whereas animal studies have consistently demonstrated an¬
tiproliferative effects of mifepristone on endometrium, it
has been reported that onapristone exerts oestrogenic effects
in the rodent uterus [19]. There are however several differ¬
ences in study design between our study and the original
study using mifepristone in postmenopausal women, which
could possibly account for some of the difference in findings
[10]. In the mifepristone study, endometrial assessments
were made following 6 days of combined mifepristone (100
or 200mg) and oestradiol therapy, after a period of 9 days
ofunopposed oestrogen exposure. In our study, endometrial
assessments were made in the eighth week of combined
onapristone (1 or lOmg) and oestradiol therapy, without
any prior period of oestrogen priming. When one compares
the oestradiol only-treated endometrium with those who
received onapristone, there was no significant difference in
endometrial thickness, histology, or in the pattern of distri¬
bution of immunostaining for ER, PR or Ki 67. This would
suggest that onapristone, was unable to antagonise the mi-
togenic effects of oestradiol. Reassuringly there was no ev¬
idence of endometrial hyperplasia, although this is perhaps
not surprising in view of the relatively short duration of
treatment (8 weeks) with oestrogen and the small numbers
ofbiopsies available for analysis. Indeed, use of unopposed
oestradiol for 10-12 weeks (followed by 2 weeks of pro¬
gestogen therapy) forms the basis of many commercially
available 'long-cycle' or 'quarterly' hormone replacement
therapy regimes for menopausal women. Studies of such
regimes have reported rates of simple hyperplasia of around
15% after 10 weeks of unopposed oestradiol therapy [20].
The finding of an increase in AR immunostaining intensity
within the glandular epithelium in endometrium of women
treated with lOmg onapristone, does however suggest that
there may be a subtle effect of onapristone on the en¬
dometrium, which may be dose-related. Increased androgen
receptor expression within glandular epithelium has previ¬
ously been demonstrated in association with mifepristone
use in women of reproductive age [12,21], It has even been
suggested that this may be a possible mechanism for the
antiproliferative effect of mifepristone, since there is both
in both in vivo and in vitro evidence that androgens can
inhibit endometrial cell growth [12,22],
Unfortunately the study had to be terminated prematurely
due to concern about elevation of liver function tests in
a separate study using onapristone, and so fewer endome¬
trial samples than anticipated were available for assessment.
While we observed one subject in our study to have raised
serum transaminases, elevated liver function tests have also
been reported in association with the antiprogestin mifepri¬
stone [23-25].
Prolonged administration of onapristone did not signif¬
icantly affect serum concentrations of either Cortisol or
androstenedione as measured throughout the study. This
suggests that onapristone in the doses used in this study,
exerts no significant anti-glucocorticoid activity. This is
consistent with previous reports in pre-menopausal women,
which demonstrated an absence of significant glucocorti¬
coid activity using onapristone in either a single 400mg
dose or in a daily doses of 5-50 mg [14,24],
A suppression in FSH levels was observed in all subjects
throughout the study consistent with the effect of oestradiol
treatment. However, the additive suppressive effect of 10mg
onapristone on FSH concentrations, together with the sup¬
pressive effect of this dose on serum LH concentrations was
an unexpected finding. It has previously been reported that
mifepristone potentiates the supression of gonadotrophins in
postmenopausal women reveiving oestradiol [10]. Whether
such an effect represents a progesterone agonist effect at
the level of the hypothalamo-pituitary axis, or is an intrinsic
property of antiprogestins is unknown.
In conclusion therefore, the antiprogestin onapristone,in
contrast to mifepristone, did not exert progesterone-agonist
effects on postmenopausal endometrium. Furthermore, it
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did not exhibit obvious antiproliferative effects on the en¬
dometrium, as assessed by measurements of endometrial
thickness, histology or immunohistochemistry for either
the proliferation marker Ki 67, or ER and PR immunos-
taining. Subtle dose-related effects of onapristone on the
endometrium cannot however be excluded in view of a
subjective increase in intensity of immunostaining for AR
within glandular epithelium associated with lOmg onapris¬
tone treatment.
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\CKGROUND: We have previously shown that the progesterone antagonist mifepristone is a contraceptive when
ven in a dose of 2 or 5 mg per day. The majority ofwomen experience amenorrhoea rather than the irregular break
rough bleeding usually occurring with other estrogen-free contraceptive pills, such as progestogen-only pill (POP),
'e investigated the effects of low-dose mifepristone on endometrial parameters which may be associated with
tanges in endometrial function, such as microvasculature, vascular endothelial growth factor (VEGF) and glucocor-
:oid receptor (GR) content. METHODS AND RESULTS: Endometrial biopsies were collected from 16 women
Tore (late proliferative phase) and 60 and 120 days after taking 2 or 5 mg mifepristone daily for 120 days. Seven of
e eight women who received 2 mg mifepristone and all eight women who received 5 mg were amenorrhoeic during
e study. Mean estradiol (E2) concentrations remained in the mid-proliferative range, and the majority (9/16) of
amen showed proliferative endometrial histology at 60 and 120 days following treatment. There was a significant
crease in the density of the endometrial stroma (P < 0.05) and microvessels (P < 0.01) following 120 days of treat-
ent. Immunocytochemistry showed that GR, hitherto localized specifically in endometrial stroma, was up-regulated
the nuclei of glands (P < 0.05) and surface (luminal) epithelium (P < 0.01) by 60 days and maintained at 120 days,
lere was a significant reduction in stromal VEGF protein expression by day 120 of treatment (P< 0.01). CONCLUSION:
le high incidence of amenorrhoea in women taking mifepristone may be related to changes in the regulation of
iscular function.
y words: contraception/endometrium/glucocorticoid receptor/mifepristone/vascular endothelial growth factor
troduction
ifepristone is a potent antagonist of both progesterone and
ucocorticoids. In daily low doses, it acts as a contracep-
re by inhibiting ovulation and by altering endometrial
nction (Brown et al., 2002; Baird et al., 2003a,b). Cur-
atly used estrogen-free contraceptive methods such as
ogestogen-only pill (POP) are often discontinued because
a high incidence of troublesome side effects, such as
eak through bleeding (Belsey and Farley, 1988). In con-
ist, the majority ofwomen who take mifepristone have no
riods. Although traditionally amenorrhoea has been clas¬
hed as a disadvantage, many women now regard the
sence ofperiods as a desirable side benefit (Glasier et al.,
03). The mechanisms underlying these disturbances in
dometrial function are poorly understood and not clearly
ated to levels of endogenous or exogenous steroid hor-
mes (Fraser et al., 1996).
Locally produced vasoactive substances probably play a key
role in regulating endometrial angiogenesis, although these are
influenced substantially by different dosage regimens and
routes of administration of contraceptive steroids (Smith,
2001). Vascular endothelial growth factor (VEGF) promotes
microvascular endothelial cell proliferation, migration and
assembly into new vessels (Ferrara and Davis-Smyth, 1997),
and estrogen has been shown to promote angiogenesis by regu¬
lating the expression ofVEGF (Albrecht et al., 2003). Prostag¬
landins (PGs) influence contractility of endometrial vessels
and their permeability (Albrecht et al., 2003). An increase in
the local concentration of PGs in the endometrium is involved
in the mechanism ofmifepristone-induced vaginal bleeding in
the luteal phase (Hapangama et al., 2002). Glucocorticoids
modulate PG production in endometrial stromal cells and
fibroblasts (Pakrasi etal., 1983; Schatz etal., 1986; Neulen etal.,
1989; Delvin et al., 1990; Illouz et al., 2000). Glucocorticoid
12© The Author 2006. Published by Oxford University Press on behalfofthe European Society ofHuman Reproduction and Embryology. All rights reserved.
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Mifepristone and endometrial glucocorticoid receptor
receptor (GR) is strongly expressed in the nuclei of endome¬
trial cells in the stromal compartment of human endometrium
during the menstrual cycle (Bamberger et al., 2001; Henderson
et al., 2003). Although the exact physiological role of gluco¬
corticoids and GR in the human endometrium is unknown, it
has been suggested that they have an angiostatic role (Small
et al., 2005).
We have previously reported the effects of daily low-dose
mifepristone on the histology of the endometrium, sex hor¬
mone receptors and various proliferation markers (Baird et al.,
2003a,b; Narvekar et al., 2004). Mifepristone treatment is
associated with a striking up-regulation of the expression of
androgen receptors (ARs) in the glands and with an increase in
stromal density. The aim of this study was to look at the effects
of low-dose mifepristone on endometrial microvessel density,
VEGF and GR protein expression and correlate with endome¬
trial histology and bleeding patterns.
Materials and methods
Human endometrial samples were obtained from 16 women with
regular menstrual cycles (25-35 days), who were a subset of 58 vol¬
unteer women from Edinburgh, as previously reported (Brown et al.,
2002; Baird et al., 2003a; Narvekar et al., 2004). The local ethics
committees (Institutional Review Board) approved the studies, and all
the women provided written informed consent. Subjects were ran¬
domly allocated to receive 2 (n = 8) or 5 mg (n = 8) of mifepristone
daily for the 120 treatment days. Subjects had a mean age of 30.5
years (range 24-40) and a mean BMI of 24.5 kg/m2 (range 21-34).
Endometrial biopsies were collected using a Pipelle endometrial sam¬
pling device (Prodimed, Neuilly-en-Thelle, France) in the late follicu¬
lar phase of the pretreatment cycle (day 12), after 60 days of
mifepristone treatment and after 120 days of treatment. Specimens
were fixed in normal buffered formalin, processed and embedded in
paraffin wax. Endocrine and endometrial findings have been reported
previously (Brown et al., 2002; Baird et al., 2003a; Narvekar et al.,
2004).
Immunocytochemistry
Immunocytochemistry was performed for the immunolocalization of
VEGF, CD31 (endothelial marker) and GR. Immunostaining procedures
followed those previously published (Nayak et al., 2000; Bamberger
etal., 2001). All antibodies were tested individually at a range of
dilutions and different antigen retrieval conditions to determine the
protocol which gave the least background and highest specific stain¬
ing (Table I). Positive and negative controls were included. All tissue
sections were initially prepared in a similar manner. Five-micrometre
paraffin-embedded tissue sections were dewaxed in Histoclear
(National Diagnostics, UK) and rehydrated in descending grades of
alcohol to distilled water. The tissue sections were subjected to anti¬
gen retrieval in a pressure cooker (5 min) or microwave (10 min)
using 0.01 M sodium citrate at pH 6 (Table I) and were then allowed
to cool for 20 min. Endogenous peroxidase activity was quenched by
immersion in 3% hydrogen peroxide (BDH, Poole, UK) in methanol
for 30 min at room temperature. Non-specific binding of the primary
antibody was blocked by incubating the sections for 20 min at room
temperature in a 1:5 dilution of normal immune serum (Autogen Bio-
clear, Holly Ditch Farm, Wilts, UK) in buffer containing 5% bovine
serum albumin. Sections were incubated at 4°C with primary and con¬
trol antibodies overnight. An avidin-biotin-peroxidase system was
used as the detection system. The sections were incubated with bioti-
nylated secondary antibody (Vector Laboratories, Peterborough, UK)
in normal immune serum followed by avidin-biotin-peroxidase com¬
plex (Vectastain horse-radish peroxidase and Vectastain Elite PK
6101, Vector Laboratories) for 30-60 min each at room temperature.
All tissue sections underwent an identical epitope visualization step.
The peroxidase substrate 3,3'-diaminobenzidine (DAKO) was used as
chromogen. Sections were then counterstained with haematoxylin,
dehydrated in ascending grades of alcohol to xylene and mounted
using Pertex (Cellpath pic., Hemel Hempstead, UK).
CD31
Sections were incubated at 4°C either with mouse anti-human CD31
(Novacastra Laboratories, Newcastle upon Tyne, UK) overnight at a
1:800 dilution in normal horse serum (NHS) or similarly with a con¬
trol mouse immunoglobulin (Ig)Gl antibody at 1:8000 dilution in
NHS.
VEGF
Sections were incubated overnight at 4°C either with polyclonal rabbit
anti-human VEGF (SantaCruz Biotechnology, CA, USA) antibody at
1:600 dilution in normal goat serum (NGS) or similarly with a control
VEGF preabsorbed antibody at 1:60 dilution in NGS.
GR
Non-specific binding of avidin and biotin was blocked by incubating
with avidin and biotin for 15 min each followed by non-immune rab¬
bit serum (NRS) for 20-30 min at room temperature. Sections were
incubated at 4°C either with monoclonal mouse anti-human GR IgG2a
(Novocastra Laboratories, Newcastle upon Tyne, UK) at a dilution of
1:40 in NRS or similarly with a control mouse IgG2a antibody at
1:320 dilution in NRS.
Semi-quantitative immunocytochemistry score
Location and intensity of immunostaining were measured for VEGF
and GR using a semi-quantitative scoring system. Sections were scored
blind by two observers (blind to study groups and to other's results).
This scoring system is a standard method used in previous studies
(Wang et al., 1998; Critchley et al., 2001; Narvekar et al., 2004), and a
Table I. Immunochemistry protocols for vascular endothelial growth factor (VEGF), glucocorticoid receptor (GR) and the endothelial marker CD31
Receptor Buffer Antigen retrieval Non-immune serum Antibodies Stock solution (mg/ml) Dilution Detection system
VEGF TBS/TBST Microwave Normal goat serum VEGF 0.2 1:600 ABC-Elite 30 min
VEGF pre-absorbed 0.02 1:60
GR PBS/PBST Pressure cook Normal rabbit serum GR 0.124 1:40 ABC-HRP 60 min
Mouse IgG2a 1.0 1:320
CD31 PBS/PBST Pressure cook Normal horse serum CD31 0.1 1:800 ABC-Elite 30 min
Mouse IgGl 1.0 1:8000
HRP, horse-radish peroxidase; Ig, immunoglobulin; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline with added Tween; TBS, Tris-buffered
saline; TBST, Tris-buffered saline with added Tween.
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igh correlation has been demonstrated between objectively measured
amunoreactivity (image analysis) and subjective semi-quantitative
;oring of immunostaining patterns (Wang et al., 1998). Immunostain-
Lg intensity and distribution of epitopes in all tissue sections were
isessed on an arbitrary four-point scale: 0 = no staining, 1 = mild
aining, 2 = moderate staining and 3 = intense staining.
essel counts and stromal density
essel counts and stromal density were measured using image ana-
sis. The system used a Carl Zeiss Axistop 2 microscope (x40 objec-
ve) connected to a Macintosh G3 computer, using Openlab 2.08
lage analysis software (Improvision, Coventry, UK). At least 12
elds of view were selected at random from each tissue section at a
agnification of x40. The glands and stroma from each digitized
rage were interactively dissected.
CD31 immunoexpression was used to identify endothelial cells
Lees et al., 1993). All immunostained (brown) structures were con-
dered positive and counted for each digitized image, even if lumen
as not identified. A similar methodology has been described to study
langes in vessel density following Norplant use (Hickey et al.,
>99). The results were averaged and expressed as vessels per square
illimetre. Endometrial stromal density appears to be increased fol-
wing daily low-dose mifepristone (Baird et al., 2003a). To compen-
te for this, the total number of cells not expressing CD31 (blue
lematoxylin) was measured separately for each digitized image
;ing Openlab colour discrimination software, and the results are also
:pressed as vessels per 1000 stromal nuclei. This method of image
talysis has previously been described and validated in our laborato-
5S (Critchley et al., 1996; Wang et al., 1998).
Stromal density was expressed as the total number of stromal nuclei
rown CD31 and blue haematoxylin) per square millimetre of
idometrial tissue.
atistical methods
atistical analysis was performed using the Statistical Package for the
)cial Sciences (SPSS, Chicago, IL, USA) and Excel 2002 (Microsoft
arporation). Continuous data are expressed as mean with SE and cat-
;orical data as median with range. Non-parametric tests (Friedman
st, Wilcoxon-signed rank test and Mann-Whitney test), with and
ithout Bonferroni correction, were used to compare study variables
various time points.
esults
ndometrial histology, serum estradiol and bleedingpatterns
11 16 pretreatment endometria were sampled in the prolifera-
/e phase. Following treatment, 9/16 endometria were still
oliferative at 60 and 120 days. Four endometria showed
'Stic dilatation of the glands and five inactive epithelium at
) and 120 days of treatment, respectively. Serum estradiol
i2) levels remained in the mid-proliferative range follow-
g treatment (511 ± 70.21 pmol/1, pretreatment; 459 ±
).94 pmol/1, mifepristone 60 days; 290 ± 63.39 pmol/1,
ifepristone 120 days). There was no significant change in
e level of E2 following treatment (P > 0.05, Bonferroni
irrection). Seven of the eight women on 2 mg mifepristone
id all eight women on 5 mg of mifepristone were completely
aenorrhoeic during treatment. Detailed description ofmenstrual
lysiology, endocrinology and endometrial histology has been
ported previously (Brown et al., 2002; Baird et al., 2003a).
lere was no significant difference (P > 0.05, Mann-Whitney




















Day 60 Day 12
Figure 1. Density of endometrial stroma (a) and microvessel (b and
c) in women before and after treatment with mifepristone. The values
are expressed as median (horizontal bar), mean (square dot) and
box plots showing 50% of values (box) with range (whiskers), (a)
P < 0.01 (Wilcoxon test), significant increase, mifepristone treatment
versus pretreatment; (b) P < 0.05 (Wilcoxon test), significant
increase, mifepristone treatment versus pretreatment.
test) between women treated with 2 or 5 mg mifepristone for
any parameters studied except for the degree of GR protein
expression in the vascular endothelium at 60 days of treatment
[median (range) at 60 days = 3 (3), 2-mg group; 2 (2-3), 5-mg
114
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group; P = 0.012, Bonferroni correction, Mann-Whitney test].
As the GR expression was identical by 120 days in the two
groups and there were no differences in any of the other 36
parameters tested, it was considered that this difference could
have occurred by chance. Therefore, the 2- and 5-mg data sets
were combined, and results reported are for all 16 subjects.
Stromal density
An average of 0.5 mm2 (SE = 0.05) of endometrial stroma was
examined in the pretreatment samples and 0.37 mm2 (SE = 0.04)
in the treatment samples. Stromal density, expressed as nuclei per
square millimetre of endometrial tissue, increased significantly
(24%) by day 60 of treatment (P < 0.001), and the increase (18%)
was maintained at 120 days (P < 0.05, Figure la; 8057 ± 355,
pretreatment; 10 003 ± 355, day 60; 9510 ± 351, day 120).
Microvessel density
Vessel density per square millimetre of endometrial tissue
increased (47%) by day 60 of treatment (P < 0.01, Figures lb
and 2). This increase was highly significant and was maintained
(49%) at 120 days (P < 0.01, Figure lb; 267 ± 18, pretreatment;
392 ± 32, day 60; 398 ± 37, day 120). To compensate for an
increase in stromal density, microvessel density was calculated
per total nuclei in each endometrial sample. There was a mod¬
est (P = 0.08, ns) increase (15%) by day 60 and a significant
(P < 0.01) increase (34%) by day 120 of treatment (Figure lc;
and Figure 2b and c; 33 ± 1.9, pretreatment; 38 ± 2.1, day 60;
42 ± 2.75, day 120).
VEGF
VEGF protein was strongly expressed in the cytoplasm of
endometrial glands and surface epithelium. Expression in the
stroma was patchy and faint (Table II, Figure 2e). VEGF expres¬
sion remained unchanged in the glandular [median (range) = 2
(1-3) pretreatment, 1 (1-3) day 60 and 1 (0-2) day 120], surface
epithelium [median (range) = 1 (0-3) pretreatment, 1 (0-3) day
60 and 1 (0-2) day 120] and endothelial cells [median (range) =
1 (0-2) pretreatment, 0.5 (0-2) day 60 and 1 (0-1) day 120] fol¬
lowing treatment with mifepristone. There was a decrease (P <
0.01) in the stromal expression [median (range) = 1 (0-2) pre¬
treatment, 0 (0-2) day 60 and 0 (0-1) day 120] ofVEGF follow¬
ing 120 days of treatment (Table II, Figure 2f and g).
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Figure 2. Immunoexpression of the endothelial marker CD31, vascular endothelial growth factor (VEGF) and glucocorticoid receptor (GR) in
endometrial glands (Gl.), stroma (Str.), surface epithelium (surf.) and vascular endothelium (Ves.) before and after treatment with mifepristone.
Scale bar (a, j and p) = 50 pm; positive immunoexpression = brown. Significant increase in microvessel (arrows) density following treatment
(b and c), significant decrease in stromal VEGF following treatment for 120 days (g) and significant increase ofGR immunoexpression following
treatment for 60 (k and 1) and 120 days (m and n) compared to follicular pretreatment day 12 endometrium; note the absence ofGR immunoexpres¬
sion in glands during pretreatment day 12 endometrium (j) and significant expression following treatment (1 and n); also note the strong expression
ofGR in vascular endothelium (p, q and r); negative controls are included.
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able II. Vascular endothelial growth factor immunoexpression expressed as
iean (median) in endometrium before and after treatment with daily
ifepristone
Mifepristone group (n = 16)
Day 12 Day 60 Day 120
pretreatment mifepristone mifepristone
urface 1.43(1) 1.40(1) 1.40(1)
lands 1.63 (2) 1.40(1) 1.25(1)
troma 0.94 (1) 0.33 (0) 0.31 (0)*
ndothelium 0.69(1) 0.64 (0.5) 0.44 (0)
P = 0.004 (Wilcoxon test), significant decrease, day 120 mifepristone
eatment versus day 12 pretreatment.
able HI. Glucocorticoid receptor immunoexpression expressed as mean
nedian) in endometrium before and after treatment with daily mifepristone
Mifepristone group (n = 16)
Day 12 Day 60 Day 120
pretreatment mifepristone mifepristone
urface 0(0) 1.13(1)* 1.47 (1)*
lands 0(0) 0.44 (0)** 0.69 (1)*
troma 1.75(2) 2.13 (2) 1.94(2)
ndothelium 2.47 (3) 2.63 (3) 2.56 (3)
P< 0.01, significant increase (Wilcoxon test), mifepristone treatment versus
-etreatment; **P < 0.05, significant increase (Wilcoxon test), mifepristone
eatment versus pretreatment.
R
he pretreatment proliferative phase endometrial samples
lowed strong GR immunoexpression in the nuclei of stromal
nedian (range) = 2 (0-3)] and endothelial [median (range) = 3
1-3); Table III, Figure 2p] cells and a complete absence of
xpression in the surface epithelium [median (range) = 0 (0-0);
igure 2i] and glands [median (range) = 0 (0-0); Table III,
igure 2i and j]. Following treatment with mifepristone, nuc-
:ar immunoexpression was induced in glands [median (range)
0 (0-2) day 60 and 1 (0-2) day 120, P < 0.05] and surface
pithelium [median (range) = 1 (0-3) day 60 and 1 (1-3) day
20, P < 0.01], This was evident by 60 days and maintained at
20 days (Table III, Figure 2k-n). Immunoexpression in the
roma [median (range) = 2 (1-3) day 60 and 2 (1-3) day 120]
id endothelial cells [median (range) = 3 (2-3) day 60 and 3
1-3) day 120; Figure 2q and r] was unchanged.
discussion
his study extends our previous report of the effects of daily
>w-dose mifepristone on endometrial development (Brown
f al., 2002; Baird et al., 2003a,b; Narvekar et al., 2004). Here,
re show that mifepristone-induced amenorrhoea is associated
ith an increase in glandular GR and microvessel density and a
ecrease in stromal VEGF.
Histological appearance of the endometrium does not corre-
:te well with menstrual patterns, except with the development
fextreme histological atrophy, which typically predicts amen-
rrhoea. In the primate model, continuous mifepristone
induces marked endometrial atrophy, and the spiral arteries are
the primary targets that are damaged or inhibited by progester¬
one antagonists such as mifepristone (Chwalisz et al., 2000).
Microvessel density increases in conditions of spontaneous
(post-menopausal) and induced (Norplant, danazol and gosere-
lin) endometrial atrophy, and the mechanisms involved may
vary according to the nature of the atrophic stimulus (Hickey
et al., 1996, 1999). In women exposed to high- and medium-
dose progestogens and long-term users of levonorgestrel-
releasing intrauterine system (Mirena), a decrease in endome¬
trial vascular density has been observed (Song et al., 1995;
Oliveira-Ribeiro et al., 2004). In this study, over 90% women
were amenorrhoeic. The endometrium was proliferative, and
there was a significant increase in microvessel density. We
used CD31 to identify the vessels because preliminary studies
with the alternative immunohistochemical marker CD34 were
unsatisfactory. The use of CD31 may explain the discrepancy
in the numerical count of vessels per area of endometrium
between our study and that by other investigators (Hickey et al.,
1996; Lau et al., 1999; Schindl et al., 2001). A study that used
CD31 to identify vessels in endometrial samples of 16 norm¬
ally menstruating premenopausal women showed wide indi¬
vidual variation in vessel density and no clear trend or
difference over the menstrual cycle (Moller et al., 2001).
VEGF is a major regulator of endothelial cell proliferation,
angiogenesis, vasculogenesis and capillary hyperpermeability
(Ferrara and Davis-Smyth, 1997; Ferrara, 1999a,b; Smith,
2001). The presence ofVEGF mRNA, protein and its receptors
has been demonstrated in the human and primate endometrium
throughout the menstrual cycle (Torry et al., 1996; Ferrara and
Davis-Smyth, 1997; Meduri et al., 2000; Nayak et al., 2000;
Moller et al., 2002; Nayak and Brenner, 2002; Sugino et al.,
2002), and proliferative endometrium demonstrates prominent
glandular immunoreactivity and faint, inconsistent staining in
stromal cells, similar to observations in this study (Sugino
etal., 2002). Mifepristone abolished VEGF expression in the
endometrial glandular epithelium of cynomolgous monkeys
(Greb et al., 1997), and this might represent a mechanism for
the suppression of angiogenesis and severe endometrial atro¬
phy observed following mifepristone treatment in the primate
model. In this study, VEGF immunoexpression was signifi¬
cantly reduced in the stroma following mifepristone treatment.
There was a non-significant reduction in glandular VEGF
immunoexpression, whereas microvessel density was signifi¬
cantly increased following treatment. It has been suggested that
VEGF may not be the primary regulator of endothelial cell pro¬
liferation in the human endometrium (Gargett et al., 1999).
Besides VEGF, other factors such as angiopoetin and fibroblast
growth factor also regulate endometrial angiogenesis (Smith,
2001). VEGF regulates vascular permeability, and the decrease
in stromal VEGF may explain the increase in stromal density
following treatment with mifepristone (Ferrara, 1999a,b).
The most striking observation in this study was the change in
the expression of GR protein and its location. In the normal men¬
strual cycle, GR is located only in the nuclei of endometrial stro¬
mal and endovascular cells and is absent in the glands (Bamberger
et al., 2001). In this study, the pretreatment proliferative phase
samples showed a strong nuclear receptor expression in the
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stroma and a complete absence in the glands and surface epi¬
thelium. Following treatment with low-dose mifepristone,
there was a significant induction ofnuclear GR protein expres¬
sion in both glands and surface epithelium. Although the pres¬
ence of GR has been reported in the luminal (surface)
epithelium of rat uterus (Korgun et al., 2003), this is the first
study to report the presence of nuclear GRs in endometrial
gland cells. Mifepristone binds strongly to GR and progester¬
one receptor but more weakly to AR (Spitz and Bardin, 1993),
and we have previously reported that chronic treatment with
low-dose mifepristone up-regulates AR and down-regulates
progesterone receptor in the endometrium (Narvekar et al.,
2004). The underlying cellular mechanisms are poorly under¬
stood, but the striking temporo-spatial up-regulation ofAR and
GR in the glands and surface epithelium suggests that they
share common mechanistic pathways. However, it is unlikely
that the changes described in this study are the result of a
change in the levels of Cortisol because this dose of mifepris¬
tone has no demonstrable effect on the pituitary-adrenal axis
(Brown et al., 2002).
The exact physiological role of GR and glucocorticoids in
the human endometrium is not clear. The expression pattern
points to a functional role in the complex process of deciduali-
zation (Bamberger et al., 2001). Several effects of glucocorti¬
coids on endometrial cells have been reported. Uterine events
such as menstruation, implantation, cervical softening and par¬
turition share similarity with non-reproductive inflammatory
situations (Kelly, 1996). At high concentrations, glucocorti¬
coids inhibit most immunological responses and are well-
known anti-inflammatory agents. PGs have a pivotal role in
menstruation and endometrial bleeding (Baird et al., 1996),
and glucocorticoids have been shown to suppress PGF2 alpha
production (Schatz et al., 1986; Neulen et al., 1989; Delvin
et al., 1990; Illouz et al., 2000) and phospholipase A2 (Pakrasi
et al., 1983), one of the enzymes considered to be rate-limiting
in generating free arachidonic acid for PG synthesis. An
increase in the local concentration of PGs in the endometrium
has been postulated in the mechanism of bleeding observed
following administration of mifepristone in the mid-luteal
phase (Hapangama et al., 2002). The expression of GR in
endothelial cells suggests a role for glucocorticoids in modula¬
tion of angiogenesis in the endometrium as has been reported
in the rat aorta (Small et al., 2005). Endogenous and exoge¬
nous glucocorticoids exert tonic inhibition, whereas treatment
with a GR antagonist enhances angiogenesis in the mouse
model (Small et al., 2005). An increase in GR expression could
potentiate the effects of circulating glucocorticoids on the
endometrium, thereby suppressing local PG concentrations and
inhibiting angiogenesis. Contrary to theoretical expectations,
we have demonstrated a small increase in microvessel density.
This increase may represent a counting artefact in endometrial
sections following stromal compaction and gland dilatation. A
better understanding of the role of glucocorticoids and andro¬
gens and their receptors in the endometrium is needed to recon¬
cile the different endometrial effects into a working hypothesis.
Glucocorticoids may also modulate human fertility. Ele¬
vated levels of glucocorticoids disrupt normal uterine develop¬
ment and implantation (Campbell, 1978; Monheit and Resnik,
1981; Bigsby, 1993; Hicks et al., 1994). Mechanisms by which
glucocorticoids may influence implantation include their
known effects on actin polymerization, lysosomal activity, PG
synthase, PGE nitric oxide synthase and matrix metalloprotein-
ases (Salamonsen, 1996), all of which have known roles in
implantation. Excess glucocorticoid exposure can disturb the
normal pattern of growth and differentiation of the primate
fetus (Arcuri et al., 1997). On the other hand, Cortisol may
modulate local immunosuppressive activity within the decidua
by inhibiting the production of anti-inflammatory cytokines,
such as interleukin-1 (Snyder and Unanue, 1982), thus protect¬
ing the developing blastocyst from maternal immune rejection
(Ricketts et al., 1998). Although low-dose mifepristone acts as
a contraceptive by inhibiting ovulation in up to 90% subjects
(Brown et al., 2002), an increase in surface (luminal) and glan¬
dular GR expression may play a role in the endometrial anti-
fertility effects ofmifepristone.
Summary
The most striking observation in this study was the change in
the expression of GR protein and its location. Glucocorticoids
and GR modulate angiogenesis. We have demonstrated an
increase in endometrial vessel density and VEGF. The high
incidence of amenorrhoea in women taking mifepristone may
be related to the regulation of vascular function.
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Abstract
Background: We have previously shown that the antigestagen mifepristone is contraceptive when given in a daily dose of 5 mg, po.
Epidemiological studies suggest that gestagen-only contraceptives may increase the risk of transmission of human immunodeficiency virus
(HIV) due to effects on the vaginal defenses to infection. We investigate the effects ofmifepristone on vaginal thickness, steroid receptor and
natural antimicrobial content and pharmacokinetics of mifepristone.
Methods: In a pilot study, eight women were given mifepristone 5 mg/day for an average of 33 days. Ovarian function was assessed by
measurement of estradiol and progesterone in blood and their metabolites in urine and by serial ultrasound of their ovaries. Vaginal biopsies
were collected before (late proliferative) and after taking mifepristone.
Results: All subjects showed a similar pattern of descending serum concentrations of mifepristone. The elimination phase half-life was
18±5.1 h (mean±SD). Mean C.mliX measured at 1 h was 641.7 nmol/L (range, 502-740 nmol/L). All eight women reported amenorrhea for
the duration of treatment and seven of eight women showed biochemical and ultrasound evidence of anovulation. There was no significant
change in vaginal thickness following treatment [342+40 pm pretreatment, 303±69 pm posttreatment (mean±SEM); p>.05]. Estrogen
(ERa, ER(3) and androgen receptor were expressed in both vaginal epithelium and subepithelial stroma, whereas progesterone receptor was
expressed predominantly in the subepithelial stroma. There was no change in receptor content and distribution following mifepristone
treatment. Natural antimicrobial mRNA [secretory leukocyte protease inhibitor, human beta defensins mRNA (HBD1, HBD2, HBD3,
HBD5), granulysin and elafin] was extracted from the vaginal tissues, and the content was unaffected by mifepristone treatment.
Conclusion: The absence of changes in vaginal thickness, steroid receptor and natural antimicrobial content and its distribution in this
preliminary study suggests that in contrast to other estrogen-free contraceptives, mifepristone is unlikely to be associated with the increased
risk of transmission of HIV and other sexually transmitted infections.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Mifepristone; Vaginal thickness; Steroid receptors; Natural antimicrobial; Pharmacodynamics
1. Introduction
The state of the vaginal microenvironment affects a
woman's risk of human immunodeficiency virus (HTV)
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transmission. Several human and nonhuman primate studies
have shown that long-acting gestagen treatment increases
the transmission of HIV [1-3], simian immunodeficiency
virus (SIV) [4] and other sexually transmitted infections
(STIs) [5,6], The underlying mechanisms are poorly
understood. Experiments on hysterectomized rhesus
monkeys suggest that the vagina, rather than the cervix or
the uterus, is the main portal of viral entry [7,8].
Epithelial thickness and integrity modulate the ease
of access of virus to immune cells and subepithelial
vasculature [9], Estrogen-induced surface keratinization
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and hyperplasia protect rhesus monkeys against SIV
inoculation [10,11], whereas estrogen-deficient women such
as those who are postmenopausal [12,13] or on long-acting
gestagens are at increased risk of HTV, presumably as a
result ofvaginal thinning. Other biological variables such as
vaginal microflora [14-16], immune cell populations
[17,18] and natural antimicrobials [19-21] also play an
important role in innate defenses of the reproductive tract.
Mifepristone, a potent antagonist ofprogesterone (P), has
the potential to be developed for contraception and other
gynecological uses [22-24]. Daily low-dose treatment
inhibits ovulation but maintains follicular development, thus
exposing reproductive tissues to unopposed estrogen. Since
gestagen treatment increases and estrogen treatment
decreases HTV/SIV transmission, the aim of the present
study was to investigate whether the antigestagen mifepris¬
tone modulates underlying mechanisms involved in trans¬
mission. We investigated vaginal morphology, steroid
receptor and natural antimicrobial [secretory leukocyte
protease inhibitor (SLPI), human beta defensins mRNA
(HBD1, HBD2, HBD3, HBD5), granulysin and elafin]
content. We also report the pharmacokinetics and pharma¬
codynamics of 5 mg mifepristone supplied by Hualian
Pharmaceuticals Co. Ltd. (Shanghai, China), which has been
used in the present study as well as in previous studies [23].
2. Subjects and methods
We report two pilot studies using 5 mg mifepristone —
the study on vaginal epithelium that was carried out in
Edinburgh and the pharmacokinetic study in Helsinki.
2.1. Effects ofmifepristone on vagina
A single-center, open, single-group study concerning
female volunteers was undertaken. Eight healthy subjects
with a mean age of35 years (range, 27-39 years) and a mean
bodymass index (BMI) of23 kg/m2 (range, 17.3-28.2 kg/m2)
who had regular menstrual cycles (25-42 days) were
recruited to the study. The women agreed to refrain from
the use of vaginal medications during the study period or
from sexual intercourse 48 h prior to vaginal biopsy. Women
who had breast-fed or had taken hormonal contraception less
than 3 months prior to the study and those with vaginal or
pelvic infections (current or past) were excluded. The
proposal was approved by the local ethics committee
(institutional review board). All women gave written
informed consent before enrolment and were screened before
entering the study. Screening included a full medical,
gynecological history and examination, including measure¬
ment of height, weight, blood pressure and pulse. Blood
samples were collected for measurement of routine clinical
chemistry and hematology (liver function tests, urea and
electrolytes, glucose, full blood count). (3HCG was measured
to exclude pregnant women from the study. Subjects were
studied for one pretreatment cycle, one cycle of treatment
(approximately 33 days) and one posttreatment cycle. Each
subject was reviewed on Day 12 of the pretreatment
menstrual cycle (Visit 1), at the end of treatment (Visit 2)
and on Day 12 ofthe posttreatmentmenstrual cycle (Visit 3).
Subjects were given a menstrual record card and were asked
to record all vaginal bleeding.
2.2. Assessment ofovarian function
Ovarian function was monitored by measurement of
ovarian steroids in urine and plasma and by transvaginal
sonography. All subjects collected twice weekly samples of
early morning urine during the study period, starting in the
early follicular phase (Days 1-5) of the pretreatment cycle.
Aliquots were frozen and stored at -20°C until assayed for
estrone glucuronide (E1G), pregnanediol glucuronide (PdG)
and creatinine (Cr). PdG was measured using a direct
enzyme immunoassay, while E1G was measured by direct
immunoassay. Ovarian follicular activity during treatment
was compared with that during the follicular phase of the
pretreatment cycle, and the activity was scored as complete
suppression, partial suppression or continued follicular
activity. Ovulation was deemed to have occurred if the
excretion of PdG exceeded 0.5 mmol/mol Cr and was at
least threefold higher than that in the preceding week.
A detailed description of this methodology is given in our
previous report [23]. Blood samples were collected at all
study visits and assayed for estradiol (E2) and P using
radioimmunoassay (RIA). Assay characteristics and meth¬
odology have been described in our previous reports [23].
A transvaginal ultrasound scan was carried out at all study
visits, and ovarian dimensions, follicle number and diameter
and presence of ovarian cysts were recorded.
2.3. Vaginal biopsy
A full-thickness vaginal biopsy was taken from the
lateral vaginal wall 4 cm proximal to the hymeneal ring on
Day 12 of the pretreatment cycle (Visit 1) and, again, after
completion of treatment (Visit 2). One ampoule of Citanest
with octapressin (3%; prilocaine hydrochloride, 30 mg/mL;
felypressin, 0.03 U/mL; Dentsply) was injected into the
lateral vaginal wall as a local anesthetic and hemostatic
agent. This also elevated the target vaginal tissue sufficient¬
ly to permit easy access for a biopsy. Vaginal biopsy was
performed using a long Schumacher forceps. Vaginal tissues
were stored in RNAlater (Applied Ltd., Cambridgeshire,
UK; RNAlater is an aqueous storage reagent to stabilize and
protect RNA) and neutral-buffered formalin (NBF; for
future preparation of paraffin-embedded tissue for immu-
nohistochemistry). A second biopsy was taken if adequate
sample was not obtained from the first biopsy. Vaginal
bleeding from the biopsy site was controlled using either
silver nitrate or, if necessary, a Vicryl 3-0 suture (Ethicon,
UK), depending on the amount of bleeding.
An endometrial biopsy was collected using Pipelle
endometrial sampler (Prodimed, Neuilly-en-Thelle, France)
at end of treatment (Visit 2), fixed in NBF and embedded in
paraffin. Endocervical and posterior fornix swabs were
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Fig. 1. Vaginal thickness measurement Average thickness between surface
and basement membrane (trace tool, Image Proplus 4.5, Media Cybernetics).
collected at all study visits and cultured for pathogenic
organisms, for example, gonococcus, trichomonas and
streptococcus, which might influence the parameters studied
in target vaginal tissues.
2.4. Safety parameters
At each study visit, blood pressure and pulse were
measured, and blood was taken for measurement of routine
clinical chemistry and hematology. In addition, each subject
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was asked to report any health problems or adverse events
that had occurred since the last visit.
2.5. Vaginal thickness measurement
Vaginal tissue samples were embedded in paraffin, and
serial 5-pm sections were cut at a 90° angle to the vaginal
surface epithelial layers. The sections were stained with
hematoxylin and eosin, and digital images were captured at
x 10 eyepiece magnification using a Spot microscope
connected to a Windows PC computer. Image Proplus 4.5
(Media Cybernetics, Silver Spring, CO, USA) software was
calibrated to match the eyepiece used to capture the image.
The surface and basement membranes of vaginal epithelium
were outlined using a trace tool within the software (Fig. 1).
The software automatically calculated the average distance
between the two traced outlines.
2.6. Immunohistochemical (IHC) localization of estrogen
receptor alpha (ERcc), estrogen receptor beta (ERft),
progesterone receptor (PR), androgen receptor (AR) and
proliferation marker phospho-histone H3 (PH3)
Immunohistochemistry was carried out on both the
vaginal and endometrial biopsies for the following proteins
of interest: ERa (Novocastra, Newcastle-upon-Tyne, UK),
ER(i (Serotec, Oxford, UK), PR (A+B) (Novocastra), AR
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
PH3 (Upstate Biotechnology, Poole, UK) and SLPI (Hycult
Biotechnology, Cambridge, UK). All antibodies used were
mouse monoclonal, except for PH3, which was a rabbit
polyclonal. They were tested individually at a range of
dilutions and at different antigen retrieval conditions to
determine the protocol that gave the least background and
Table 1
Immunohistochemistry protocol









Pressure cook: 0.01 M sodium 1:100 mouse anti-ERa MIgGI 1:1300 Biotinylated secondary
citrate, pH 6, 5 min 3 h at room temperature and ABC detection
MIgGI 1:13,000 (Vision Biosystems)
Vagina Biotinylated secondary Pressure cook: 0.05 M
Endometrium and ABC-streptavidin glycine/EDTA, pH 8, 7 min
3 h at roo
1:1000 mouse anti-ERa
3 h at room temperature
1:40 mouse anti-ERp
Overnight at 4°C
Vagina Goat antimouse Microwave: 0.01 M sodium 1:80 mouse anti-PR
Endometrium envision system citrate, pH 6, 10 min 37°C for 60 min
Vagina Biotinylated secondary Pressure cook: 0.01 M sodium 1:400 rabbit anti-AR





Pressure cook: 0.01 M sodium
citrate, pH 6, 5 min
SLPI Vagina Biotinylated secondary Microwave: 0.01 M sodium




























a The anti-ERp antibody has been previously preabsorbed with the peptide to which it had been raised [25].
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highest specific staining (Table 1). Positive and negative
controls were included in every run. In most cases, negative
controls were performed by adding a matched IgG control
antibody (mouse IgG, Sigma, Poole, Dorset, UK; rabbit IgG,
Vector Laboratories, Peterborough, UK) of the same species
and at the same antibody concentration as the primary
antibody. Protocols were carried out either on the bench or
with the use of a Bond-X automated immunohistochemistry
staining machine (Vision Biosystems, Newcastle, UK).
All tissue sections were initially prepared in a similar
manner. Five-micron paraffin-embedded tissue sections
were dewaxed in Histoclear (National Diagnostics, Hessle,
UK) and rehydrated in descending grades of alcohol to
distilled water (dH20). Antigen retrieval was then carried
out by heating the sections either in a microwave oven
(setting: high) or in a Tefal Clipso pressure cooker (Setting
2/high, Tefal, Nottingham, UK). The buffer concentration
and duration of antigen retrieval varied depending on
protocol (Table 1). Sections were left to cool in both cases
for 20 min. Endogenous peroxidase activity was quenched
by immersion in 3% hydrogen peroxide (BDH, Poole, UK)
in methanol for 30 min at room temperature. For AR only,
sections were incubated in avidin for 15 min at room
temperature (Vector Laboratories), followed by incubation
in biotin (Vector Laboratories), also for 15 min at room
temperature. Nonspecific binding of the primary antibody
was blocked by incubating the sections for 20 min at room
temperature in a 1:5 dilution of nonimmune serum (Autogen
Bioclear, Holly Ditch Farm, Wilts, UK) in phosphate-
buffered saline containing 5% bovine serum albumin. All
immunostaining methods employed a detection system
dependent on visualization of the reaction using a horse¬
radish peroxidase enzyme and the chromagen 3' 3-diami-
nobenzidine (DAB). After the DAB step, the sections were
counterstained in hematoxylin before dehydrating them in
ascending grades ofalcohol and mounting them from xylene
with Pertex (Cellpath pic., Hemel Hempstead, UK). Full
details of each individual protocol are given in Table 1.
2.7. IHC analysis
We used a descriptive methodology as there is no
quantitative or semiquantitative methodology established
for analysis of vaginal tissue samples in our laboratory. The
intensity and distribution of immunostaining for ERa, ER[3,
PR, AR, PH3 and SLPI are described for vagina (epithelium
and stroma) and endometrium (glands, stroma and surface
epithelium), and differences between pre- and posttreatment
samples were analyzed.
2.8. RNA extraction
Tissue was minced using a standard sterile surgical scalpel
blade and immersed in 2 mL of Tris-buffered saline (Sigma-
Aldrich, St. Louis, MO, USA). The mixture was homoge¬
nized for 60 s and incubated overnight at 4°C. The following
day, tissue sample was warmed to room temperature and
200 pg of bromochloropropane was added. The mixture was
centrifuged at 14,000 rpm at 4°C for 15 min, and aqueous-
phase RNA (supernatant) was transferred to a fresh tube. Five
hundred microliters of isopropanol was added and incubated
at 4°C for 60 min. The mixture was centrifuged for 10 min;
the supernatantwas discarded, and the pellet was washed with
1 mL of70% ethanol. The mixture was centrifuged for 5 min,
and the supernatant was discarded, allowing the pellet to dry
for 5 min. The pellet was resuspended in 20 pL of RNA
solution. To standardize measurements between the various
biopsy specimens, we assessed the same amount ofRNA in
each sample. The amount of specific amplicon is related to
ribosomal 18S, which is constant relative to the amount of
cDNA present and, subsequently, to an experimental internal
control. The RNA was reverse transcribed (TaqMan Reverse
Transcription Reagents Kit, Applied Biosystems, FosterCity,
USA) and polymerase chain reaction (PCR) amplified (Taq¬
Man Universal Master Mix, No Amp Erase UNG, Applied
Biosystems) according to the manufacturer's instructions.
PCR amplification ofcDNAwas performed on an ABI Prism
7700 Sequence Detection System (Applied Biosystems).
Specific forward and reverse primers (300 nmol/L) and probe
(200 nmol/L, all synthesized by BioSource UK, Nivelles,
Belgium) for the natural antibiotic were also added. Ribo¬
somal 18S cDNA was measured using TaqMan Ribosomal
RNA Control Reagents (VIC dye, Applied Biosystems) in
each sample as an internal control following the manufactur¬
er's protocol. Samples were measured in triplicate, and no
template controls were included in all runs. Primers and
probes for quantitative PCR were designed using
the PRIMER EXPRESS program (Applied Biosystems;
Table 2
Sequences of quantitative PCR primers and probes for natural antimicrobials
Forward primer Reverse primer Probe
SLPI GCATCAAATGCCTGGATCCT GCATCAAACATTGGCCATAAGTC TGACACCCCAAACCCAACAAGGAGG
HBD1 TCAGCAGTGGAGGGCAATG CCTCTGTAACAGGTGCCTTGAAT CTCTATTCTGCCTGCCCGATCTTTACCAA
HBD2 CTGATGCCTCTTCCAGGTGTTT CTGGATGACATATGGCTCCACTCT AAGGCAGGTAACAGGATCGCCTATACCACCA
HBD3 CAGAGGCGGCCGGTGT CGAGCACTTGCCGATCTGTT CTGTGCTCAGCTGCCTTCCAAAGGA
HBD4 GGCAGTCCCATAACCACATATTC TGCTGCTATTAGCCGTTTCTCTT TGTCCAATTCAAATTCGCTTCTCACTGGA
HBD5 ACCTCAGGTTCTCAGGCAAGAG AGAGGGACTCACGGGTAGCA CTGCTATTGCCGAACCGGCCGT
Granulysin CAGGGTGTGAAAGGCATCTCA GGAGCATGGCTGCAAGGA CGGCTGCCCCACCATGGC
Elafin TGGCTCCTGCCCCATTATC CAGTATCTTTCAAGCAGCGGTTAG ATCCGGTGCGCCATGTTGAATCC
All probes were labeled with 5' FAM and 3' TAMRA fluorophores.
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Table 2) [26-31], and probes were fluorescently labeled with
the proprietary dyes FAM (5') and TAMRA (3').
2.9. Pharmacokinetic study
A pharmacokinetic study of 5 mg of mifepristone was
carried out among the same cohort of women who had
previously participated in another pharmacokinetic study
[32]. The study was approved by the Institutional Review
Board of the Helsinki Central Hospital and the Finnish
National Agency for Medicines; all subjects signed an
informed consent document. Subject characteristics, meth¬
odology, collection of sample, analysis of serum levels of
mifepristone and calculation of pharmacokinetic parameters
were as described previously [32]. In brief, six healthy
women, with regular menstrual cycles (23-36 days), a mean
age of 32 years (range, 21^15) and a BM3 that ranges from
19 to 26 kg/m2, volunteered for the study. The 10-mg
mifepristone tablets supplied by Hualian Pharmaceuticals
Co. Ltd. were halved, and a dose of 5 mg, po, was ingested
on Day 10 or 11 of the menstrual cycle. Blood samples were
collected at 0, 1, 2, 4 and 8 h and, thereafter, daily for the
next 6 days and on Day 10 following mifepristone ingestion.
Mifepristone was measured in serum by RIA after extraction
with «-hexane:ethyl acetate and separation by column
chromatography using Chromosorb® [33], The detection
limit is 0.36 nmol/L, and the intra-assay and interassay
coefficients of variation were 8.4% and between 10.3% and
13.6%, respectively.
2.10. Statistical analysis
Statistical analysis was performed using SPSS (SPSS,
Inc., Chicago, IL, USA) and Excel 2002 (Microsoft
Corporation, Reading, UK). Sex steroid, vaginal thickness
and pharmacokinetic data are expressed as mean with either
standard error of the mean or standard deviation. Menstrual
cycle data are expressed as mean and range. Nonparametric
tests (Friedman's test, Wilcoxon Signed Rank Test and
Mann-Whitney test) were used to compare sex steroid level,
menstrual data, vaginal thickness and natural antimicrobial
RNA content before and after treatment.
3. Results
3.1. Effects ofmifepristone on vagina
All eight subjects completed the study. The subjects
took mifepristone 5 mg/day, po, for an average of 33 days
(range, 28^40).
The average length of the control menstrual cycle was
27 days (range, 24—29), while that of the control menstrual
period was 5.7 days (range, 4-9). All eight women reported
amenorrhea during ingestion ofmifepristone. The time from
discontinuing the mifepristone treatment to the next
bleeding episode was 17 days (range, 10-23); thus, the
length of the mifepristone cycle was 50 days (range, 38-63).
Average length of the bleeding episode after discontinuation
of mifepristone was 5.1 days (range, 4—7).
During the treatment with mifepristone, seven of the
eight subjects experienced either complete suppression of
ovarian activity (3/8 women, Fig. 2A, Subject 8) or
persistent follicular activity but no ovulation (4/8 subjects,
Fig. 2B, Subject 4). In the remaining subject (Subject 7,
Fig. 2C), there was a threefold rise in the excretion of
pregnanediol in the first 10 days of treatment, suggesting the
formation of a corpus luteum. However, there was no
menstrual bleeding when the level of pregnanediol dropped
14 days after starting the mifepristone. In this subject, a
persistent ovarian cyst with a 42-mm diameter was detected
at completion of treatment (Day 40) when the level of
P (14 nmol/L) was slightly raised, which was consistent
with a persistent unruptured partially luteinized follicle.
Mifepristone 5mg/day
-24 -16 16 28 36 44 52 60 68
Fig. 2. Excretion of metabolites of ovarian steroids in women taking 5 mg
of mifepristone for 31-36 days. Estrone, E1G; pregnanediol, PdG; x-axis
shows timescale; Day 0, start of treatment. Pretreatment (negative values),
treatment (boxed) and follow-up cycles are shown. Black bars represent
menstrual episodes; arrow denotes vaginal biopsy. (A) Complete suppres¬
sion of ovarian activity. (B) Persistent follicular activity but no ovulation.
(C) Single ovulatory episode and no menstruation following fall in
pregnanediol levels.
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Pre-mifepristone Post-mifepristone Endometrium
Fig. 3. IHC localization of ERa, ER(3, PR, AR and PH3 in the vagina [epithelium (epth) and stroma (str)] and endometrium [gland (glnd) and stroma (str)]
before and after treatment with 5 mg mifepristone. Scale bar= 100 |im; inserts denote negative controls. Strong expression of ERa (A and B), ERp (D and E)
and AR (J and K) in the basal and parabasal layers of epithelium and a relative lack of PR (G and H) in the epithelium (there was no observed change following
treatment); PH3 expression in the basal layers (M and N; arrows) and endometrium [postmifepristone (O; arrows)]; strong expression of all steroid receptors in
the posttreatment endometrium (C, F, I and L); SLP1 confined to superficial layers of vaginal epithelium (P and Q) and endometrial glands (R).
Multiple follicles were detected by transvaginal ultra¬
sound (diameter of the largest ranged from 10 to 29 mm) in
all eight subjects. The concentrations of E2 in blood
samples collected at Visit 2 on the last day of mifepristone
treatment were compatible with persistent follicular activity
(496±57 pmol/L). In seven of eight women, the concen¬
tration of P was <10 nmol/L (3±1 nmol/L), indicating lack
of ovulation.
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3.2. Endometrial histology
Endometrial biopsies obtained at the end ofmifepristone
treatment displayed inactive or weakly proliferative endo¬
metrium in seven of the eight subjects. In one subject
(Subject 9), tortuous glands with evidence of intraluminal
secretion were seen. As expected, there was strong
immunostaining of ERa and ERp as well as of PR (A+B)
and AR in both glands and stroma. Histological evidence of
mitosis was absent or infrequent in all samples.
3.3. Vaginal histology and vaginal thickness
Vaginal biopsy was obtained in all subjects without
complications both before and after mifepristone administra¬
tion. In seven of eight subjects the pretreatment vaginal
biopsy was performed between Day 6 and Day 16 of the
follicular phase prior to ovulation as confirmed by the
hormone levels (mean±SEM: E2, 659±141 pmol/L, P,
4.3±10 nmol/L). In the remaining subject (Subject 5),
ovulation had already occurred on the day of biopsy (Day
14 of menstrual cycle) as indicated by high circulating
concentration ofP (44 nmol/L). Posttreatment vaginal biopsy
was performed on Day 33 (range, 28-40) of treatment.
The histology of the vagina showed the expected basal
layer of epithelium mounted by up to 20 layers of more
superficial desquamating cells (Fig. 1). Vaginal thickness
was not altered during administration of mifepristone
(342±40 pm vs. 303±69 pm; p=.2, NS).
3.4. Steroid receptor expression in the vagina
(EM, ERfl, AR and PR)
There was nuclear staining of ERa, ER(3 and AR in
both vaginal stroma and in the epithelium. Immunoreactiv-
ity extended through the basal and intermediate layers but
not through the superficial layer of vaginal epithelium
(Fig. 3). Staining was far more evident in the epithelium as
compared with the stroma. There was no significant
difference in sex steroid receptor immunostaining after
mifepristone administration.
Apart from a few scattered nuclei in the stroma, the basal
layer of vaginal epithelium immunostaining for PR was
confined to stroma (Fig. 3). There was no significant
difference in PR immunoreactivity after administration
ofmifepristone.
3.5. PH3 immunoreactivity
PH3 immunostaining was confined to scattered nuclei in
the basal layers of the vaginal epithelium (Fig. 3). There was
no significant change in immunoexpression following
treatment with mifepristone.
3.6. Natural antimicrobial mRNA and protein expression
SLPI mRNA was present in vagina, and this epitope was
localized to the superficial layer of the vaginal epithelium
both before and after mifepristone administration
















Fig. 4. Serum levels (mean±SD) of mifepristone following ingestion of
5 mg. The data are depicted on both linear (lower) and semilogarithmic
(insert) scales.
the superficial layers of luminal and glandular epithelium of
the endometrium (Fig. 3). SLPI mKNA expression was
unchanged following treatment with mifepristone (p>.05,
Wilcoxon test). HBD1, HBD2, HBD3, HBD5, granulysin
and elafin mRNA were present in the vagina. The
expression was unchanged following treatment with mife¬
pristone (p>.05, Wilcoxon test).
3.7. Safety parameters
There was no derangement in heart rate, blood pressure
or in hematology and biochemistry parameters including
liver function tests during the study. Vaginal and cervical
bacteriology swab tests cultured negative for pathogenic
organisms in all subjects. Vaginal biopsy was well
tolerated by all women. One woman had possible low-
grade endometritis following endometrial biopsy and was
successfully treated with a 7-day course of antibiotics.
3.8. Pharmacokinetics of 5 mg mifepristone
Serum levels (mean±SD) of mifepristone following
ingestion of 5 mg mifepristone are summarized in Fig. 4.
Mean Cmax measured at 1 h was 641.7 nmol/L (range, 502-
740 nmol/L). All subjects showed a similar pattern of
descending serum concentrations of mifepristone. The
elimination phase half-life was 18±5.1 h (mean±SD). The
mean (SD) areas-under-concentration-curves AUCo_8 h and
AUCq_24 h were 2.4 (0.5) and 4.8 (1.3) pmol/L, respectively.
4. Discussion
The vagina is a key portal of entry for HIV and other
STIs. In this article, we report the effect of a potential new
contraceptive pill on different parameters involved in the
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natural defenses of the vagina to infection. Vaginal epithelial
thickness, steroid receptor and natural antimicrobial content
and distribution were unchanged following treatment with
mifepristone for 30-40 days. Vaginal epithelial thickness is
regulated by the levels of circulating estrogen. Epithelial
thickness is maximal at time of ovulation [34-37] and
decreases in the luteal phase and postmenopause [36]. There
is a significant reduction in circulating estrogen levels
following long-term gestagen treatment [37]. Severe vaginal
atrophy has been demonstrated in primate studies, and this
clearly increases the risk of SIV transmission [4]. However,
the response of human vaginal epithelium to gestagen-
induced hypoestrogenism is variable. A small but significant
decrease (10%) in thickness has been demonstrated in one
study [37], whereas most other studies have demonstrated
no change [38,39]. Paradoxically, vaginal epithelial hyper¬
plasia has been reported in users of depot medroxyproges¬
terone acetate (DMPA), oral contraceptive pill and P
implants [39^41]. E2 levels in all three treatment groups
were significantly lower compared with normal menstruat¬
ing women. The steroid receptor content and distribution
were similar except for PR, which was suppressed in the
DMPA group.
It is difficult to reconcile all available data into a working
hypothesis due to differences in study designs and
methodology. The vagina has diverse embryological origins
[42]; Ildgruben et al. used a cross-sectional study design and
sampled lateral vaginal fornices, whereas we used a
longitudinal study design and sampled lateral midvaginal
wall in keeping with other reports [41].
Although vaginal epithelium clearly responds to circu¬
lating estrogen, the underlying cellular and molecular
mechanisms are poorly understood. We localized PH3, a
marker for mitosis and cellular proliferation, to a few
scattered nuclei in the basal layers of the vaginal epithelium.
The strong nuclear expression of ER and AR in the basal
and parabasal layers suggests a role in the regulation of
epithelial proliferation. Estrogen treatment induces surface
keratinization and hyperplasia of primate vaginal epitheli¬
um, and we expected a similar change in mifepristone-
treated vaginal samples due to unopposed estrogen effect.
The observed epithelial thickness in control samples in the
present study (mean pretreatment thickness, 342 pm) is
comparable to other reports [38-40]. Thickness was
unchanged following mifepristone treatment, and this agrees
with similar work in cynomolgus monkeys [43]. There are
several possible explanations for our findings. Firstly,
mifepristone treatment did not have any effect on level of
circulating steroid hormones. Secondly, PR was localized to
a few scattered nuclei in the basal layers of vaginal
epithelium and, hence, mifepristone, a high-affinity PR
ligand, did not have any direct epithelial effects.
Consistent with previous reports, we have demonstrated
a strong immunoexpression of ER and AR as well as a
relative lack of PR in the vaginal epithelium compared to
subepithelial stroma [44-51]. The distribution of steroid
receptors has obvious implications for the development of
topical and parenteral steroid treatment. Available data,
including the present study, indicate that it is likely that
estrogen preparations will act via epithelial ER, whereas
P preparations are likely to have an endocrine and paracrine
effect after binding with the subepithelial PR. The role of
AR in the genital tract is unclear, but AR may play a role in
regulating endometrial proliferation [52-54] and in modu¬
lating vaginal blood flow [50] and female genital sexual
arousal [49].
The endometrium sampled at the end of mifepristone
treatment showed persistent proliferative histology and
strong ER, PR and AR expression, which is consistent with
our previous reports [54,55] and which demonstrates that
the mifepristone preparation used in this study is compara¬
ble to that we have used previously from another source
(Exelgyn, Paris).
The expression, regulation and role of natural antimicro¬
bial compounds in the female reproductive tract are
extensively reviewed elsewhere [29]. We have investigated
natural antimicrobials that regulate innate protection at
mucosal interfaces. SLPI has been shown to play an
important role in limiting transmission of HTV [20,56,57]
and other lower genital tract infection [19]. SLPI mRNA has
been demonstrated in vaginal fluid previously [19,20], In
the present article, we demonstrate mRNA in vaginal tissue
and immunolocalize the protein to the superficial layers of
the vaginal epithelium. The expression in superficial layers
of surface and glandular endometrium is in keeping with
previous reports [26]. HBD1 [58] and elafin [59] mRNA
have been reported in human vagina. We show that HBD2,
HBD3, HBD5 and granulysin mRNA are present in vaginal
tissue. HBD4 mRNA was not previously demonstrated.
Natural antimicrobial expression is modulated by hormonal
treatment, and up-regulation of endometrial SLPI by P is
attenuated in the presence of mifepristone [31], Reassur¬
ingly, expression and distribution of natural antimicrobials
were unchanged following mifepristone treatment.
Low-dose mifepristone suppressed menstruation and
ovulation in a majority ofwomen in the present study. This
adds to similar observations in our previous reports [23,60]
and also demonstrates the biological activity ofmifepristone
supplied by Hualian Pharmaceuticals Co. Ltd. The pharma¬
cokinetic properties of the 5-mg dose from the above
supplier follow a first-order linear kinetic pattern [32,61].
The half-life of 18 h is shorter than the 20 h previously
reported for 10 mg mifepristone, whereas the AUCo_24 h was
half that of the 10-mg dose [32], All women received
planned treatment for at least 5 days beyond the expected
date of menstruation (33 days) so that any posttreatment
vaginal bleeding was due to withdrawal of mifepristone
rather than to a spontaneous menstruation. Fortuitously,
Subject 7 was administered mifepristone for 40 days. She
did not bleed, although there was evidence of ovulation and
formation of corpus luteum followed by a significant
decrease in pregnanediol levels. This supports our previous
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reported findings that mifepristone-induced amenorrhea is a
result of direct endometrial effects that are possibly
mediated by a rise in glandular and luminal glucocorticoid
and AR [62],
In summary, we have shown that low-dose mifepristone
does not influence vaginal thickness and proliferation. We
have demonstrated that ER (ERa and ERfJ), PR, AR,
SLPI and other natural antimicrobials are present in the
human vagina. There is no change in epitope expression
following mifepristone treatment. The presence and distri¬
bution of vaginal steroid receptors have implications for
the development of topical and systemic preparations to
modulate this sex steroid responsive organ in health and
disease.
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CONTRACEPTION
Toward developing a once-a-month pill: a double-blind,
randomized, controlled trial of the effect of three
single doses of mifepristone given at midcycle on the
pattern of menstrual bleeding
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Objective: To test the feasibility of timing the administration ofmifepristone as a once-a-month contraceptive pill
on the 12th day before the next menses, as calculated from the length of the previous menstrual cycles.
Design: Double-blind, randomized, controlled trial.
Setting: Five family planning centers across the world.
Patient(s): Three hundred ninety-nine women attending family planning clinics.
Intervention(s): Randomized to receive 10, 25, or 200 mg of mifepristone or a placebo.
Main Outcome Measure(s): Lengthening or shortening of the normal menstrual cycle length following admin¬
istration of the drug by at least 5 days.
Result(s): The menstrual period came within 5 days of the predicted date in 88% ofwomen receiving the placebo,
84% ofwomen receiving 10 mg, 72% ofwomen receiving 25 mg of mifepristone, and only 48% ofwomen treated
with 200 mg of mifepristone. Increasing the dose of mifepristone was associated with an increased chance of
having a delayed period (PC.001). Only 45% of women were in the peri-ovulatory phase of the cycle according
to LH and P measurements on the day of drug administration. Women treated before ovulation were more likely
to have delayed menses with all three doses of mifepristone.
Conclusion(s): Because of the disruption in cycle length, it appears unlikely that mifepristone administered once
a month, at a calendar-based time, would provide a reliable method of contraception. (Fertil Steril® 2006;86:
819-24. ©2006 by American Society for Reproductive Medicine.)
Key Words: Mifepristone, once-a-month pill, pattern of menstrual bleeding
The anti-P mifepristone, given once per month, is an effec¬
tive method of contraception (1-3). In 1999, we performed a
questionnaire study in Edinburgh, Cape Town, Hong Kong,
and Shanghai to examine women's attitudes toward the
concept of a once-a-month pill. We concluded that a once-
a-month pill would be a popular form of contraception to
many women in different cultures (4).
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For successful development as a once-a-month contracep¬
tive pill, the timing of administration of mifepristone is
critical. Administered 48 hours after the LH surge, shortly
after ovulation, 200 mg of mifepristone does not alter the
length of the menstrual cycle and bleeding is not usually
induced (5, 6). This dose markedly retards endometrial de¬
velopment to a degree that is likely to prevent implantation
(5-8). It also changes uterine contractility to a pattern that is
usually observed in the late luteal phase (9), perhaps adding
to the contraceptive effect.
However, if it is administered during the follicular phase
of the menstrual cycle (i.e., too early), mifepristone inhibits
follicular development, delays the midcycle LH surge, and
prolongs the length of the cycle (10, 11). Administration of
mifepristone in the midluteal to late luteal phase (i.e., too
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late) induces bleeding within a few days, and this is often
followed by a second bleed at the time of the expected
menses (10, 12). Thus, a single dose of mifepristone admin¬
istered outside the critical time results in irregular bleeding,
which many women find unacceptable.
In the two studies that demonstrated the efficacy of the
method, the administration of mifepristone was timed accu¬
rately by identifying the midcycle peak ofLH in the urine. In
Sweden, this was determined with urine test sticks (13); in
Edinburgh, Scotland, home-use fertility monitors were used
(14). Both approaches are expensive and probably too de¬
manding on user compliance to be used routinely. In the
Edinburgh study for example, 11.2% of LH surges were
missed because of imperfect use of the monitor (15).
We have recently demonstrated that mifepristone given on
the day of the LH surge (LH+0), also retards endometrium
sufficiently to prevent implantation, without interfering with
ovulation (16). This observation widens the potential "win¬
dow of opportunity" for administering mifepristone as a
once-a-month contraceptive to at least 3 days (LH + 0 to LH
+ 2). It prompted us to design a study to test the feasibility
of timing once-a-month mifepristone administration without
the assistance of technology. Instead, we used a calendar
approach, given a single dose of mifepristone on day of
menses minus 12, which was estimated from the mean of the
subject's previous menstrual cycles. The effect of three
different doses of mifepristone (10, 25, or 200 mg) on the
length of the menstrual cycle and pattern ofmenstrual bleed¬
ing was compared with the placebo.
The rationale for testing the three doses of mifepristone
was as follows. Contraceptive potential of 10 and 200 mg of
mifepristone has been reported. Doses <10 mg do not inhibit
ovulation (17-19), and although the endometrium is dis¬
rupted, the pregnancy rate is disappointingly high (18, 19). A
dose of 200 mg is reportedly contraceptive, but if it is given
at the wrong time (i.e., too early or too late), it will fre¬
quently result in menstrual irregularity (10). A dose of 10 mg
of mifepristone is reportedly effective when used for emer¬
gency contraception (20), but it has an effect on endometrial
development that is less marked than the effect of 200 mg
(21). This dose may be less likely to cause cycle disruption
but is also less likely to be effective. A dose of 25 mg
appeared to be a sensible compromise between the antinida-
tory effects on the endometrium, efficacy, and potential for
cycle disruption by mifepristone.
MATERIALS AND METHODS
This was a multicenter, double-blind parallel group study in
female volunteers. The intention was to recmit a total of 400
subjects (80 per center) from women 18-40 years old at¬
tending family planning clinics in five centers: Edinburgh
(Scotland), Sagamu (Nigeria), Cape Town (South Africa),
and Hong Kong and Shanghai (People's Republic of China).
The women were required to use barrier methods for the
duration of the study or have a copper intrauterine device
(IUD) in situ, or were relying on sterilization (subject or
partner). Recruitment criteria included a history of regular
menstrual cycles of 25-35 days varying within <3 days in
the last 3 months. Women who had a significant medical
condition, who were breastfeeding, or had used hormonal
contraception within 3 months before the study were ex¬
cluded. The local ethical committee (institutional review
board) approved the proposal in each center. Written in¬
formed consent was obtained from all subjects.
A full medical and gynecological history and examination
were obtained at recruitment (visit 1). Normal cycle lengths
were defined as follows. Cycle length and range was calcu¬
lated from the dates of the last three menstrual periods for
women who kept a written record (retrospective normal
cycle length, n = 87). Women who did not provide a record
of the dates of menstruation but claimed to have very regular
cycles were asked to give an estimate of normal cycle length
and a range of variation (reported normal cycle length, n =
199). Women who did not keep a record of their cycles and
who were unsure of their normal cycle length kept a pro¬
spective record of the next three cycles before the interven¬
tion cycle (prospective normal cycle length, n = 105).
The duration of menstrual bleeding was determined in the
same manner. For the duration of the study, all episodes of
vaginal bleeding were recorded on a menstrual diary card,
and spotting and bleeding were differentiated. Women con¬
tacted the investigators in the first week of the intervention
cycle and attended the clinic 12 days before the anticipated
date of next menses, as estimated from their normal cycle
length (visit 2). Pregnancy was excluded by a urine preg¬
nancy test, and subjects were randomized to receive 10 mg,
25 mg, or 200 mg of mifepristone or a placebo. A blood
sample was collected for the measurement of LH and P.
Women were reminded to record any menstrual bleeding or
adverse events on the record card. At approximately the
expected time of the onset of menses following treatment,
the subject was contacted (usually by phone) and asked to
return the record card to the clinic (visit 3) after the onset of
menses.
The study medication was dispensed as 10, 25, or 200 mg
of mifepristone or placebo tablets provided by the Shanghai
Hualian Pharmaceutical Company Ltd. (Shanghai, People's
Republic of China). The mifepristone tablets came in three
different sizes; therefore, three sizes of placebo were pro¬
duced to match the size and color of mifepristone tablets.
Each subject received a bottle containing one mifepristone
(10, 25, or 200 mg) plus two different-sized placebo tablets.
Women in the placebo group received all three placebo
tablets. This was a double-blind study. Randomization at
visit 2 was performed by blocked computer-generated ran¬
domization for each center to ensure a good balance of
numbers in the different treatment groups. Sealed envelopes
were used to conceal the treatment allocation until the
women were registered as definite participants.
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Blood samples collected by venepuncture on day of drug
administration (visit 2) were centrifuged and the serum was
stored at -20°C until analysis. Standard radioimmunoassay
techniques were used in each center for the measurement of
LH and P. On the basis of the laboratory normal values, the
samples were classified as originating from three stages of
the ovarian cycle: follicular LH < 10IU/L and P <5 nmol/L;
luteal LH <10 IU/L and P >20 nmol/L; peri-ovulatory LH
> 10 IU/L and/or P 5-20 nmol/L.
Statistical Analysis
The main aim of the study was to investigate the effect of
mifepristone on the time interval between the day of admin¬
istration of the drug and the start of the next menses (i.e., on
the length of the menstrual cycle).
A menstrual period was defined as >2 days of blood loss
(i.e., bleeding or spotting), with at > I day of bleeding, and
bounded at each end by £^2 bleeding- and spotting-free days
(22) Isolated days of bleeding, or runs of spotting without
bleeding, were excluded. If there was s 1 day separating the
two sets of blood loss, this was counted as a single menstrual
period.
The length of the intervention cycle was compared with
that of the normal cycle length (as defined earlier) and to the
cycle length of women treated with the placebo. The primary
outcome for this study was a lengthening of S:5 days in the
normal menstrual cycle length following administration of
the drug. A cutoff of 5 days was considered clinically sig¬
nificant because this degree of disruption would likely result
in a woman seeking advice (particularly if her period was
delayed) and would be sufficient to jeopardize the contra¬
ceptive effectiveness of the regimen.
The proportion of cycles significantly disrupted was com¬
pared between adjacent randomized groups (i.e., placebo vs.
10 mg, 10 vs. 25 mg, and 25 vs. 200 mg) by x2 tests, with
Yates' correction at 5% level of significance. In addition, a
secondary analysis of the incidence of lengthened cycles was
performed across all four study groups using tests for
trends. The x2 tests were used to compare the outcomes in
different stages of the cycle on the basis of hormone mea¬
surements. Pearson correlation and two-sample /-tests were
used to test for associations between demographic factors
and length of cycles, and paired /-tests were used to compare
the lengths of different cycles. The number of times each
patient reported adverse events of specific types was tested
against the study drug dose using tests for linear associ¬
ation and compared between centers by Kruskal-Wallis tests.
This was calculated on the basis of an estimated incidence of
delayed cycles of 5% in the placebo group. With 73 women
in each group, the study had >80% power to detect signif¬
icant differences on the order of 20% between adjacent pairs
of actively treated groups. A total of 100 women were
recruited to allow for dropouts.
RESULTS
Starting from December 2001, a total of 399 women were
recruited: 79 from Hong Kong and 80 from each of the other
four centers. Recruitment finished in April 2003. The women
were randomized into four equally sized groups; they were
given a single dose of a placebo or 10, 25, or 200 mg of
mifepristone; 391 of the 399 women were observed after the
administration of drug. Eight women were withdrawn; six
became pregnant before the first postdrug menstrual episode,
and two did not supply any diary data. Two women became
pregnant in the cycle following the intervention cycle and
were included in primary analysis. The four groups were
similar in age, parity, and body mass index (BMI). Mean
values (ranges) were 31 (18-40) years for age, 1.2 (0-6) for
parity, and 24 (15-48) for BMI. Although the overall mean
cycle length was similar between the centers (29.3 ± 5.4
days), there was considerable variation both between and
within women in whom repeated measurements (mean range
1.94 [SD 2.18] days on the basis of 281 prospective men¬
strual episodes) were available before the intervention cycle.
Similarly, the length of the intervention cycle varied among
women in the placebo-treated group. Only 85 (87.6%) of 97
women had intervention cycle lengths ± 5 days of normal
cycle length (Table 1).
There was a statistically significant, dose-related tendency
for disruption of cycle length (of more than ± 5 days) in the
women who received mifepristone (Table 1), from 16% of
women treated with 10 mg to 52% of women treated with
200 mg ofmifepristone (x2 = 23.88; P<.001). However, the
table 1
Percent of subjects with length of intervention cycle within and outside 5 days of preintervention
cycle.
Treatment group Within ± 5 days Shortened (<5 days) Lengthened (>5 days)
Placebo, % (range) 89 (81-94) 8(4-15) 3(1-9)
10 mg, % (range) 84 (75-90) 6(3-13) 10(6-18)
25 mg, % (range) 72 (63-81) 10(6-18) 18(12-27)
200 mg, % (range) 48 (38-58) 26 (18-35) 26(19-36)
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TABLE 2
Phase of cycle in relation to ovulation during which subjects received treatment and percent of

















Placebo 94 41 5(1-16) 7(2-19) 16 6(1-30) 31 (14-56) 37 14(6-28) 0(0-9)
10 mg 97 40 0(0-9) 15(7-29) 13 8(1-33) 62(36-82) 44 11 (5-24) 0(0-8)
25 mg 99 43 9(4-22) 19(11-35) 23 4(1-21) 48(29-67) 33 15(7-31) 0(0-10)
200 mg 98 54 9(4-20) 35 (24-49) 12 8(1-35) 83(55-95) 32 59(42-74) 9(3-24)
Narvekar. Mifepristone and once-a-month contraceptive pill.
difference between adjacent drug groups with respect to
menstrual delay was not significantly different (Table 1) for
placebo versus 10 mg (x2= 2.97; P=.08); for 10 mg versus
25 mg (x2 = 1.88; P=. 17); and for 25 mg versus 200 mg (x2
= 1.54; P=.21). A dose-related increase in the proportion of
women experiencing menstrual cycles of a shorter duration
was also demonstrated (Table 1), but the difference between
placebo and mifepristone only reached statistical signifi¬
cance in the group treated with 200 mg (25%) (x2 = 19.34;
Pc.001).
This degree of cycle disruption was unexpected and led us
to suspect that the administration of mifepristone in relation
to ovulation was mistimed. The hormone data were therefore
used to classify the time of the ovarian cycle when the drug
was given in the 389 women for whom the data were
available (Table 2). When all the groups and centers were
combined, treatment (i.e., mifepristone or placebo) was
given in the periovulatory period, which was the optimum
time, in only 179 (46%) of 389 of cycles. In 64 (16%) of 389,
it was given in the follicular phase (i.e., before ovulation). In
the remainder (38%), it was given too late in the luteal phase.
The degree of cycle disruption was much less in the women
who were given mifepristone in the periovulatory period
(Table 2). Ninety-five of the 137 women in this group (69%)
had their next menses within 5 days of the expected time. In
contrast, in the 200-mg group, 83% of the women who took
the mifepristone in the follicular phase had a delay of more
than 5 days in the onset of the next menses, whereas in 59%
of those taking it in the luteal phase, the menstrual cycle was
shortened (Table 2).
The mean value (±SD) for the length of the preinter-
vention cycle (LI) based on available diary data (n = 159
subjects) was 29.3 ± 5.4 days, and this did not differ
significantly from that of the normal cycle length of 29.2
± 2.0 days or from that of the length of intervention cycle
(L2) in the placebo group (mean 28.8 ± 3.9 days). Thus,
no evidence was found of an effect off the placebo on
cycle length. The LI correlated with the length of the
normal cycle as reported or recorded retrospectively by
the women (P<.001), and in most cases, the two were
within 3 days of each other. Ten cases were between 4 and
10 days discrepant, and only four cases were more than 10
days different. There was a borderline significant negative
correlation between LI and age (r = —0.14; P=.007), and
normal cycle length also indicated a negative correlation
with age (r = -0.17; PC.001). The LI also correlated with
heart rate (r = +0.20; P<.01) but not with height, weight,
blood pressure, center, race, or parity. The mean duration of
preintervention menstrual episodes was 5.0 ± 1.8 days
(based on 637 episodes) and of bleeding-free intervals was
25 ± 3.2 days (based on 279 episodes).
A few women (0, 2%, 1%, and 14% of women in the
placebo, 10-, 25-, and 200-mg groups, respectively) men¬
struated within a few days of administration of the tablets
and experienced a second bleeding episode at the anticipated
time of next menstruation. This bleeding pattern was
strongly associated (P<.001) with administration of the drug
in the luteal phase of the cycle.
DISCUSSION
To be effective as a once-a-month contraceptive pill, mife¬
pristone must be administered in a dose sufficient to prevent
implantation and at the correct time in the cycle to minimize
menstrual disruption. The ideal time to administer mifepris¬
tone is just after the start of the LH surge and before the
endometrium is primed for a P-withdrawal bleed. We have
previously identified a 3-day window of opportunity around
the time of ovulation (16).
In the present study, we have attempted to identify this
critical time of administration on the basis of a prediction of
the length of menstrual cycle. This study clearly demon¬
strates that such a calendar approach to timing the adminis¬
tration of once-a-month mifepristone is not practical.
Even with the 3-day window of opportunity, treatment
was mistimed in more than half the cycles. Although normal
cycle length and length of the preintervention cycle corre¬
lated well, an unexpected variation in the length of interven-
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tion cycle occurred, with 11% of women in the placebo
group demonstrating a variation of >10 days. This was
significantly more than our prestudy assumption (5%) and
may explain why mifepristone was mistimed.
Large databases of menstrual diaries (23, 24) have dem¬
onstrated that each woman has her own central trend and
variation in menstrual cycle lengths. It may be possible to
devise a more accurate formula to predict the length of the
menstrual cycle ifmore menstrual data were available. It was
previously reported that when data pertaining to the previous
12 menstrual cycles is available, prediction of the onset of
the next menstrual cycle within the range of previous cycles
is possible in <90% of women (25). Nevertheless, this
requires a complex mathematical formula, and such meth¬
odology defeats the very purpose of our study, which was to
find a reliable and simple method of timing administration. A
large number of studies describing bleeding patterns have
observed discrepancies between women's claims of a regular
menstrual cycle of usually 28 days and the actual regularity
of such patterns revealed by prospective recording. Regard¬
less of the way in which we calculated normal cycle lengths
(i.e., retrospective recording, prospective recording, and re¬
ported normal length), no difference was found in the prin¬
cipal outcome measure (variation in cycle length of >5
days) among the three calculated groups.
The effect of treatment on cycle length was related to both
the dose of mifepristone and to the timing of administration
in relation to ovulation. Even the lowest dose (10 mg) caused
cycle disruption in 16% of women, and disappointingly, a
25-mg dose disrupted the cycle in over one in four women.
In contrast, although treatment with a placebo was associated
with some change in cycle length, almost 90% of women
menstruated within the expected time. Administration in the
follicular phase prolonged the cycle, presumably by delay in
the onset of LH surge (10, 11, 26-28). Only the highest dose
(200 mg) of mifepristone caused a significant shortening of
cycle by inducing a withdrawal bleed when administered in
the luteal phase (12). More than 1 in 10 women treated with
200 mg of mifepristone experienced two bleeding episodes:
one at P withdrawal and the other at the expected time of
menstruation. Even women who received treatment during
the peri-ovulatory phase of the menstrual cycle indicated a
significant dose-dependent trend in cycle disruption (length¬
ening). Although the exact functional form of these dose-
bleeding relationships cannot be defined, such dose-related
effects on menstrual cycle length, on the basis of the timing
of administration in relation to ovulation, have not been
reported previously.
We used cross-sectional data on LH and P to classify
women into ovulatory categories. This is almost certainly
less accurate than composite longitudinal data on the basis of
follicle growth tracking (by ultrasound), and serum and
urinary LH and P and their metabolites. Results from a large,
randomized, multicenter trial investigating the efficacy of
10, 50, and 600 mg of mifepristone for emergency contra-
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ception (20) confirm considerable disruption in the cycle if
mifepristone is given at random days of the cycle.
Women with irregular cycles or cycles with a normal
variation in length of more than 3 days were excluded from
this study. If a calendar-based approach to timing the ad¬
ministration of mifepristone is inaccurate in women with
very regular cycles, it would not be a very practical contra¬
ceptive for routine use. Many women find irregular bleeding
intolerable; it is the most common reason for discontinuation
of all hormonal methods of contraception (22). Menstruation
is often regarded as an inconvenience, and unpredictable
bleeding is even worse. Moreover, women worry that some¬
thing is wrong or that they may be pregnant. Mifepristone
disrupts menstruation even if given at the correct periovula-
tory time in the cycle and, as such, may be unacceptable for
practical use, even if a better and simpler method of timing
administration is devised.
In summary, we have demonstrated that it is unlikely that
mifepristone administered once a month at a calendar-based
time would provide a reliable method of contraception.
There was a greater variation in menstrual cycles in our
subjects than previously reported in similar or other popula¬
tions, and a dose-related lengthening or shortening of men¬
strual cycle occurs if mifepristone is given in the follicular or
luteal phase, respectively. Even correct periovulatory admin¬
istration of single 10- and 25-mg mifepristone doses dis¬
rupted menstruation. It is difficult to envisage how an easy
and reliable way of defining the correct timing could be
devised. Even if such a method was devised, considerable
dose-related disruption may render mifepristone unaccept¬
able as a once-a-month pill for practical use.
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